{"PMC7127605": [["Material and MethodsThe following new procedure for bacterial sampling was used.Material and MethodsTwenty-three patients for this portion of the study were debonded in the private office of the principle investigator (P.M.G.).", [["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["new procedure", "TREATMENT", 34, 47], ["bacterial sampling", "TREATMENT", 52, 70], ["the study", "TEST", 142, 151]]], ["The bonding resin used was chemically cured composite adhesive (Reliance Phase II; Reliance Orthodontic Products, Itasca, Ill).Material and MethodsPatient exclusion criteria were no signs of respiratory infection, no antibiotic therapy at least 2 weeks before debanding, no steroid use during orthodontic therapy, no dental prophylaxis within 30 days preceding debanding, and at least 10 brackets per arch present.Material and MethodsA modified bleeding index was recorded before sampling.", [["respiratory", "ANATOMY", 191, 202], ["respiratory infection", "DISEASE", 191, 212], ["steroid", "CHEMICAL", 274, 281], ["bleeding", "DISEASE", 445, 453], ["steroid", "CHEMICAL", 274, 281], ["steroid", "SIMPLE_CHEMICAL", 274, 281], ["The bonding resin", "TREATMENT", 0, 17], ["chemically cured composite adhesive (Reliance Phase II", "TREATMENT", 27, 81], ["Orthodontic Products", "TREATMENT", 92, 112], ["respiratory infection", "PROBLEM", 191, 212], ["antibiotic therapy", "TREATMENT", 217, 235], ["steroid use", "TREATMENT", 274, 285], ["orthodontic therapy", "TREATMENT", 293, 312], ["dental prophylaxis", "TREATMENT", 317, 335], ["MethodsA modified bleeding index", "PROBLEM", 427, 459], ["no signs of", "UNCERTAINTY", 179, 190], ["respiratory", "ANATOMY", 191, 202], ["infection", "OBSERVATION", 203, 212], ["no", "UNCERTAINTY", 271, 273], ["brackets", "OBSERVATION", 388, 396], ["arch", "ANATOMY", 401, 405], ["bleeding", "OBSERVATION", 445, 453]]], ["The patient's age and total number of teeth to be debonded were also recorded.Material and MethodsBaseline ambient air samples were collected in an enclosed room measuring 10 \u00d7 10.5 \u00d7 11.5 feet with a transparent vinyl resuscitation mask (CE 0086; Ace Surgical Supply, Brockton, Mass) connected to a 3- to 6-in sterile latex rubber surgical tube of 1/4 \u00d7 3/32-in diameter, fitted to an industrial air-suction pump (SKC Model 224-XR; SKC, Inc, Eighty Four, Pa).", [["teeth", "ANATOMY", 38, 43], ["CE 0086", "CHEMICAL", 239, 246], ["vinyl", "CHEMICAL", 213, 218], ["patient", "ORGANISM", 4, 11], ["teeth", "ORGAN", 38, 43], ["patient", "SPECIES", 4, 11], ["MethodsBaseline ambient air samples", "TEST", 91, 126], ["a transparent vinyl resuscitation mask", "TREATMENT", 199, 237], ["CE", "TEST", 239, 241], ["Ace Surgical Supply", "TREATMENT", 248, 267], ["Brockton", "TREATMENT", 269, 277], ["Mass", "PROBLEM", 279, 283], ["sterile latex rubber surgical tube", "TREATMENT", 311, 345], ["an industrial air-suction pump", "TREATMENT", 383, 413], ["SKC Model", "TEST", 415, 424], ["XR", "TEST", 429, 431], ["SKC", "TEST", 433, 436], ["ambient air", "OBSERVATION", 107, 118], ["Mass", "OBSERVATION", 279, 283], ["latex rubber", "OBSERVATION", 319, 331], ["surgical tube", "OBSERVATION", 332, 345]]], ["The mask had a porthole on its right side that intimately accommodated a high-speed handpiece (Fig 1).", [["The mask", "TREATMENT", 0, 8], ["a high-speed handpiece", "TREATMENT", 71, 93], ["right", "ANATOMY_MODIFIER", 31, 36]]], ["The hole was cut to permit free rotation of the handpiece, yet allowed only minimal air to escape at the junction of the mask and handpiece.", [["The hole", "TREATMENT", 0, 8], ["the handpiece", "TREATMENT", 44, 57], ["handpiece", "TREATMENT", 130, 139], ["hole", "OBSERVATION_MODIFIER", 4, 8], ["minimal", "OBSERVATION_MODIFIER", 76, 83], ["air", "OBSERVATION", 84, 87], ["mask", "ANATOMY", 121, 125]]], ["The pump was connected to a sterilized 0.22 \u03bcm millipore filter mounted in an ethylene oxide sterilized 37-mm cassette with support pad.", [["ethylene oxide", "CHEMICAL", 78, 92], ["ethylene oxide", "CHEMICAL", 78, 92], ["ethylene oxide", "SIMPLE_CHEMICAL", 78, 92], ["pad", "ORGANISM_SUBDIVISION", 132, 135], ["The pump", "TREATMENT", 0, 8], ["a sterilized 0.22 \u03bcm millipore filter", "TREATMENT", 26, 63], ["an ethylene oxide sterilized", "TREATMENT", 75, 103], ["support pad", "TREATMENT", 124, 135]]], ["Pump intake was calibrated at 4 mL per minute to simulate the average normal adult breathing flow rate.", [["Pump intake", "TREATMENT", 0, 11], ["adult", "OBSERVATION_MODIFIER", 77, 82], ["breathing flow", "OBSERVATION", 83, 97]]], ["Two control samples were collected at the head of the dental chair in the same room that was used to debond the patient.Material and MethodsThe brackets were removed from the teeth with standard orthodontic debonding pliers.", [["samples", "ANATOMY", 12, 19], ["head", "ANATOMY", 42, 46], ["teeth", "ANATOMY", 175, 180], ["head", "ORGANISM_SUBDIVISION", 42, 46], ["patient", "ORGANISM", 112, 119], ["teeth", "ORGAN", 175, 180], ["patient", "SPECIES", 112, 119], ["Two control samples", "TEST", 0, 19], ["The brackets", "TREATMENT", 140, 152], ["standard orthodontic debonding pliers", "TREATMENT", 186, 223], ["brackets", "OBSERVATION", 144, 152], ["teeth", "ANATOMY", 175, 180]]], ["The patient was not permitted to rinse but could expectorate after the brackets were removed.Material and MethodsThe resuscitation mask contacted the subject's face lightly and was kept in position by the investigator (Fig 2).Material and MethodsThe sampler was activated, and the remaining bonding resin was removed from the patient's teeth by using the high-speed handpiece operating at 30,000 rpm without suction or water coolant.", [["teeth", "ANATOMY", 336, 341], ["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 326, 333], ["teeth", "ORGAN", 336, 341], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 326, 333], ["the brackets", "TREATMENT", 67, 79], ["The resuscitation mask", "TREATMENT", 113, 135], ["The sampler", "TREATMENT", 246, 257], ["the remaining bonding resin", "TREATMENT", 277, 304], ["the high-speed handpiece operating", "TREATMENT", 351, 385], ["suction or water coolant", "TREATMENT", 408, 432], ["resuscitation mask", "OBSERVATION", 117, 135], ["bonding resin", "OBSERVATION", 291, 304]]], ["A spiral fluted carbide finishing bur (FG #7901; SS White Burs, Inc, Lakewood, NJ) was used for all debonding procedures.", [["carbide", "CHEMICAL", 16, 23], ["A spiral fluted carbide finishing bur", "TREATMENT", 0, 37], ["SS White Burs", "TREATMENT", 49, 62], ["Inc, Lakewood, NJ)", "TREATMENT", 64, 82], ["all debonding procedures", "TREATMENT", 96, 120]]], ["The patient was instructed to remain silent during the entire procedure.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["the entire procedure", "TREATMENT", 51, 71]]], ["The sampler was turned off as soon as bonding resin removal was completed.", [["The sampler", "TREATMENT", 0, 11], ["bonding resin removal", "TREATMENT", 38, 59]]], ["The total time of sampler operation was recorded.Material and MethodsThe patient was asked to remain still for 10 minutes.", [["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["sampler operation", "TREATMENT", 18, 35], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["The cassettes were sealed and transported to an off-site oral microbiologic laboratory.", [["oral", "ANATOMY", 57, 61], ["oral", "ORGANISM_SUBDIVISION", 57, 61], ["The cassettes", "TREATMENT", 0, 13]]], ["Each cassette was opened in the laboratory within 5 hours in a contained, aerobic chamber.", [["Each cassette", "TREATMENT", 0, 13], ["aerobic chamber", "OBSERVATION", 74, 89]]], ["Each filter was placed on a blood agar plate.", [["blood", "ANATOMY", 28, 33], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["Each filter", "TREATMENT", 0, 11], ["a blood agar plate", "TREATMENT", 26, 44], ["filter", "OBSERVATION", 5, 11]]], ["The plates were inverted and aerobically incubated at 35\u00b0C for 4 days.", [["The plates", "TREATMENT", 0, 10]]], ["The colonies were then identified by an oral microbiologist, aerobically incubated for another 2 to 4 days, and assessed with dark-field microscopy for determination of morphotype and bright-field microscopy to observe gram-stained smears.", [["colonies", "ANATOMY", 4, 12], ["oral", "ANATOMY", 40, 44], ["oral", "ORGANISM_SUBDIVISION", 40, 44], ["dark-field microscopy", "TEST", 126, 147], ["morphotype", "PROBLEM", 169, 179], ["bright-field microscopy", "TEST", 184, 207], ["gram-stained smears", "TEST", 219, 238], ["colonies", "OBSERVATION", 4, 12]]], ["Growth viability of the colonies was then determined.", [["colonies", "ANATOMY", 24, 32]]], ["Microorganisms were identified and compared with the control sample to determine genus and species.Material and MethodsThe first 11 samples were collected with the industry-approved technique for particulate sampling.", [["samples", "ANATOMY", 132, 139], ["Microorganisms", "PROBLEM", 0, 14], ["the control sample", "TEST", 49, 67], ["particulate sampling", "TEST", 196, 216]]], ["This method used a 37-mm metallic cyclone (aluminum funnel) connected via a vinyl hose leading to an autoclaved 0.22-\u03bcm filter mounted in factory-sterilized plastic cassettes.", [["aluminum", "CHEMICAL", 43, 51], ["aluminum", "CHEMICAL", 43, 51], ["vinyl", "CHEMICAL", 76, 81], ["factory-sterilized plastic cassettes", "DNA", 138, 174], ["a 37-mm metallic cyclone (aluminum funnel)", "TREATMENT", 17, 59], ["a vinyl hose", "TREATMENT", 74, 86], ["an autoclaved 0.22-\u03bcm filter", "TREATMENT", 98, 126]]], ["These filters allowed only bacteria of 0.22-\u03bcm diameter or less to be retained for future culture and assay.", [["These filters", "TEST", 0, 13], ["bacteria", "PROBLEM", 27, 35], ["future culture", "TEST", 83, 97], ["assay", "TEST", 102, 107], ["bacteria", "OBSERVATION_MODIFIER", 27, 35]]], ["It was difficult to determine whether the samples were contaminated because the autoclaved filter and cassettes, which were assembled before sampling by the investigator using a dental mask and gloved hands, became contaminated during handling.", [["samples", "ANATOMY", 42, 49], ["the samples", "TEST", 38, 49], ["the autoclaved filter and cassettes", "TREATMENT", 76, 111], ["a dental mask", "TREATMENT", 176, 189], ["contaminated", "OBSERVATION", 215, 227]]], ["The cassettes could not be autoclaved without perishing because they could not tolerate the heat and pressure of the autoclave.Material and MethodsThe rest of the samples were then collected by using cassettes with 0.22-\u03bcm filters that were placed into the cassettes before ethylene oxide sterilization.", [["samples", "ANATOMY", 163, 170], ["ethylene oxide", "CHEMICAL", 274, 288], ["ethylene oxide", "CHEMICAL", 274, 288], ["ethylene oxide", "SIMPLE_CHEMICAL", 274, 288], ["The cassettes", "TREATMENT", 0, 13], ["perishing", "TREATMENT", 46, 55], ["pressure of the autoclave", "TREATMENT", 101, 126], ["0.22-\u03bcm filters", "TREATMENT", 215, 230], ["ethylene oxide sterilization", "TREATMENT", 274, 302], ["oxide sterilization", "OBSERVATION", 283, 302]]], ["This was accomplished by arrangement with a hospital facility to ensure full sterilization.", [["full sterilization", "TREATMENT", 72, 90], ["full sterilization", "OBSERVATION", 72, 90]]], ["Sterilized rubber tubing replaced the vinyl tubing.", [["vinyl", "CHEMICAL", 38, 43], ["Sterilized rubber tubing", "TREATMENT", 0, 24], ["the vinyl tubing", "TREATMENT", 34, 50], ["rubber tubing", "OBSERVATION", 11, 24], ["vinyl tubing", "OBSERVATION", 38, 50]]], ["Additionally, the collection cyclone was replaced by a modified vinyl resuscitation mask that was disinfected by thorough washing in antibacterial soap.", [["vinyl", "CHEMICAL", 64, 69], ["vinyl", "SIMPLE_CHEMICAL", 64, 69], ["a modified vinyl resuscitation mask", "TREATMENT", 53, 88], ["antibacterial soap", "TREATMENT", 133, 151], ["collection", "OBSERVATION_MODIFIER", 18, 28], ["cyclone", "OBSERVATION_MODIFIER", 29, 36], ["resuscitation mask", "OBSERVATION", 70, 88]]], ["The flexible resuscitation mask effectively adapted to the patient's lower facial contours during debonding.Material and MethodsAfter it was established that the collection technique was effective in harvesting airborne microbes, 2 commonly used dental masks, Fluid Resistant Molded Face Mask (3M ESPE Dental Products, St Paul, Minn) and Allegiance Caliber Brand Instagard Face Mask (Allegiance Healthcare, McGaw Park, Ill), were tested for efficacy in preventing bacteria from operator inhalation (Fig 3).", [["facial", "ANATOMY", 75, 81], ["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["The flexible resuscitation mask", "TREATMENT", 0, 31], ["MethodsAfter", "TREATMENT", 121, 133], ["the collection technique", "TREATMENT", 158, 182], ["dental masks", "TREATMENT", 246, 258], ["Fluid Resistant Molded Face Mask", "TREATMENT", 260, 292], ["3M ESPE Dental Products", "TREATMENT", 294, 317], ["Allegiance Caliber Brand Instagard Face Mask", "TREATMENT", 338, 382], ["bacteria", "PROBLEM", 464, 472], ["flexible", "OBSERVATION_MODIFIER", 4, 12], ["resuscitation mask", "OBSERVATION", 13, 31], ["lower", "ANATOMY_MODIFIER", 69, 74], ["facial", "ANATOMY", 75, 81], ["Face Mask", "OBSERVATION", 283, 292], ["Caliber", "OBSERVATION_MODIFIER", 349, 356]]], ["Additionally, the industrial N-95 mask (MSA Affinity Plus, model #PL-200-2; Approved Gas Masks, Beltsville, Md) from a local hardware store, but also used by health care professionals treating severe acute respiratory syndrome and H5N1 avian influenza patients, was tested.", [["N-95", "CHEMICAL", 29, 33], ["acute respiratory syndrome", "DISEASE", 200, 226], ["H5N1 avian influenza", "DISEASE", 231, 251], ["patients", "ORGANISM", 252, 260], ["H5N1 avian influenza", "SPECIES", 231, 251], ["patients", "SPECIES", 252, 260], ["MSA Affinity", "TEST", 40, 52], ["model #PL", "TEST", 59, 68], ["a local hardware store", "TREATMENT", 117, 139], ["severe acute respiratory syndrome", "PROBLEM", 193, 226], ["H5N1 avian influenza patients", "PROBLEM", 231, 260], ["severe", "OBSERVATION_MODIFIER", 193, 199], ["acute", "OBSERVATION_MODIFIER", 200, 205], ["respiratory syndrome", "OBSERVATION", 206, 226]]], ["The mask tests were accomplished by the placement of a 37-mm diameter mask remnant over the collection filter in the cassette for use.", [["The mask tests", "TEST", 0, 14], ["a 37-mm diameter mask remnant", "TREATMENT", 53, 82], ["the collection filter", "TREATMENT", 88, 109], ["collection filter", "OBSERVATION", 92, 109]]], ["The assembly was then sterilized with ethylene oxide.", [["ethylene oxide", "CHEMICAL", 38, 52], ["ethylene oxide", "CHEMICAL", 38, 52], ["ethylene oxide", "SIMPLE_CHEMICAL", 38, 52], ["ethylene oxide", "TREATMENT", 38, 52]]], ["A different mask type was used for each of the 3 subjects.", [["A different mask type", "TREATMENT", 0, 21], ["different", "OBSERVATION_MODIFIER", 2, 11], ["mask type", "OBSERVATION", 12, 21]]], ["Sampling was then conducted as listed above, by using a split-mouth design as follows.Material and MethodsAll bands and bonds were removed with pliers.", [["Sampling", "TEST", 0, 8], ["Material", "TREATMENT", 86, 94], ["MethodsAll bands and bonds", "TREATMENT", 99, 125], ["pliers", "TREATMENT", 144, 150]]], ["Half of the subject's mouth (right or left side, both maxillary and mandibular teeth) was then sampled during removal of bonding resin as previously described, by using the sterilized cassette (without mask remnant) prepared with the identical filter assembly as described above.Material and MethodsThe first cassette was then removed, and a second sterilized cassette was attached to the mask and pump.", [["mouth", "ANATOMY", 22, 27], ["right", "ANATOMY", 29, 34], ["left side", "ANATOMY", 38, 47], ["maxillary", "ANATOMY", 54, 63], ["mandibular teeth", "ANATOMY", 68, 84], ["mouth", "ORGAN", 22, 27], ["right", "ORGANISM_SUBDIVISION", 29, 34], ["maxillary", "ORGAN", 54, 63], ["teeth", "ORGAN", 79, 84], ["sterilized cassette", "DNA", 173, 192], ["sterilized cassette", "DNA", 349, 368], ["removal of bonding resin", "TREATMENT", 110, 134], ["the sterilized cassette", "TREATMENT", 169, 192], ["mask remnant", "TREATMENT", 202, 214], ["the identical filter assembly", "TREATMENT", 230, 259], ["a second sterilized cassette", "TREATMENT", 340, 368], ["the mask", "TREATMENT", 385, 393], ["pump", "TREATMENT", 398, 402], ["mouth", "ANATOMY", 22, 27], ["right", "ANATOMY_MODIFIER", 29, 34], ["left", "ANATOMY_MODIFIER", 38, 42], ["both", "ANATOMY_MODIFIER", 49, 53], ["maxillary", "ANATOMY", 54, 63], ["mandibular teeth", "ANATOMY", 68, 84], ["filter", "OBSERVATION", 244, 250]]], ["This cassette contained 1 of the 3 commercial dental masks placed at the intake port of the cassette lumen so that incoming air passed through the mask material and then to the filter via the suction generated by the pump.", [["lumen", "ANATOMY", 101, 106], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 101, 106], ["the 3 commercial dental masks", "TREATMENT", 29, 58], ["the cassette lumen", "TREATMENT", 88, 106], ["the mask material", "TREATMENT", 143, 160], ["the suction", "TREATMENT", 188, 199], ["the pump", "TREATMENT", 213, 221], ["cassette lumen", "OBSERVATION", 92, 106], ["air", "OBSERVATION", 124, 127], ["filter", "OBSERVATION", 177, 183], ["suction", "OBSERVATION", 192, 199]]], ["Bonding resin was then removed with the handpiece at the other side of the mouth.", [["mouth", "ANATOMY", 75, 80], ["mouth", "ORGANISM_SUBDIVISION", 75, 80], ["Bonding resin", "TREATMENT", 0, 13], ["the handpiece", "TREATMENT", 36, 49], ["mouth", "ANATOMY", 75, 80]]], ["This technique was intended to determine whether microbes were effectively trapped by the dental mask before reaching the sampling filter.Material and MethodsThe cassettes were then sent to the laboratory for study of growth viability under anaerobic conditions followed by inspection by the microbiologist to determine differences in quantity of bacteria colony formation with and without the mask material.Material and MethodsThe collected samples were cultured on the same day as collection.", [["colony", "ANATOMY", 356, 362], ["samples", "ANATOMY", 442, 449], ["This technique", "TREATMENT", 0, 14], ["the dental mask", "TREATMENT", 86, 101], ["the sampling filter", "TREATMENT", 118, 137], ["bacteria colony formation", "PROBLEM", 347, 372], ["the mask material", "TREATMENT", 390, 407], ["The collected samples", "TEST", 428, 449], ["bacteria colony formation", "OBSERVATION", 347, 372]]], ["Each filter was placed on a blood agar plate that was inverted and anaerobically incubated at 35\u00b0C for approximately 4 days.", [["blood", "ANATOMY", 28, 33], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["Each filter", "TREATMENT", 0, 11], ["a blood agar plate", "TREATMENT", 26, 44], ["filter", "OBSERVATION", 5, 11]]], ["The agar plates were then removed from the incubator for inspection.", [["The agar plates", "TREATMENT", 0, 15], ["inspection", "TEST", 57, 67], ["agar plates", "OBSERVATION", 4, 15]]], ["The filter was removed, and the colonies were identified by an oral microbiologist using a 2-times magnification lens.", [["colonies", "ANATOMY", 32, 40], ["oral", "ANATOMY", 63, 67], ["oral", "ORGANISM_SUBDIVISION", 63, 67], ["The filter", "TREATMENT", 0, 10], ["filter", "OBSERVATION", 4, 10]]], ["The total number of each species type was recorded as the number of colony-forming units.", [["colony", "ANATOMY", 68, 74], ["each species type", "PROBLEM", 20, 37], ["total", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16]]], ["The same procedure was repeated for all collected filters.", [["The same procedure", "TREATMENT", 0, 18], ["all collected filters", "TREATMENT", 36, 57]]], ["Each representative colony was subsequently cultured onto another agar plate and reincubated for another 2 to 4 days for further microbiologic identification with the following testing methods: dark-field microscopy, gram-stain microscopy, speciation via chemical identification method, and growth viability under aerobic conditions.", [["colony", "ANATOMY", 20, 26], ["another agar plate", "TEST", 58, 76], ["further microbiologic identification", "TEST", 121, 157], ["dark-field microscopy", "TEST", 194, 215], ["gram-stain microscopy", "TEST", 217, 238], ["chemical identification method", "TEST", 255, 285], ["colony", "OBSERVATION", 20, 26]]], ["These 4 techniques are summarized below.Material and MethodsIn dark-field microscopy, from a freshly grown 4-day culture, a single isolate was removed from the agar plate with a sterile loop and smeared onto a glass slide with 1 drop of distilled water.", [["culture", "TEST", 113, 120], ["a single isolate", "TREATMENT", 122, 138], ["the agar plate", "TREATMENT", 156, 170], ["a sterile loop", "TREATMENT", 176, 190], ["a glass slide", "TREATMENT", 208, 221]]], ["The slide was examined under a 1000-times dark-field microscope for bacterial morphotyping (eg, cocci, rod).", [["bacterial morphotyping", "PROBLEM", 68, 90], ["cocci", "PROBLEM", 96, 101], ["cocci", "OBSERVATION", 96, 101]]], ["All identifications were conducted by the same oral microbiologist.Material and MethodsIn the gram-stain microscopy, from a freshly grown 4-day culture, a single isolate was removed from the agar plate and smeared onto a glass slide for gram staining.", [["oral", "ANATOMY", 47, 51], ["oral", "ORGANISM_SUBDIVISION", 47, 51], ["the gram-stain microscopy", "TEST", 90, 115], ["culture", "TEST", 144, 151], ["a single isolate", "TREATMENT", 153, 169], ["the agar plate", "TEST", 187, 201], ["gram staining", "TEST", 237, 250]]], ["After the sample was dried, the cells were fixed and stained with crystal violet basic dye for 1 minute.", [["sample", "ANATOMY", 10, 16], ["cells", "ANATOMY", 32, 37], ["cells", "CELL", 32, 37], ["the cells", "TREATMENT", 28, 37], ["crystal violet basic dye", "TREATMENT", 66, 90]]], ["This dye is absorbed by all bacteria in a similar manner.", [["all bacteria", "PROBLEM", 24, 36], ["absorbed", "OBSERVATION_MODIFIER", 12, 20]]], ["The slides were then treated for an additional minute with a mordant (I2-KI mixture) to fix the stain, washed briefly with 95% alcohol for 10 seconds to destain the sample, and then counterstained with a paler dye of different color (safranin) for 30 seconds.", [["sample", "ANATOMY", 165, 171], ["alcohol", "CHEMICAL", 127, 134], ["safranin", "CHEMICAL", 234, 242], ["alcohol", "CHEMICAL", 127, 134], ["alcohol", "SIMPLE_CHEMICAL", 127, 134], ["safranin", "SIMPLE_CHEMICAL", 234, 242], ["a mordant (I2-KI mixture", "TREATMENT", 59, 83], ["the stain", "TEST", 92, 101]]], ["Grampositive organisms retain the initial violet stain, but gramnegative organisms are decolorized by the organic solvent and thus display pink counterstain.", [["Grampositive organisms", "PROBLEM", 0, 22], ["the initial violet stain", "TEST", 30, 54], ["gramnegative organisms", "PROBLEM", 60, 82], ["pink counterstain", "OBSERVATION", 139, 156]]], ["All bacteria slides were then examined under the oil immersion lens for gross identification of the species.Material and MethodsFor growth viability under aerobic conditions, a single isolate was removed from the agar plate with a sterile loop and transferred onto another agar plate, which was then aerobically incubated at 35\u00b0C. Confirmation of growth was documented after 4 days of incubation.Material and MethodsIn the chemical identification method, from a freshly grown 4-day culture, a single isolate was removed from the agar plate with a sterile loop and transferred into growth broth and subjected to a 24-hour incubation period before chemical testing.", [["All bacteria slides", "PROBLEM", 0, 19], ["the oil immersion lens", "TREATMENT", 45, 67], ["the species", "PROBLEM", 96, 107], ["a single isolate", "TREATMENT", 175, 191], ["the agar plate", "TREATMENT", 209, 223], ["a sterile loop", "TREATMENT", 229, 243], ["another agar plate", "TREATMENT", 265, 283], ["incubation", "TREATMENT", 385, 395], ["a single isolate", "TREATMENT", 491, 507], ["a sterile loop", "TREATMENT", 545, 559], ["chemical testing", "TEST", 646, 662], ["bacteria", "OBSERVATION", 4, 12], ["growth", "OBSERVATION_MODIFIER", 347, 353]]], ["Each species was subjected to a panel of wells (MicroScan: Rapid Anaerobe ID Panel and MicroScan: Pos Combo Panel Type 12; DADE Behring, West Sacramento, Calif) to increase identification accuracy.", [["Rapid Anaerobe ID Panel", "TEST", 59, 82], ["MicroScan", "TEST", 87, 96]]], ["The sample was placed in each well, and the composite reaction of the sample generated a numeric code that was correlated to positive species identification.ResultsTwenty-three patients were sampled (age range, 13\u201366 years) with the new collection method.", [["sample", "ANATOMY", 4, 10], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185], ["The sample", "TREATMENT", 0, 10], ["the composite reaction", "PROBLEM", 40, 62], ["positive species identification", "PROBLEM", 125, 156], ["the new collection method", "TREATMENT", 229, 254], ["new", "OBSERVATION_MODIFIER", 233, 236], ["collection", "OBSERVATION", 237, 247]]], ["Table Isummarizes their ages, number of brackets removed, sample collection time, and bleeding indexes.", [["bleeding", "DISEASE", 86, 94], ["brackets", "TREATMENT", 40, 48], ["sample collection time", "TEST", 58, 80], ["bleeding indexes", "PROBLEM", 86, 102], ["brackets removed", "OBSERVATION", 40, 56], ["bleeding indexes", "OBSERVATION", 86, 102]]], ["The average age was 25.62 years, and the average number of bonds removed was 13.22 per patient.", [["patient", "ORGANISM", 87, 94], ["patient", "SPECIES", 87, 94]]], ["Total bonds removed were 304.", [["Total bonds", "TEST", 0, 11]]], ["Table IIlists the aerosolized bacterial colonies collected from each patient.ResultsTwo ethylene-oxide sterilized cassettes (numbers 25 and 26) that served as controls operated under pump intake.", [["colonies", "ANATOMY", 40, 48], ["ethylene-oxide", "CHEMICAL", 88, 102], ["ethylene-oxide", "CHEMICAL", 88, 102], ["patient", "ORGANISM", 69, 76], ["ethylene-oxide", "SIMPLE_CHEMICAL", 88, 102], ["aerosolized bacterial colonies", "CELL_LINE", 18, 48], ["patient", "SPECIES", 69, 76], ["the aerosolized bacterial colonies", "PROBLEM", 14, 48], ["Two ethylene-oxide sterilized cassettes", "TREATMENT", 84, 123], ["aerosolized", "OBSERVATION_MODIFIER", 18, 29], ["bacterial colonies", "OBSERVATION", 30, 48]]], ["Cassette 25 was exposed to the debanding room (operatory) ambient air only, and cassette 26 was attached to the resuscitation mask and worn in the operatory by the investigator to detect exhaled microbes.", [["cassette 26", "DNA", 80, 91], ["the resuscitation mask", "TREATMENT", 108, 130]]], ["These cassettes were subjected to the same processes as all other cassettes and had no bacterial growth.ResultsThe 2 commercially marketed dental masks tested offered no protection from aerosolized bacteria liberated during orthodontic debonding.", [["These cassettes", "TREATMENT", 0, 15], ["bacterial growth", "PROBLEM", 87, 103], ["dental masks", "TREATMENT", 139, 151], ["aerosolized bacteria", "PROBLEM", 186, 206], ["orthodontic debonding", "PROBLEM", 224, 245]]], ["The control cassettes and the experimental cassettes were indistinguishable in terms of bacterial colony growth, with abundant colonization on each agar plate (Fig 4).ResultsThe industrial mask, however, prevented contamination and colonization of the plates, demonstrating effective protection from at least aerosolized oral bacteria (Fig 5).DiscussionOral bacteria and pathogens have been implicated as potential sources of systemic infections.", [["colony", "ANATOMY", 98, 104], ["oral", "ANATOMY", 321, 325], ["systemic infections", "DISEASE", 426, 445], ["oral", "ORGANISM_SUBDIVISION", 321, 325], ["control cassettes", "DNA", 4, 21], ["The control cassettes", "TREATMENT", 0, 21], ["the experimental cassettes", "TREATMENT", 26, 52], ["bacterial colony growth", "PROBLEM", 88, 111], ["abundant colonization", "PROBLEM", 118, 139], ["The industrial mask", "TREATMENT", 174, 193], ["contamination", "PROBLEM", 214, 227], ["colonization of the plates", "TREATMENT", 232, 258], ["effective protection", "TREATMENT", 274, 294], ["aerosolized oral bacteria", "PROBLEM", 309, 334], ["DiscussionOral bacteria", "PROBLEM", 343, 366], ["pathogens", "PROBLEM", 371, 380], ["systemic infections", "PROBLEM", 426, 445], ["bacterial colony growth", "OBSERVATION", 88, 111], ["abundant", "OBSERVATION_MODIFIER", 118, 126], ["colonization", "OBSERVATION", 127, 139], ["industrial mask", "OBSERVATION", 178, 193], ["systemic", "OBSERVATION_MODIFIER", 426, 434], ["infections", "OBSERVATION", 435, 445]]], ["Improved methodology in collection of oral microbiota liberated during debonding procedures is needed to assess risks to both patients and clinicians.", [["oral", "ANATOMY", 38, 42], ["oral", "ORGANISM_SUBDIVISION", 38, 42], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["debonding procedures", "TREATMENT", 71, 91]]], ["This investigation has shown that our sampling technique was effective and useful in collection of aerosolized bacteria.DiscussionWith the sampling method described here, comparison of the control cassettes to the debond cassettes disclosed significant aerosolization of oral and pharyngeal bacteria.", [["oral", "ANATOMY", 271, 275], ["pharyngeal bacteria", "ANATOMY", 280, 299], ["oral", "ORGANISM_SUBDIVISION", 271, 275], ["control cassettes", "DNA", 189, 206], ["debond cassettes", "DNA", 214, 230], ["This investigation", "TEST", 0, 18], ["our sampling technique", "TEST", 34, 56], ["aerosolized bacteria", "PROBLEM", 99, 119], ["significant aerosolization of oral and pharyngeal bacteria", "PROBLEM", 241, 299], ["aerosolized bacteria", "OBSERVATION", 99, 119], ["significant", "OBSERVATION_MODIFIER", 241, 252], ["aerosolization", "OBSERVATION", 253, 267], ["pharyngeal bacteria", "ANATOMY", 280, 299]]], ["This finding agrees with Toroglu et al32 and Ireland et al31 In our investigation, the duration of the postdebonding bacterial cloud was not determined.", [["our investigation", "TEST", 64, 81], ["the postdebonding bacterial cloud", "PROBLEM", 99, 132], ["bacterial cloud", "OBSERVATION", 117, 132]]], ["Greco and Greene,30 however, demonstrated that the particulate cloud persisted for more than 10 minutes after debonding, increasing the risks to clinician and patient.", [["patient", "ORGANISM", 159, 166], ["patient", "SPECIES", 159, 166], ["particulate", "OBSERVATION_MODIFIER", 51, 62], ["cloud", "OBSERVATION", 63, 68]]], ["Although many species collected were nonpathogenic in situ, bacterial seeding of systems such as the respiratory tract and eyes can be pathogenic due to endotoxin production or compromised host defense.DiscussionBecause of the numerous species in the oral and pharyngeal flora, relatively few species were identified.", [["respiratory tract", "ANATOMY", 101, 118], ["eyes", "ANATOMY", 123, 127], ["oral", "ANATOMY", 251, 255], ["pharyngeal flora", "ANATOMY", 260, 276], ["endotoxin", "CHEMICAL", 153, 162], ["respiratory tract", "ORGANISM_SUBDIVISION", 101, 118], ["eyes", "ORGAN", 123, 127], ["endotoxin", "GENE_OR_GENE_PRODUCT", 153, 162], ["oral", "ORGANISM_SUBDIVISION", 251, 255], ["pharyngeal flora", "MULTI-TISSUE_STRUCTURE", 260, 276], ["many species", "PROBLEM", 9, 21], ["nonpathogenic", "PROBLEM", 37, 50], ["bacterial seeding of systems", "PROBLEM", 60, 88], ["the respiratory tract", "PROBLEM", 97, 118], ["pathogenic", "PROBLEM", 135, 145], ["endotoxin production", "PROBLEM", 153, 173], ["compromised host defense", "PROBLEM", 177, 201], ["the numerous species in the oral and pharyngeal flora", "PROBLEM", 223, 276], ["relatively few species", "PROBLEM", 278, 300], ["bacterial seeding", "OBSERVATION", 60, 77], ["respiratory tract", "ANATOMY", 101, 118], ["eyes", "ANATOMY", 123, 127], ["host defense", "OBSERVATION", 189, 201], ["numerous", "OBSERVATION_MODIFIER", 227, 235], ["species", "OBSERVATION", 236, 243], ["pharyngeal flora", "ANATOMY", 260, 276]]], ["However, identification was conducted in a clinical oral microbiologic laboratory that is used to target periodontal pathogens, and thus identification techniques for many other pathogens were unavailable.", [["oral", "ANATOMY", 52, 56], ["periodontal", "ANATOMY", 105, 116], ["oral", "ORGANISM_SUBDIVISION", 52, 56], ["target periodontal pathogens", "PROBLEM", 98, 126], ["identification techniques", "TEST", 137, 162], ["many other pathogens", "PROBLEM", 167, 187]]], ["It is logical to assume that additional species of bacteria, viruses, and other microbes were aerosolized but unidentified.DiscussionSeveral potentially pathogenic species aerosolized and isolated in this study were33: Propionibacterium acnes: causes uveitis and endophthalmitis; Actinomyces viscosus: 1 of several species causing actinomycosis, which involves chronic granulomatous lesions of the thoracic cavity; Streptococcus mitis: associated with subacute bacterial endocarditis; S cohnii-cohnii: causes ophthalmia; and other staphylococcus species that cause many human infections.DiscussionThe wide age range of the subjects (13-66 years; mean, 25.62 years) might be related to the variation of bacterial florae identified in this study.", [["actinomycosis", "ANATOMY", 331, 344], ["granulomatous lesions", "ANATOMY", 369, 390], ["thoracic cavity", "ANATOMY", 398, 413], ["Propionibacterium acnes", "DISEASE", 219, 242], ["uveitis", "DISEASE", 251, 258], ["endophthalmitis", "DISEASE", 263, 278], ["Actinomyces viscosus", "DISEASE", 280, 300], ["actinomycosis", "DISEASE", 331, 344], ["granulomatous lesions of the thoracic cavity", "DISEASE", 369, 413], ["Streptococcus mitis", "DISEASE", 415, 434], ["bacterial endocarditis", "DISEASE", 461, 483], ["ophthalmia", "DISEASE", 509, 519], ["staphylococcus species", "DISEASE", 531, 553], ["infections", "DISEASE", 576, 586], ["Propionibacterium acnes", "ORGANISM", 219, 242], ["Actinomyces viscosus", "ORGANISM", 280, 300], ["actinomycosis", "PATHOLOGICAL_FORMATION", 331, 344], ["granulomatous lesions", "PATHOLOGICAL_FORMATION", 369, 390], ["thoracic cavity", "ORGAN", 398, 413], ["Streptococcus mitis", "ORGANISM", 415, 434], ["human", "ORGANISM", 570, 575], ["Propionibacterium acnes", "SPECIES", 219, 242], ["Actinomyces viscosus", "SPECIES", 280, 300], ["Streptococcus mitis", "SPECIES", 415, 434], ["S cohnii-cohnii", "SPECIES", 485, 500], ["human", "SPECIES", 570, 575], ["Propionibacterium acnes", "SPECIES", 219, 242], ["Actinomyces viscosus", "SPECIES", 280, 300], ["Streptococcus mitis", "SPECIES", 415, 434], ["S cohnii-cohnii", "SPECIES", 485, 500], ["human", "SPECIES", 570, 575], ["bacteria", "PROBLEM", 51, 59], ["viruses", "PROBLEM", 61, 68], ["pathogenic species aerosolized", "PROBLEM", 153, 183], ["this study", "TEST", 200, 210], ["Propionibacterium acnes", "PROBLEM", 219, 242], ["uveitis", "PROBLEM", 251, 258], ["endophthalmitis", "PROBLEM", 263, 278], ["Actinomyces viscosus", "PROBLEM", 280, 300], ["several species", "PROBLEM", 307, 322], ["actinomycosis", "PROBLEM", 331, 344], ["chronic granulomatous lesions of the thoracic cavity", "PROBLEM", 361, 413], ["Streptococcus mitis", "PROBLEM", 415, 434], ["subacute bacterial endocarditis", "PROBLEM", 452, 483], ["ophthalmia", "PROBLEM", 509, 519], ["other staphylococcus species", "PROBLEM", 525, 553], ["many human infections", "PROBLEM", 565, 586], ["bacterial florae", "PROBLEM", 702, 718], ["this study", "TEST", 733, 743], ["bacteria", "OBSERVATION", 51, 59], ["aerosolized", "OBSERVATION", 94, 105], ["uveitis", "OBSERVATION", 251, 258], ["endophthalmitis", "OBSERVATION", 263, 278], ["actinomycosis", "OBSERVATION", 331, 344], ["chronic", "OBSERVATION_MODIFIER", 361, 368], ["granulomatous", "OBSERVATION_MODIFIER", 369, 382], ["lesions", "OBSERVATION", 383, 390], ["thoracic cavity", "ANATOMY", 398, 413], ["Streptococcus mitis", "OBSERVATION", 415, 434], ["subacute", "OBSERVATION_MODIFIER", 452, 460], ["bacterial", "OBSERVATION_MODIFIER", 461, 470], ["endocarditis", "OBSERVATION", 471, 483], ["ophthalmia", "OBSERVATION", 509, 519], ["staphylococcus species", "OBSERVATION", 531, 553], ["infections", "OBSERVATION", 576, 586], ["bacterial florae", "OBSERVATION", 702, 718]]], ["Classification of mask efficacy is with particle filtration efficiency (PFE) or bacterial filtration efficiency (BFE).", [["mask efficacy", "TREATMENT", 18, 31], ["particle filtration efficiency", "PROBLEM", 40, 70], ["bacterial filtration efficiency", "PROBLEM", 80, 111], ["mask efficacy", "OBSERVATION", 18, 31], ["particle", "OBSERVATION_MODIFIER", 40, 48], ["filtration efficiency", "OBSERVATION", 49, 70], ["bacterial", "OBSERVATION_MODIFIER", 80, 89], ["filtration efficiency", "OBSERVATION", 90, 111]]], ["PFE ratings refer to the mask's ability to trap particles with a fixed nonviable particle size of 0.1 to 1.0 \u03bcm.", [["PFE ratings", "TEST", 0, 11], ["a fixed nonviable particle size", "TEST", 63, 94], ["particle", "OBSERVATION_MODIFIER", 81, 89], ["size", "OBSERVATION_MODIFIER", 90, 94]]], ["BFE ratings are correlated to the mask's ability to trap viable particles of 1 to 5 \u03bcm.", [["BFE", "SIMPLE_CHEMICAL", 0, 3], ["the mask", "TREATMENT", 30, 38]]], ["The catalogs of 2 large dental supply companies showed 61 and 70 different clinical masks.", [["large", "OBSERVATION_MODIFIER", 18, 23]]], ["Other dental supply catalogs list masks predominantly by BFE.", [["BFE", "PROTEIN", 57, 60]]], ["It is doubtful whether many dental practitioners are aware of PFE and BFE ratings as measures of mask efficacy.", [["PFE", "PROBLEM", 62, 65], ["mask efficacy", "TREATMENT", 97, 110]]], ["The masks in this study were those used in the principal investigator's office, because of familiarity with the manufacturer's name and advice of supply representatives.", [["this study", "TEST", 13, 23]]], ["Based on our results, masks with PFE or BFE of at least that of the N-95 are advisable (95% filtration rate at 0.3 \u03bcm).", [["N-95", "CHEMICAL", 68, 72], ["PFE", "SIMPLE_CHEMICAL", 33, 36], ["N-95", "SIMPLE_CHEMICAL", 68, 72], ["PFE", "TEST", 33, 36], ["filtration rate", "TEST", 92, 107]]], ["PFE and BFE ratings and the efficacy values we determined are independent of mask adaptation.", [["PFE", "TEST", 0, 3], ["BFE ratings", "TEST", 8, 19]]], ["Facial hair and the adaptation of the mask to the operator's face also affect protection levels.34 Finally, mask users must be aware that viruses are significantly smaller than 0.1 to 5.0 \u03bcm and are commonly aerosolized.26 Thus, clinicians should consider the use of high-speed suction during all debonding procedures, but reduction of aerosolized viruses by high-speed suction has yet to be verified.ConclusionsA new method of bacterial sampling was introduced to collect aerosol generated during orthodontic debonding procedures and will be used in future studies of airborne aerosols.", [["Facial hair", "ANATOMY", 0, 11], ["Facial hair", "MULTI-TISSUE_STRUCTURE", 0, 11], ["the mask", "TREATMENT", 34, 42], ["viruses", "PROBLEM", 138, 145], ["high-speed suction", "TREATMENT", 267, 285], ["all debonding procedures", "TREATMENT", 293, 317], ["aerosolized viruses", "PROBLEM", 336, 355], ["high-speed suction", "TREATMENT", 359, 377], ["A new method of bacterial sampling", "TREATMENT", 412, 446], ["aerosol", "TREATMENT", 473, 480], ["orthodontic debonding procedures", "TREATMENT", 498, 530], ["hair", "ANATOMY", 7, 11], ["significantly", "OBSERVATION_MODIFIER", 150, 163], ["smaller", "OBSERVATION_MODIFIER", 164, 171], ["aerosolized", "OBSERVATION", 208, 219], ["aerosolized viruses", "OBSERVATION", 336, 355], ["new", "OBSERVATION_MODIFIER", 414, 417]]], ["The diameters of the bacterial species collected by this technique are sufficiently small to be inhaled and deposited in the alveolar spaces of patients and clinicians.", [["alveolar", "ANATOMY", 125, 133], ["alveolar", "MULTI-TISSUE_STRUCTURE", 125, 133], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["the bacterial species", "PROBLEM", 17, 38], ["this technique", "TEST", 52, 66], ["diameters", "OBSERVATION_MODIFIER", 4, 13], ["bacterial species", "OBSERVATION", 21, 38], ["small", "OBSERVATION_MODIFIER", 84, 89], ["inhaled", "OBSERVATION", 96, 103], ["alveolar", "ANATOMY_MODIFIER", 125, 133]]], ["In a pilot study of 2 brands of commonly used dental masks, the clinician remained unprotected from aerosolized bacteria because of the mask pore size exceeded the bacterial diameter.", [["pore", "ANATOMY", 141, 145], ["a pilot study", "TEST", 3, 16], ["dental masks", "TREATMENT", 46, 58], ["aerosolized bacteria", "PROBLEM", 100, 120], ["the mask pore size", "TREATMENT", 132, 150], ["size", "OBSERVATION_MODIFIER", 146, 150], ["bacterial diameter", "OBSERVATION", 164, 182]]], ["An industrial mask was effective in preventing transmission of aerosolized bacteria.", [["An industrial mask", "TREATMENT", 0, 18], ["aerosolized bacteria", "PROBLEM", 63, 83], ["industrial mask", "OBSERVATION", 3, 18], ["aerosolized bacteria", "OBSERVATION", 63, 83]]], ["Clinicians should choose a protective mask with the most efficient PFE and BFE rating and the best facial adaptation possible.", [["facial", "ANATOMY", 99, 105], ["a protective mask", "TREATMENT", 25, 42], ["BFE rating", "TEST", 75, 85]]], ["Further mask efficacy study is ongoing.ConclusionsWe thank Lillian Wu for her assistance in culturing the samples with timely, devoted expertise.", [["Further mask efficacy study", "TEST", 0, 27]]], ["Her skills were invaluable to the success of this investigation.", [["this investigation", "TEST", 45, 63]]]], "6a843ac62faa3323474aeee714e09cfc7ee9f8af": [["E Letters to the editorTo the Editor W e read with interest the recent article by Brown et al, 1 titled \"Barrier System for Airway Management of COVID-19 Patients\" which described the use of a plastic drape attached to a plastic bag as a protective measure during endotracheal intubation and extubation.", [["endotracheal", "ANATOMY", 264, 276], ["Airway", "MULTI-TISSUE_STRUCTURE", 124, 130], ["Patients", "ORGANISM", 154, 162], ["Patients", "SPECIES", 154, 162], ["Barrier System", "TREATMENT", 105, 119], ["Airway Management", "TREATMENT", 124, 141], ["a plastic drape", "TREATMENT", 191, 206], ["a plastic bag", "TREATMENT", 219, 232], ["a protective measure", "TREATMENT", 236, 256], ["endotracheal intubation", "TREATMENT", 264, 287], ["extubation", "TREATMENT", 292, 302], ["Airway", "ANATOMY", 124, 130], ["plastic bag", "OBSERVATION", 221, 232], ["endotracheal intubation", "OBSERVATION", 264, 287]]], ["We wish to commend the authors on developing this technique, which has a great benefit of containing and facilitating the disposal of contaminated surfaces surrounding the patient's airway at the end of the surgical case.E Letters to the editorBecause of its close geographical proximity to China, Taiwan had been on alert for Coronavirus Disease 2019 (COVID-19) as early as December 31, 2019.", [["airway", "ANATOMY", 182, 188], ["Coronavirus Disease", "DISEASE", 327, 346], ["patient", "ORGANISM", 172, 179], ["airway", "MULTI-TISSUE_STRUCTURE", 182, 188], ["patient", "SPECIES", 172, 179], ["E", "SPECIES", 221, 222], ["this technique", "TREATMENT", 45, 59], ["Coronavirus Disease", "PROBLEM", 327, 346], ["COVID", "TEST", 353, 358], ["airway", "ANATOMY", 182, 188]]], ["2 As more and more information was learned regarding the virulence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we used a plastic drape at our institution to protect anesthesia professionals during airway manipulation but made modifications to our technique as problems arose during proof of concept and real-world use.", [["airway", "ANATOMY", 218, 224], ["acute respiratory syndrome coronavirus", "DISEASE", 77, 115], ["airway", "MULTI-TISSUE_STRUCTURE", 218, 224], ["severe acute respiratory syndrome coronavirus", "SPECIES", 70, 115], ["SARS-CoV-2", "SPECIES", 119, 129], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 70, 115], ["a plastic drape", "TREATMENT", 140, 155], ["anesthesia professionals", "TREATMENT", 186, 210], ["airway manipulation", "TREATMENT", 218, 237], ["our technique", "TREATMENT", 264, 277], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["respiratory syndrome", "OBSERVATION", 83, 103], ["airway", "ANATOMY", 218, 224]]], ["We found that when intubation of the airway was challenging, manipulating the laryngoscope under a sheet proved to be problematic.", [["airway", "ANATOMY", 37, 43], ["airway", "MULTI-TISSUE_STRUCTURE", 37, 43], ["intubation", "TREATMENT", 19, 29], ["the laryngoscope", "TREATMENT", 74, 90], ["a sheet", "TREATMENT", 97, 104], ["airway", "ANATOMY", 37, 43]]], ["Although Brown et al 1 proposed the removal of the clear drape during midlaryngoscopy as an option should difficulties with intubation arise, elimination of the barrier sheet defeats its purpose of protecting the operating room staff, and may further aerosolize viral particles on and under the drape when it is removed in an emergent manner.E Letters to the editorTo facilitate intubation, we make the following adaptations to the plastic sheet.", [["E", "SPECIES", 342, 343], ["the removal", "TREATMENT", 32, 43], ["the clear drape", "TREATMENT", 47, 62], ["midlaryngoscopy", "TREATMENT", 70, 85], ["intubation", "TREATMENT", 124, 134], ["the barrier sheet", "TREATMENT", 157, 174], ["further aerosolize viral particles", "TREATMENT", 243, 277], ["the drape", "TREATMENT", 291, 300], ["intubation", "TREATMENT", 379, 389], ["clear drape", "OBSERVATION", 51, 62]]], ["We cut a small 3 \u00d7 3 cm cross in the drape with a surgical blade and reinforce the perimeter of the cross with tape so it does not widen over the course of the case (Figure, panel A).", [["a small 3 \u00d7 3 cm cross in the drape", "TREATMENT", 7, 42], ["a surgical blade", "TREATMENT", 48, 64], ["tape", "TREATMENT", 111, 115], ["small 3 \u00d7 3 cm", "OBSERVATION_MODIFIER", 9, 23], ["surgical blade", "OBSERVATION", 50, 64]]], ["The purpose of this first X is to connect the anesthesia breathing circuit to the oxygen facemask under the drape (Figure, panel B) .", [["oxygen", "CHEMICAL", 82, 88], ["oxygen", "CHEMICAL", 82, 88], ["oxygen", "SIMPLE_CHEMICAL", 82, 88], ["the anesthesia breathing circuit", "TREATMENT", 42, 74], ["the oxygen facemask", "TREATMENT", 78, 97], ["the drape", "TREATMENT", 104, 113]]], ["A second 2 \u00d7 2 cm cross is cut and reinforced in close proximity to the first ( Figure, panel A) .", [["A second 2 \u00d7 2 cm cross", "TREATMENT", 0, 23]]], ["The purpose of this second X is for passage of the videolaryngoscope, endotracheal tube, or Yankauer suction tip.E Letters to the editorAt our institution, we use the Trachway video light stylet (Markstein Sichtec Medical Corp., Taichung, Taiwan) as the preferred video-assisted intubating device (\u22485000 cases in 2019).", [["endotracheal tube", "ANATOMY", 70, 87], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 70, 87], ["E", "SPECIES", 113, 114], ["the videolaryngoscope", "TREATMENT", 47, 68], ["endotracheal tube", "TREATMENT", 70, 87], ["Yankauer suction tip", "TREATMENT", 92, 112], ["intubating device", "TREATMENT", 279, 296], ["endotracheal tube", "OBSERVATION", 70, 87]]], ["Because of its small profile, only a small X is needed to introduce the intubating device and endotracheal tube (Figure, panel C).", [["endotracheal tube", "TISSUE", 94, 111], ["the intubating device", "TREATMENT", 68, 89], ["endotracheal tube", "TREATMENT", 94, 111], ["small", "OBSERVATION_MODIFIER", 15, 20], ["profile", "OBSERVATION_MODIFIER", 21, 28], ["small", "OBSERVATION_MODIFIER", 37, 42], ["endotracheal tube", "OBSERVATION", 94, 111]]], ["When using the video stylet, we cover the second cross with a small transparent film dressing, making a small nick in the center of the dressing with a surgical blade.", [["the video stylet", "TREATMENT", 11, 27], ["a small transparent film dressing", "TREATMENT", 60, 93], ["the dressing", "TREATMENT", 132, 144], ["a surgical blade", "TREATMENT", 150, 166], ["small", "OBSERVATION_MODIFIER", 104, 109], ["nick", "OBSERVATION", 110, 114], ["dressing", "OBSERVATION", 136, 144], ["surgical blade", "OBSERVATION", 152, 166]]], ["As the stylet and endotracheal tube are introduced, the hole in the film will dilate in size to accommodate the endotracheal tube, while the elasticity of the dressing allows it to adhere around the tube, minimizing the defect in the plastic barrier.", [["endotracheal tube", "ANATOMY", 18, 35], ["endotracheal tube", "ANATOMY", 112, 129], ["tube", "ANATOMY", 199, 203], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 18, 35], ["endotracheal tube", "TISSUE", 112, 129], ["tube", "TISSUE", 199, 203], ["the stylet and endotracheal tube", "TREATMENT", 3, 35], ["the hole in the film", "TREATMENT", 52, 72], ["the endotracheal tube", "TREATMENT", 108, 129], ["the dressing", "TREATMENT", 155, 167], ["the tube", "TREATMENT", 195, 203], ["the defect", "PROBLEM", 216, 226], ["the plastic barrier", "TREATMENT", 230, 249], ["endotracheal tube", "OBSERVATION", 18, 35], ["hole", "OBSERVATION_MODIFIER", 56, 60], ["dilate", "OBSERVATION", 78, 84], ["size", "OBSERVATION_MODIFIER", 88, 92], ["endotracheal tube", "OBSERVATION", 112, 129], ["elasticity", "OBSERVATION_MODIFIER", 141, 151], ["dressing", "OBSERVATION", 159, 167], ["tube", "OBSERVATION", 199, 203], ["defect", "OBSERVATION", 220, 226], ["plastic barrier", "OBSERVATION", 234, 249]]], ["If a videolaryngoscope is utilized for intubation, the cross is widened to 3 \u00d7 3 cm to accommodate passage of both the disposable blade and the endotracheal tube.", [["endotracheal tube", "ANATOMY", 144, 161], ["endotracheal tube", "TISSUE", 144, 161], ["a videolaryngoscope", "TREATMENT", 3, 22], ["intubation", "TREATMENT", 39, 49], ["the disposable blade", "TREATMENT", 115, 135], ["the endotracheal tube", "TREATMENT", 140, 161], ["widened", "OBSERVATION_MODIFIER", 64, 71], ["disposable blade", "OBSERVATION", 119, 135], ["endotracheal tube", "OBSERVATION", 144, 161]]], ["A transparent dressing should not be utilized with videolaryngoscopy as the film's adhesive nature may interfere with the maneuvering of laryngoscope or endotracheal tube, but a dressing can be placed Adaptation to the Plastic Barrier Sheet to Facilitate Intubation During the COVID-19 Pandemic Figure.", [["endotracheal tube", "ANATOMY", 153, 170], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 153, 170], ["A transparent dressing", "TREATMENT", 0, 22], ["videolaryngoscopy", "TEST", 51, 68], ["the film", "TEST", 72, 80], ["laryngoscope", "TREATMENT", 137, 149], ["endotracheal tube", "TREATMENT", 153, 170], ["a dressing", "TREATMENT", 176, 186], ["Intubation", "TREATMENT", 255, 265], ["transparent", "OBSERVATION_MODIFIER", 2, 13], ["dressing", "OBSERVATION", 14, 22], ["endotracheal tube", "OBSERVATION", 153, 170]]], ["Adaptation to plastic sheet to facilitate endotracheal intubation.", [["endotracheal", "ANATOMY", 42, 54], ["endotracheal intubation", "TREATMENT", 42, 65], ["endotracheal intubation", "OBSERVATION", 42, 65]]], ["A, Two diagonal crosses are cut into the drape and reinforced with tape.", [["Two diagonal crosses", "TREATMENT", 3, 23], ["the drape", "TREATMENT", 37, 46], ["tape", "TREATMENT", 67, 71], ["drape", "OBSERVATION", 41, 46]]], ["B, First cross allows connection of breathing circuit to oxygen facemask.", [["oxygen", "CHEMICAL", 57, 63], ["oxygen", "CHEMICAL", 57, 63], ["oxygen", "SIMPLE_CHEMICAL", 57, 63], ["breathing circuit", "TREATMENT", 36, 53], ["oxygen facemask", "TREATMENT", 57, 72]]], ["C, Second cross allows introduction of video stylet and endotracheal tube.E Letters to the editorwww.anesthesia-analgesia.orgANesthesiA & ANALGesiALetters to the Editor over the X after successful intubation to reduce the size of the defect in the plastic sheet.", [["endotracheal tube", "ANATOMY", 56, 73], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 56, 73], ["E", "SPECIES", 74, 75], ["video stylet", "TREATMENT", 39, 51], ["endotracheal tube", "TREATMENT", 56, 73], ["anesthesia-analgesia.orgANesthesiA", "TREATMENT", 101, 135], ["ANALGesiALetters", "TREATMENT", 138, 154], ["successful intubation", "TREATMENT", 186, 207], ["the defect", "PROBLEM", 230, 240], ["endotracheal tube", "OBSERVATION", 56, 73], ["size", "OBSERVATION_MODIFIER", 222, 226], ["defect", "OBSERVATION", 234, 240], ["plastic sheet", "OBSERVATION", 248, 261]]], ["Typical airway maneuvers, such as jaw thrust by an assistant, can still be performed over the sheet.", [["airway", "ANATOMY", 8, 14], ["jaw", "ANATOMY", 34, 37], ["airway", "MULTI-TISSUE_STRUCTURE", 8, 14], ["jaw", "ORGANISM_SUBDIVISION", 34, 37], ["Typical airway maneuvers", "TREATMENT", 0, 24], ["airway", "ANATOMY", 8, 14], ["maneuvers", "OBSERVATION", 15, 24]]], ["If mask ventilation is needed after an initial laryngoscopy attempt, we can easily shift the plastic drape back over to the first cross to allow resumption of mask ventilation.ANesthesiA & ANALGesiAA benefit of utilizing a plastic sheet as the barrier device is that it is simple and inexpensive and can be constructed with existing materials in the hospital, such as a surgical drape or even a plastic trash bag.", [["mask ventilation", "TREATMENT", 3, 19], ["an initial laryngoscopy", "TEST", 36, 59], ["the plastic drape", "TREATMENT", 89, 106], ["mask ventilation", "TREATMENT", 159, 175], ["ANesthesiA", "TREATMENT", 176, 186], ["a plastic sheet", "TREATMENT", 221, 236], ["the barrier device", "TREATMENT", 240, 258], ["a surgical drape", "TREATMENT", 368, 384], ["a plastic trash bag", "TREATMENT", 393, 412], ["trash bag", "OBSERVATION", 403, 412]]], ["The use of a transparent acrylic intubation shield has been proposed and may afford improved visibility but would require construction of the device as well as disinfection of the unit after each use.", [["a transparent acrylic intubation shield", "TREATMENT", 11, 50], ["construction of the device", "TREATMENT", 122, 148], ["acrylic intubation", "OBSERVATION", 25, 43]]], ["3 In addition, patient anatomy may preclude effective manipulation of the airway through the 2 circular openings.", [["airway", "ANATOMY", 74, 80], ["patient", "ORGANISM", 15, 22], ["airway", "MULTI-TISSUE_STRUCTURE", 74, 80], ["patient", "SPECIES", 15, 22], ["may preclude", "UNCERTAINTY", 31, 43], ["airway", "ANATOMY", 74, 80], ["circular", "OBSERVATION_MODIFIER", 95, 103], ["openings", "OBSERVATION_MODIFIER", 104, 112]]], ["A potential negative aspect of our modified drape technique is the theoretical transmission of viral particles into the operating room through the defect in the barrier.", [["barrier", "TISSUE", 161, 168], ["our modified drape technique", "TREATMENT", 31, 59], ["viral particles", "TREATMENT", 95, 110], ["the defect", "PROBLEM", 143, 153], ["viral particles", "OBSERVATION", 95, 110], ["defect", "OBSERVATION", 147, 153]]], ["However, we feel that the risk of contamination is low, and our modified technique improves the success rate of the initial intubation attempt, especially when a difficult airway is encountered.", [["airway", "ANATOMY", 172, 178], ["airway", "MULTI-TISSUE_STRUCTURE", 172, 178], ["contamination", "PROBLEM", 34, 47], ["the initial intubation attempt", "TREATMENT", 112, 142], ["a difficult airway", "PROBLEM", 160, 178], ["contamination", "OBSERVATION", 34, 47], ["airway", "ANATOMY", 172, 178]]], ["If additional protection is desired, using 2 plastic drapes as a double layer can further reduce the risk of accidental transmission, as the Xs on both sheets would have to be aligned in order for aerosolization of viral particles to occur.ANesthesiA & ANALGesiAAlthough we have been carefully removing the drape after successful intubation, we feel that Brown et al 1 and other authors make an excellent point that the sheet can be left in place for the duration of surgery, and the patient can be subsequently extubated under the drape, shielding anesthesia providers and other operating room personnel when the endotracheal tube is removed.", [["endotracheal tube", "ANATOMY", 614, 631], ["patient", "ORGANISM", 484, 491], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 614, 631], ["patient", "SPECIES", 484, 491], ["2 plastic drapes", "TREATMENT", 43, 59], ["a double layer", "TREATMENT", 63, 77], ["accidental transmission", "TREATMENT", 109, 132], ["the Xs", "TEST", 137, 143], ["aerosolization of viral particles", "TREATMENT", 197, 230], ["ANesthesiA", "TREATMENT", 240, 250], ["the drape", "TREATMENT", 303, 312], ["successful intubation", "TREATMENT", 319, 340], ["Brown et al 1", "PROBLEM", 355, 368], ["the sheet", "TREATMENT", 416, 425], ["surgery", "TREATMENT", 467, 474], ["shielding anesthesia providers", "TREATMENT", 539, 569], ["the endotracheal tube", "TREATMENT", 610, 631], ["viral particles", "OBSERVATION", 215, 230], ["left", "OBSERVATION", 433, 437], ["endotracheal tube", "OBSERVATION", 614, 631]]], ["4 During these trying times, it is encouraging to see how health care professionals over the globe are readily sharing clinical insights, and we hope that our experiences with a simple modification to the barrier sheet method may help others improve their success rate of initial intubation while still providing protection to anesthesia professionals during the COVID-19 pandemic.", [["a simple modification", "TREATMENT", 176, 197], ["the barrier sheet method", "TREATMENT", 201, 225], ["initial intubation", "TREATMENT", 272, 290], ["anesthesia professionals", "TREATMENT", 327, 351], ["the COVID", "TEST", 359, 368]]]], "c85f571a674c7fed0ccb9176e9cf9f3d3659ca32": [["Main textOn December 31, 2019, the Health Commission in Wuhan, China, announced 27 cases of viral pneumonia.", [["viral pneumonia", "DISEASE", 92, 107], ["viral pneumonia", "PROBLEM", 92, 107], ["viral", "OBSERVATION_MODIFIER", 92, 97], ["pneumonia", "OBSERVATION", 98, 107]]], ["On January 8, 2020, the Chinese Center for Disease Control and Prevention announced that a novel coronavirus was the causative pathogen and was subsequently designated as 2019-nCoV.", [["coronavirus", "DISEASE", 97, 108], ["coronavirus", "ORGANISM", 97, 108], ["Disease Control", "TREATMENT", 43, 58], ["a novel coronavirus", "PROBLEM", 89, 108], ["the causative pathogen", "PROBLEM", 113, 135]]], ["Anxiety quickly grew in the general public after a preeminent Chinese epidemiologist, Dr Zhong Nanshan, confirmed human-to-human transmission in a televised interview in the evening of January 20, and three days later the entire city of Wuhan was put into quarantine: all public transportation was suspended, and outbound trains and flights were halted.", [["Anxiety", "DISEASE", 0, 7], ["human", "ORGANISM", 114, 119], ["human", "ORGANISM", 123, 128], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 123, 128], ["Anxiety", "PROBLEM", 0, 7]]], ["As of February 6, 2020, more than 28,000 cases of 2019-nCoV have been confirmed globally.Main textUsing the first 425 confirmed patients of 2019-nCoV in Wuhan, a previous report estimated that the epidemic doubled in size every 7.4 days.", [["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["globally", "OBSERVATION_MODIFIER", 80, 88], ["size", "OBSERVATION_MODIFIER", 217, 221]]], ["With a mean serial interval of 7.5 days, the basic reproduction number was estimated to be 2.2 (95% confidence interval [CI] , 1.4 -3.9) (Li et al., 2020) .", [["CI", "TEST", 121, 123]]], ["Using internationally exported cases from Wuhan (known days of symptom onset from December 25, 2019 to January 19, 2020) and flight travel data, another report estimated that the basic reproduction number is 2.7 (95% CrI, 2.5 -2.9) .", [["CrI", "TEST", 217, 220]]], ["Other analyses using the series of new confirmed cases have reported larger estimates of the basic reproduction number (Read et al., 2020; Zhao et al., 2020) .Dataset preparation and visualizationUsing information published by governments and news media, we constructed a dataset of 2019-nCoV patients that are confirmed outside mainland China as of February 4, 2020.", [["patients", "ORGANISM", 293, 301], ["patients", "SPECIES", 293, 301], ["Dataset preparation", "TREATMENT", 159, 178], ["visualization", "TEST", 183, 196], ["larger", "OBSERVATION_MODIFIER", 69, 75]]], ["We excluded patients who arrived in these countries and regions after January 23 or were reported to have exposure to 2019-nCoV outside Wuhan.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["For each cluster of cases (two cases are considered to belong to the same cluster if they had close contact outside Wuhan), we kept the first confirmed case and discarded the other cases as they were likely infected during their travel outside Wuhan.", [["infected", "OBSERVATION", 207, 215]]], ["After applying this selection criterion, we obtained a sample of 46 coronavirus cases who were most certainly exported from Wuhan.Dataset preparation and visualizationBased on the trajectories of these cases, we simulated the dates they were infected as follows.", [["coronavirus", "DISEASE", 68, 79], ["coronavirus", "ORGANISM", 68, 79], ["Dataset preparation", "TREATMENT", 130, 149], ["infected", "OBSERVATION", 242, 250]]], ["Among the 46 cases, one (18 th case in Singapore) has missing symptom onset dates.", [["missing symptom onset dates", "PROBLEM", 54, 81]]], ["We used the mice software package (van Buuren & Groothuis-Oudshoorn, 2011) to obtain 100 imputations of the missing symptom onset date.", [["mice", "ORGANISM", 12, 16], ["mice", "SPECIES", 12, 16], ["the mice software package", "TREATMENT", 8, 33]]], ["For each imputation of symptom onset, we simulated the infection time based on Gamma-distributed incubation period that are have the same mean (5.2 days) and 95th percentile (12.5 days) as previous estimates (Li et al., 2020) .", [["infection", "DISEASE", 55, 64], ["symptom", "PROBLEM", 23, 30], ["the infection time", "PROBLEM", 51, 69], ["infection", "OBSERVATION", 55, 64]]], ["We repeated the simulation until the infection time is consistent with the case's trajectory and known exposure to other confirmed cases.", [["infection", "DISEASE", 37, 46], ["the simulation", "TREATMENT", 12, 26], ["the infection", "PROBLEM", 33, 46], ["infection", "OBSERVATION", 37, 46], ["consistent with", "UNCERTAINTY", 55, 70]]], ["In particular, because infection must be prior to the patient's arrival if we assume all the cases were infected in Wuhan, this allows us to greatly narrow down the infection time.", [["infection", "DISEASE", 23, 32], ["infection", "DISEASE", 165, 174], ["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["infection", "PROBLEM", 23, 32], ["infection", "OBSERVATION", 23, 32], ["infection", "OBSERVATION", 165, 174]]], ["We repeated the simulation of infection time for 100 times and obtained a distribution of infection time for the 46 cases ( Figure 1 ).Statistical modelWe modeled, # , the number of new infections in Wuhan on day since December 1, 2019 and assume it was growing exponentially up till January 23: # = ' \u00d7 +# , 1 \u2264 \u2264 , where is the growth exponent and = 31 + 23 = 54 is the length of the series considered.", [["infection", "DISEASE", 30, 39], ["infection", "DISEASE", 90, 99], ["infections", "DISEASE", 186, 196], ["infection time", "TREATMENT", 30, 44], ["infection", "PROBLEM", 90, 99], ["the growth exponent", "TEST", 326, 345], ["the series", "TEST", 382, 392], ["infection", "OBSERVATION", 30, 39], ["infection", "OBSERVATION", 90, 99], ["new", "OBSERVATION_MODIFIER", 182, 185], ["infections", "OBSERVATION", 186, 196]]], ["We assumed, # , the number of new infections in Wuhan on day who subsequently traveled to one of the selected Asian countries and regions, follows a Poisson distribution:Statistical modelwhere ? is the rate of travel on day .", [["infections", "DISEASE", 34, 44], ["new", "OBSERVATION_MODIFIER", 30, 33], ["infections", "OBSERVATION", 34, 44]]], ["The sum is from to because each person infected on day can only travel out of Wuhan from day to day (corresponding to January 23, 2020 when all outbound trains and flights were halted).", [["person", "SPECIES", 32, 38]]], ["Since we collected this dataset 13 days after the outbound travel e ban, which is more than the estimated 95 th percentile of the incubation period (Li et al., 2020) , we assume that all 2019-nCoV cases traveled from Wuhan to the selected countries and regions have already been confirmed.Statistical modelWe expected that the international travel from Wuhan was relatively stable during this period.", [["stable", "OBSERVATION_MODIFIER", 374, 380]]], ["This motivated our working model for ? : 1.Statistical model? = for the entire study period; We considered another two choices of the travel rate as sensitivity analysis:Statistical model2. ? = before January 21 and ? = 2 \u00d7 on and after January 21; 3. ? = 0 before January 23 and ? = \u00d7 on January 23.", [["the entire study", "TEST", 68, 84]]], ["The second choice is intended to model the possible panic effect after human-to-human transmission was publicly confirmed.", [["panic", "DISEASE", 52, 57], ["human", "ORGANISM", 71, 76], ["human", "ORGANISM", 80, 85], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 80, 85], ["panic effect", "PROBLEM", 52, 64]]], ["We only included it to compare our results with assuming a simple exponential model for # with no offset, thereby ignoring the effect of the January 23 travel ban.Model fitting and statistical inferenceWe computed, [ # ], the mean of # using the simulated distribution of infection dates.", [["infection", "DISEASE", 272, 281], ["offset", "PROBLEM", 98, 104], ["infection dates", "PROBLEM", 272, 287], ["infection", "OBSERVATION", 272, 281]]], ["Using data from January 1 to January 15, we fitted the following linear regression for log ( [ # ]) with offset log( \u2212 + 1) that is derived from the statistical model above assuming constant travel rate:Model fitting and statistical inferencelog( [ # ]) \u2212 log( \u2212 + 1) = log( \u00d7 ' ) + .", [["offset log", "TEST", 105, 115], ["statistical inferencelog", "TEST", 221, 245], ["log", "TEST", 256, 259]]], ["We compared the fit of this model with the other two choices of the travel rate.Model fitting and statistical inferenceTo quantify the uncertainty of the estimated growth exponent, we performed a Bayesian analysis for this statistical model with diffuse priors.", [["Model fitting and statistical inference", "PROBLEM", 80, 119], ["the estimated growth exponent", "PROBLEM", 150, 179], ["a Bayesian analysis", "TEST", 194, 213], ["growth", "OBSERVATION_MODIFIER", 164, 170], ["exponent", "OBSERVATION_MODIFIER", 171, 179], ["diffuse", "OBSERVATION_MODIFIER", 246, 253]]], ["The prior we used for ' is such that the number of new infections on January 1, 2020 has prior mean 50 and standard deviation 100.", [["infections", "DISEASE", 55, 65], ["new infections", "PROBLEM", 51, 65], ["new", "OBSERVATION_MODIFIER", 51, 54], ["infections", "OBSERVATION", 55, 65]]], ["CC-BY 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Model fitting and statistical inferenceis the (which was not peer-reviewed) The copyright holder for this preprint .Model fitting and statistical inferenceregions by the population of Wuhan.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 224, 244], ["this preprint", "TREATMENT", 249, 262], ["Model fitting and statistical inferenceregions", "PROBLEM", 264, 310], ["med", "ANATOMY", 92, 95]]], ["We expected that the posterior of the number of new infections # would be very sensitive to the choice of the prior mean of , but the posterior of the growth exponent would be insensitive to the choice of prior.Model fitting and statistical inferenceWe fitted the models for 100 realizations of the infection counts from January 1 to January 20, expecting the public confirmation of human-to-human transmission on January 20 might have lowered the epidemic growth in the next few days.", [["infections", "DISEASE", 52, 62], ["infection", "DISEASE", 299, 308], ["human", "ORGANISM", 383, 388], ["human", "ORGANISM", 392, 397], ["human", "SPECIES", 383, 388], ["human", "SPECIES", 392, 397], ["human", "SPECIES", 383, 388], ["human", "SPECIES", 392, 397], ["new infections", "PROBLEM", 48, 62], ["Model fitting", "TREATMENT", 211, 224], ["the infection counts", "PROBLEM", 295, 315], ["posterior", "OBSERVATION_MODIFIER", 21, 30], ["number", "OBSERVATION_MODIFIER", 38, 44], ["new", "OBSERVATION_MODIFIER", 48, 51], ["infections", "OBSERVATION", 52, 62], ["posterior", "ANATOMY_MODIFIER", 134, 143], ["growth", "OBSERVATION_MODIFIER", 151, 157], ["exponent", "OBSERVATION", 158, 166], ["infection", "OBSERVATION", 299, 308]]], ["We did not use infections before January 1 because the simulation could be unreliable for early infections.", [["infections", "DISEASE", 15, 25], ["infections", "DISEASE", 96, 106], ["infections", "PROBLEM", 15, 25], ["early infections", "PROBLEM", 90, 106], ["infections", "OBSERVATION", 96, 106]]], ["We also fitted the models using all infections as a sensitivity analysis.", [["infections", "DISEASE", 36, 46], ["all infections", "PROBLEM", 32, 46], ["a sensitivity analysis", "TEST", 50, 72]]], ["We computed the posterior means and credible intervals by pooling posterior samples for different realizations of the infection counts.Simulated infection timeWe obtained the distribution of the mean counts of new infections among the cases and found that it was growing exponentially till January 18 but was dropping from January 19 to 23 ( Figure 2 , Panel A).", [["posterior samples", "ANATOMY", 66, 83], ["infection", "DISEASE", 118, 127], ["infection", "DISEASE", 145, 154], ["infections", "DISEASE", 214, 224], ["pooling posterior samples", "TEST", 58, 83], ["the infection counts", "PROBLEM", 114, 134], ["Simulated infection timeWe", "PROBLEM", 135, 161], ["new infections", "PROBLEM", 210, 224], ["posterior", "ANATOMY_MODIFIER", 16, 25], ["infection", "OBSERVATION", 118, 127], ["infection", "OBSERVATION", 145, 154], ["new", "OBSERVATION_MODIFIER", 210, 213], ["infections", "OBSERVATION", 214, 224], ["growing", "OBSERVATION_MODIFIER", 263, 270], ["exponentially", "OBSERVATION_MODIFIER", 271, 284]]], ["However, the correction factor \u2212 + 1 is our working model predicts the mean counts to be decreasing whenSimulated infection timeThis equation shows that the stationary point is 1/ days before January 24.", [["infection", "DISEASE", 114, 123], ["the mean counts", "TEST", 67, 82], ["whenSimulated infection", "PROBLEM", 100, 123], ["This equation", "TEST", 128, 141], ["decreasing", "OBSERVATION_MODIFIER", 89, 99], ["infection", "OBSERVATION", 114, 123]]], ["Error bars in Panel A also show that the uncertainty of the estimated mean infection counts due to using Monte-Carlo simulations is small.Simulated infection timeIn fitted linear regressions for logarithm of mean infection counts versus, Modeling the effect of the travel ban on January 23 (Panels B and C, Figure 2 ) visually improves the fit to the data when compared to ignoring the travel ban (Panel D, Figure 2 ).", [["infection", "DISEASE", 75, 84], ["Monte-Carlo", "CHEMICAL", 105, 116], ["infection", "DISEASE", 148, 157], ["infection", "DISEASE", 213, 222], ["Error bars in Panel", "TEST", 0, 19], ["the estimated mean infection counts", "PROBLEM", 56, 91], ["Monte-Carlo simulations", "TREATMENT", 105, 128], ["Simulated infection time", "PROBLEM", 138, 162], ["mean infection counts", "PROBLEM", 208, 229], ["infection", "OBSERVATION", 75, 84], ["small", "OBSERVATION_MODIFIER", 132, 137], ["infection", "OBSERVATION", 148, 157], ["linear", "OBSERVATION_MODIFIER", 172, 178], ["regressions", "OBSERVATION_MODIFIER", 179, 190]]], ["The fitted growth exponent using our working model was = 0.25 (Panel B).", [["The fitted growth exponent", "PROBLEM", 0, 26], ["growth", "OBSERVATION_MODIFIER", 11, 17], ["exponent", "OBSERVATION_MODIFIER", 18, 26]]], ["This is consistent with our prediction of in the last paragraph based on the decreasing infections after January 19.", [["infections", "DISEASE", 88, 98], ["the decreasing infections", "PROBLEM", 73, 98], ["consistent with", "UNCERTAINTY", 8, 23], ["decreasing", "OBSERVATION_MODIFIER", 77, 87], ["infections", "OBSERVATION", 88, 98]]], ["On the contrary, if we assumed the travel rate doubled in the last three days, a similar calculation shows that the stationary point in Panel A should be around January 16.", [["a similar calculation", "TEST", 79, 100]]], ["These qualitative assessments show that our working model provide superior fit to the data.Simulated infection timeTo aide comparison, we included lines in panels B, C, and D, in Figure 2 corresponding to a growth rate of = 0.11 or a doubling time of 6.4 days reported by a previous analysis .", [["infection", "DISEASE", 101, 110], ["B", "CELL", 163, 164], ["C", "CELL", 166, 167], ["These qualitative assessments", "TEST", 0, 29], ["Simulated infection time", "PROBLEM", 91, 115], ["lines in panels", "TEST", 147, 162], ["a growth rate", "TEST", 205, 218], ["a previous analysis", "TEST", 272, 291], ["infection", "OBSERVATION", 101, 110]]], ["This estimate did not fit the average infection counts well.Epidemic growthIn our Bayesian model fitted using infections before January 21 and assuming constant travel rate, the posterior mean of the growth exponent was 0.25 (95% CrI, 0.17 -0.34).", [["infection", "DISEASE", 38, 47], ["infections", "DISEASE", 110, 120], ["the average infection counts", "PROBLEM", 26, 54], ["infections", "PROBLEM", 110, 120], ["the growth exponent", "TEST", 196, 215], ["CrI", "TEST", 230, 233], ["average", "OBSERVATION_MODIFIER", 30, 37], ["infection", "OBSERVATION", 38, 47], ["posterior", "ANATOMY_MODIFIER", 178, 187], ["growth", "OBSERVATION_MODIFIER", 200, 206], ["exponent", "OBSERVATION_MODIFIER", 207, 215]]], ["CC-BY 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Epidemic growthis the (which was not peer-reviewed) The copyright holder for this preprint . number of 5.7 (95% CrI, 3.4 -9.2).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 200, 220], ["this preprint", "TREATMENT", 225, 238], ["number", "TEST", 241, 247], ["CrI", "TEST", 260, 263], ["med", "ANATOMY", 92, 95]]], ["The basic reproduction number is computed using the serial interval previously reported for 2019-nCoV (Li et al., 2020) .Epidemic growthWe further performed a thorough sensitivity analysis of our results (Table 1 and Online Supplement) using a different estimation period, the other two travel rates, and the incubation period and serial interval reported for the severe acute respiratory syndrome (SARS) (Donnelly et al., 2003; Lipsitch et al., 2003) .", [["acute respiratory syndrome", "DISEASE", 371, 397], ["SARS", "DISEASE", 399, 403], ["a thorough sensitivity analysis", "TEST", 157, 188], ["the severe acute respiratory syndrome", "PROBLEM", 360, 397], ["severe", "OBSERVATION_MODIFIER", 364, 370], ["acute", "OBSERVATION_MODIFIER", 371, 376], ["respiratory syndrome", "OBSERVATION", 377, 397]]], ["We also performed a sensitivity analysis to the prior chosen for the rate of travel.", [["a sensitivity analysis", "TEST", 18, 40]]], ["Not surprisingly, we found that the estimated growth exponent is not sensitive to the choice, but the total number of infections are very sensitive to the choice (Online Supplement).DiscussionOur analysis reported a much higher growth rate of the early 2019-nCoV outbreak in Wuhan.", [["infections", "DISEASE", 118, 128], ["the estimated growth exponent", "PROBLEM", 32, 61], ["infections", "PROBLEM", 118, 128], ["DiscussionOur analysis", "TEST", 182, 204], ["growth", "OBSERVATION_MODIFIER", 46, 52], ["exponent", "OBSERVATION", 53, 61], ["infections", "OBSERVATION", 118, 128]]], ["A direct comparison can be drawn with a previous analysis that also used internationally confirmed cases to infer the epidemic size and growth in Wuhan .", [["a previous analysis", "TEST", 38, 57], ["epidemic", "OBSERVATION_MODIFIER", 118, 126], ["size", "OBSERVATION_MODIFIER", 127, 131], ["growth", "OBSERVATION_MODIFIER", 136, 142]]], ["However, their estimated doubling time is 6.4 days (95% CrI, 5.8 days -7.1 days).", [["CrI", "TEST", 56, 59]]], ["These estimates did not fit our simulated distribution of infections well, even with our impossibly extreme assumption of the travel rate (Figure 2, Panel D) .", [["infections", "DISEASE", 58, 68], ["infections", "PROBLEM", 58, 68], ["infections", "OBSERVATION", 58, 68]]], ["This shows that the epidemic may have been spreading much faster in Wuhan than these earlier estimates.DiscussionThere are several possible explanations for the large difference in epidemiological estimates.", [["the large difference", "PROBLEM", 157, 177], ["spreading", "OBSERVATION_MODIFIER", 43, 52], ["much", "OBSERVATION_MODIFIER", 53, 57], ["faster", "OBSERVATION_MODIFIER", 58, 64], ["large", "OBSERVATION_MODIFIER", 161, 166], ["difference", "OBSERVATION", 167, 177]]], ["One possible reason is the different study sample.", [["the different study sample", "TEST", 23, 49]]], ["Our selected countries and regions also have good public health surveillance systems and could more easily identified suspected cases in border control.", [["good", "OBSERVATION_MODIFIER", 45, 49]]], ["Another key distinction is that our analysis used the simulated infection time instead of the noisier symptom onset as in the previous analyses.", [["infection", "DISEASE", 64, 73], ["our analysis", "TEST", 32, 44], ["the previous analyses", "TEST", 122, 143], ["infection", "OBSERVATION", 64, 73]]], ["By using the cases' travel history (in particular, international arrival date), we can narrow down when the cases were infected.", [["infected", "PROBLEM", 119, 127], ["infected", "OBSERVATION", 119, 127]]], ["The analysis by used a more complicated susceptible-exposedinfectious-recovered (SEIR) model and only accounted for the quarantine of Wuhan in their forecast but not in their estimation.", [["The analysis", "TEST", 0, 12]]], ["However, we have convincingly demonstrated that this leads to very poor fit of the distribution of infection time.DiscussionOur analysis should be viewed in terms of its limitations.", [["infection", "DISEASE", 99, 108], ["infection time", "PROBLEM", 99, 113], ["DiscussionOur analysis", "TEST", 114, 136], ["distribution", "OBSERVATION_MODIFIER", 83, 95], ["infection", "OBSERVATION", 99, 108]]], ["We used a simple exponential growth model for the new infections and did not account for the dynamics of the epidemics like a SEIR model.", [["infections", "DISEASE", 54, 64], ["a simple exponential growth model", "TREATMENT", 8, 41], ["the new infections", "PROBLEM", 46, 64], ["new", "OBSERVATION_MODIFIER", 50, 53], ["infections", "OBSERVATION", 54, 64]]], ["We assumed a constant .", [["constant", "OBSERVATION_MODIFIER", 13, 21]]], ["CC-BY 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Discussionis the (which was not peer-reviewed) The copyright holder for this preprint .Discussionrate of travel in the study period which might not approximate the travel pattern in Wuhan---a transportation hub in central China---very well.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["this preprint", "TREATMENT", 220, 233], ["med", "ANATOMY", 92, 95]]], ["In particular, millions of people (substantial proportion of the Wuhan population) traveled back home from Wuhan before the Lunar New Year, which we did not consider in our model.", [["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33]]], ["Finally, our estimates are relatively but not entirely insensitive to the incubation period which are crucial in simulating the infection time.DiscussionDespite these potential limitations, we convincingly demonstrated that a simple theoretical model ---exponential growth with correction for the travel ban on January 23 ---provides very good fit to the internationally confirmed cases with detailed case trajectories.", [["infection", "DISEASE", 128, 137], ["a simple theoretical model ---exponential growth", "PROBLEM", 224, 272], ["infection", "OBSERVATION", 128, 137]]], ["This has important implications in designing prevention measures to control the outbreak in other cities in China and around the world.", [["prevention measures", "TREATMENT", 45, 64]]], ["On the more positive side, our simulated infection rates in January 21 to 23 showed visually significant departure from the previous growth pattern (Panel B, Figure 2 ).", [["infection", "DISEASE", 41, 50], ["our simulated infection rates", "TEST", 27, 56], ["visually significant departure", "PROBLEM", 84, 114], ["infection", "OBSERVATION", 41, 50], ["significant", "OBSERVATION_MODIFIER", 93, 104], ["departure", "OBSERVATION", 105, 114]]], ["This gives some evidence that the prevention measures following the public confirmation of human-to-human transmission in the evening of January 20 were effective.Data and reproducibilityData for this study are from public sources.", [["human", "ORGANISM", 91, 96], ["human", "ORGANISM", 100, 105], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 100, 105], ["this study", "TEST", 196, 206]]], ["We have kept the data and computer programs used in our analysis at https://github.com/qingyuanzhao/2019-nCov-Data, so the results reported in this article and previous versions of our analysis are fully reproducible. .", [["our analysis", "TEST", 52, 64], ["our analysis", "TEST", 181, 193]]], ["CC-BY 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Data and reproducibilityis the (which was not peer-reviewed) The copyright holder for this preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 209, 229], ["this preprint", "TREATMENT", 234, 247], ["med", "ANATOMY", 92, 95]]], ["Dec 15 Jan 01 Jan 15 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 r = 0.11 D .", [["r", "TEST", 30, 31], ["r", "TEST", 39, 40], ["r", "TEST", 48, 49], ["r", "TEST", 57, 58], ["r", "TEST", 66, 67], ["r", "TEST", 75, 76], ["r", "TEST", 84, 85], ["r", "TEST", 93, 94], ["r", "TEST", 102, 103], ["r", "TEST", 111, 112], ["r", "TEST", 120, 121], ["r", "TEST", 129, 130], ["r", "TEST", 138, 139], ["r", "TEST", 147, 148], ["r", "TEST", 156, 157], ["r", "TEST", 165, 166], ["r", "TEST", 174, 175], ["r", "TEST", 183, 184], ["r", "TEST", 192, 193], ["r", "TEST", 201, 202], ["r", "TEST", 210, 211], ["r", "TEST", 219, 220], ["r", "TEST", 228, 229], ["r", "TEST", 237, 238], ["r", "TEST", 246, 247], ["r", "TEST", 255, 256], ["r", "TEST", 264, 265], ["r", "TEST", 273, 274], ["r", "TEST", 282, 283], ["r", "TEST", 291, 292], ["r", "TEST", 300, 301], ["r", "TEST", 309, 310], ["r", "TEST", 318, 319], ["r", "TEST", 327, 328], ["r", "TEST", 336, 337], ["r", "TEST", 345, 346], ["r", "TEST", 354, 355], ["r", "TEST", 363, 364], ["r", "TEST", 372, 373], ["r", "TEST", 381, 382], ["r", "TEST", 390, 391], ["r", "TEST", 399, 400], ["r", "TEST", 408, 409], ["r", "TEST", 417, 418], ["r", "TEST", 426, 427], ["r", "TEST", 435, 436], ["r", "TEST", 444, 445], ["r", "TEST", 453, 454], ["r", "TEST", 462, 463], ["r", "TEST", 471, 472], ["r", "TEST", 480, 481], ["r", "TEST", 489, 490], ["r", "TEST", 498, 499], ["r", "TEST", 507, 508], ["r", "TEST", 516, 517], ["r", "TEST", 525, 526], ["r", "TEST", 534, 535], ["r", "TEST", 543, 544], ["r", "TEST", 552, 553], ["r", "TEST", 561, 562], ["r", "TEST", 570, 571], ["r", "TEST", 579, 580], ["r", "TEST", 588, 589], ["r", "TEST", 597, 598], ["r", "TEST", 606, 607], ["r", "TEST", 615, 616], ["r", "TEST", 624, 625], ["r", "TEST", 633, 634], ["r", "TEST", 642, 643], ["r", "TEST", 651, 652], ["r", "TEST", 660, 661], ["r", "TEST", 669, 670], ["r", "TEST", 678, 679], ["r", "TEST", 687, 688], ["r", "TEST", 696, 697], ["r", "TEST", 705, 706], ["r", "TEST", 714, 715], ["r", "TEST", 723, 724], ["r", "TEST", 732, 733], ["r", "TEST", 741, 742], ["r", "TEST", 750, 751], ["r", "TEST", 759, 760], ["r", "TEST", 768, 769], ["r", "TEST", 777, 778], ["r", "TEST", 786, 787], ["r", "TEST", 795, 796], ["r", "TEST", 804, 805], ["r", "TEST", 813, 814], ["r", "TEST", 822, 823], ["r", "TEST", 831, 832], ["r", "TEST", 840, 841], ["r", "TEST", 849, 850], ["r", "TEST", 858, 859], ["r", "TEST", 867, 868], ["r", "TEST", 876, 877], ["r", "TEST", 885, 886], ["r", "TEST", 894, 895], ["r", "TEST", 903, 904], ["r", "TEST", 912, 913], ["r", "TEST", 921, 922], ["r", "TEST", 930, 931], ["r", "TEST", 939, 940], ["r", "TEST", 948, 949], ["r", "TEST", 957, 958], ["r", "TEST", 966, 967], ["r", "TEST", 975, 976]]], ["CC-BY 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Data and reproducibilityis the (which was not peer-reviewed) The copyright holder for this preprint . .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 209, 229], ["this preprint", "TREATMENT", 234, 247], ["med", "ANATOMY", 92, 95]]], ["CC-BY 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Data and reproducibilityis the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 209, 229], ["this preprint", "TREATMENT", 234, 247], ["med", "ANATOMY", 92, 95]]]], "467b54359e9725df79f8baf527b0b12600fb0b30": [["Methods: Study aim was to evaluate the schedule of IST given in combination with PT-Cy as GVHD-prophylaxis post-haplo for acute leukemia (AL) and reported to the ALWP/EBMT registry.", [["acute leukemia", "ANATOMY", 122, 136], ["IST", "DISEASE", 51, 54], ["PT-Cy", "CHEMICAL", 81, 86], ["GVHD", "DISEASE", 90, 94], ["acute leukemia", "DISEASE", 122, 136], ["AL", "DISEASE", 138, 140], ["PT-Cy", "SIMPLE_CHEMICAL", 81, 86], ["acute leukemia", "CANCER", 122, 136], ["IST", "TREATMENT", 51, 54], ["PT-Cy", "TREATMENT", 81, 86], ["GVHD", "PROBLEM", 90, 94], ["prophylaxis", "TREATMENT", 95, 106], ["acute leukemia", "PROBLEM", 122, 136], ["acute", "OBSERVATION_MODIFIER", 122, 127], ["leukemia", "OBSERVATION", 128, 136], ["EBMT registry", "OBSERVATION", 167, 180]]], ["Patients were divided into 3 groups: received cyclosporine A-mycofenolate-mofetil(CSA-+MMF) initiated at day+1 (group-1, n=124) or CSA +MMF both started at day+5 (group-2, n=170) and tacrolimus + MMF from day+5 (group-3, n=215).", [["cyclosporine A-mycofenolate-mofetil", "CHEMICAL", 46, 81], ["CSA", "CHEMICAL", 82, 85], ["MMF", "CHEMICAL", 87, 90], ["CSA", "CHEMICAL", 131, 134], ["MMF", "CHEMICAL", 136, 139], ["tacrolimus", "CHEMICAL", 183, 193], ["MMF", "CHEMICAL", 196, 199], ["cyclosporine A-mycofenolate", "CHEMICAL", 46, 73], ["mofetil", "CHEMICAL", 74, 81], ["MMF", "CHEMICAL", 87, 90], ["MMF", "CHEMICAL", 136, 139], ["tacrolimus", "CHEMICAL", 183, 193], ["MMF", "CHEMICAL", 196, 199], ["Patients", "ORGANISM", 0, 8], ["cyclosporine A-mycofenolate-mofetil", "SIMPLE_CHEMICAL", 46, 81], ["CSA-+MMF", "SIMPLE_CHEMICAL", 82, 90], ["CSA +MMF", "SIMPLE_CHEMICAL", 131, 139], ["tacrolimus", "SIMPLE_CHEMICAL", 183, 193], ["MMF", "SIMPLE_CHEMICAL", 196, 199], ["Patients", "SPECIES", 0, 8], ["cyclosporine A-mycofenolate", "TREATMENT", 46, 73], ["mofetil(CSA", "TREATMENT", 74, 85], ["MMF", "TREATMENT", 87, 90], ["CSA", "TEST", 131, 134], ["MMF", "TREATMENT", 136, 139], ["tacrolimus", "TREATMENT", 183, 193]]], ["Transplants were performed from 2006-2017 and median follow up is 21 months (range 11-36).", [["Transplants", "TREATMENT", 0, 11]]], ["PT-CY was given on Day+3 and Day+5 in group-1 and on day+3 and day+4 in group-2 and 3.", [["CY", "CHEMICAL", 3, 5]]]], "PMC3958312": [["IntroductionInflammation has evolved as an adaptive process that combines the counteractive elements of tissue destruction versus healing to limit and eventually eliminate the harmful effects of irritants and infectious agents.", [["tissue", "ANATOMY", 104, 110], ["Inflammation", "DISEASE", 12, 24], ["tissue", "TISSUE", 104, 110], ["IntroductionInflammation", "PROBLEM", 0, 24], ["an adaptive process", "PROBLEM", 40, 59], ["tissue destruction", "PROBLEM", 104, 122], ["irritants", "PROBLEM", 195, 204], ["infectious agents", "TREATMENT", 209, 226], ["Inflammation", "OBSERVATION", 12, 24], ["tissue", "OBSERVATION_MODIFIER", 104, 110], ["destruction", "OBSERVATION", 111, 122], ["irritants", "OBSERVATION", 195, 204]]], ["Initial stages of inflammation that exacerbate tissue damage are often followed by subsequent regeneration/repair of tissue to restore its function (Medzhitov, 2008).", [["tissue", "ANATOMY", 47, 53], ["tissue", "ANATOMY", 117, 123], ["inflammation", "DISEASE", 18, 30], ["tissue damage", "DISEASE", 47, 60], ["tissue", "TISSUE", 47, 53], ["tissue", "TISSUE", 117, 123], ["inflammation", "PROBLEM", 18, 30], ["tissue damage", "PROBLEM", 47, 60], ["regeneration/repair of tissue", "TREATMENT", 94, 123], ["inflammation", "OBSERVATION", 18, 30], ["exacerbate tissue", "OBSERVATION_MODIFIER", 36, 53], ["damage", "OBSERVATION", 54, 60], ["repair", "OBSERVATION", 107, 113]]], ["Failure to progress to these later stages contributes to development of chronic pathologic conditions associated with numerous human diseases including pancreatitis and hepatitis, arthritis, and neurodegenerative syndromes.", [["pancreatitis", "DISEASE", 152, 164], ["hepatitis", "DISEASE", 169, 178], ["arthritis", "DISEASE", 180, 189], ["neurodegenerative syndromes", "DISEASE", 195, 222], ["human", "ORGANISM", 127, 132], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132], ["Failure", "PROBLEM", 0, 7], ["chronic pathologic conditions", "PROBLEM", 72, 101], ["numerous human diseases", "PROBLEM", 118, 141], ["pancreatitis", "PROBLEM", 152, 164], ["hepatitis", "PROBLEM", 169, 178], ["arthritis", "PROBLEM", 180, 189], ["neurodegenerative syndromes", "PROBLEM", 195, 222], ["chronic", "OBSERVATION_MODIFIER", 72, 79], ["pathologic", "OBSERVATION", 80, 90], ["numerous", "OBSERVATION_MODIFIER", 118, 126], ["human diseases", "OBSERVATION", 127, 141], ["pancreatitis", "OBSERVATION", 152, 164], ["hepatitis", "OBSERVATION", 169, 178], ["arthritis", "OBSERVATION", 180, 189], ["neurodegenerative syndromes", "OBSERVATION", 195, 222]]], ["Despite the enormous medical significance of persistent inflammation, the mechanisms that restrain the tissue damage and ensure the transition to the restorative phase largely remain to be understood (Nathan ' Ding, 2010).IntroductionChronic viral infections and growing tumors are among known inducers of persistent inflammation (Li et al, 2006).", [["tissue", "ANATOMY", 103, 109], ["tumors", "ANATOMY", 271, 277], ["inflammation", "DISEASE", 56, 68], ["Chronic viral infections", "DISEASE", 234, 258], ["tumors", "DISEASE", 271, 277], ["inflammation", "DISEASE", 317, 329], ["tissue", "TISSUE", 103, 109], ["tumors", "CANCER", 271, 277], ["persistent inflammation", "PROBLEM", 45, 68], ["the tissue damage", "PROBLEM", 99, 116], ["Chronic viral infections", "PROBLEM", 234, 258], ["growing tumors", "PROBLEM", 263, 277], ["persistent inflammation", "PROBLEM", 306, 329], ["persistent", "OBSERVATION_MODIFIER", 45, 55], ["inflammation", "OBSERVATION", 56, 68], ["Chronic", "OBSERVATION_MODIFIER", 234, 241], ["viral", "OBSERVATION_MODIFIER", 242, 247], ["infections", "OBSERVATION", 248, 258], ["growing", "OBSERVATION_MODIFIER", 263, 270], ["tumors", "OBSERVATION", 271, 277], ["persistent", "OBSERVATION_MODIFIER", 306, 316], ["inflammation", "OBSERVATION", 317, 329]]], ["Cytokines that belong to the family of type 1 interferons (IFN) protect the host against viruses and tumors (Stark et al, 1998).", [["tumors", "ANATOMY", 101, 107], ["tumors", "DISEASE", 101, 107], ["type 1 interferons", "GENE_OR_GENE_PRODUCT", 39, 57], ["IFN", "GENE_OR_GENE_PRODUCT", 59, 62], ["tumors", "CANCER", 101, 107], ["Cytokines", "PROTEIN", 0, 9], ["type 1 interferons", "PROTEIN", 39, 57], ["IFN", "PROTEIN", 59, 62], ["Cytokines", "TREATMENT", 0, 9], ["type 1 interferons (IFN)", "TREATMENT", 39, 63], ["viruses", "PROBLEM", 89, 96], ["tumors", "PROBLEM", 101, 107], ["tumors", "OBSERVATION", 101, 107]]], ["IFN act on cells through engaging a cell surface-located cognate receptor (formed by IFNAR1 and IFNAR2 chains) and subsequent stimulation of the signal transduction cascade including activation of the Janus kinases (JAK) and signal transduction and activators of transcription (STAT1/2) proteins (Uze et al, 2007).", [["cells", "ANATOMY", 11, 16], ["cell surface", "ANATOMY", 36, 48], ["IFN", "CHEMICAL", 0, 3], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["cells", "CELL", 11, 16], ["cell", "CELL", 36, 40], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 85, 91], ["IFNAR2 chains", "GENE_OR_GENE_PRODUCT", 96, 109], ["Janus kinases", "GENE_OR_GENE_PRODUCT", 201, 214], ["JAK", "GENE_OR_GENE_PRODUCT", 216, 219], ["signal transduction and activators of transcription (STAT1/2", "GENE_OR_GENE_PRODUCT", 225, 285], ["IFN", "PROTEIN", 0, 3], ["cell surface-located cognate receptor", "PROTEIN", 36, 73], ["IFNAR1", "PROTEIN", 85, 91], ["IFNAR2 chains", "PROTEIN", 96, 109], ["Janus kinases", "PROTEIN", 201, 214], ["JAK", "PROTEIN", 216, 219], ["signal transduction and activators of transcription (STAT1/2) proteins", "PROTEIN", 225, 295], ["IFN act on cells", "PROBLEM", 0, 16], ["IFNAR1 and IFNAR2 chains", "TREATMENT", 85, 109], ["the signal transduction cascade", "PROBLEM", 141, 172], ["the Janus kinases", "TREATMENT", 197, 214], ["signal transduction", "TEST", 225, 244], ["transcription (STAT1/2) proteins", "TREATMENT", 263, 295]]], ["The latter interact with IRF9 to form a specific transcriptionally active complex capable of inducing a plethora of IFN-stimulated proteins that act in concert to mediate the anti-viral, anti-tumorigenic and immunomodulatory effects of IFNs.", [["IRF9", "GENE_OR_GENE_PRODUCT", 25, 29], ["IFN", "GENE_OR_GENE_PRODUCT", 116, 119], ["IFNs", "GENE_OR_GENE_PRODUCT", 236, 240], ["IRF9", "PROTEIN", 25, 29], ["IFN-stimulated proteins", "PROTEIN", 116, 139], ["IFNs", "PROTEIN", 236, 240], ["IRF9", "TREATMENT", 25, 29], ["IFN-stimulated proteins", "TREATMENT", 116, 139], ["immunomodulatory effects of IFNs", "TREATMENT", 208, 240], ["anti-viral", "OBSERVATION", 175, 185]]], ["These effects underlie the use of pharmacologically formulated IFN for treatment of viral infections, cancers and multiple sclerosis (Stark et al, 1998; Platanias, 2005; Stark ' Darnell, 2012).IntroductionHowever, the benefits of IFN actions to the host are offset by tissue toxicities elicited by these cytokines (Trinchieri, 2010).", [["cancers", "ANATOMY", 102, 109], ["tissue", "ANATOMY", 268, 274], ["IFN", "CHEMICAL", 63, 66], ["viral infections", "DISEASE", 84, 100], ["cancers", "DISEASE", 102, 109], ["multiple sclerosis", "DISEASE", 114, 132], ["IFN", "CHEMICAL", 230, 233], ["toxicities", "DISEASE", 275, 285], ["cancers", "CANCER", 102, 109], ["IFN", "GENE_OR_GENE_PRODUCT", 230, 233], ["tissue", "TISSUE", 268, 274], ["IFN", "PROTEIN", 63, 66], ["IFN", "PROTEIN", 230, 233], ["cytokines", "PROTEIN", 304, 313], ["pharmacologically formulated IFN", "TREATMENT", 34, 66], ["viral infections", "PROBLEM", 84, 100], ["cancers", "PROBLEM", 102, 109], ["multiple sclerosis", "PROBLEM", 114, 132], ["IFN actions", "TREATMENT", 230, 241], ["tissue toxicities", "PROBLEM", 268, 285], ["viral", "OBSERVATION_MODIFIER", 84, 89], ["infections", "OBSERVATION", 90, 100], ["multiple", "OBSERVATION_MODIFIER", 114, 122], ["sclerosis", "OBSERVATION", 123, 132]]], ["Importantly, while anti-viral effects of IFN action could be achieved at low concentrations, a higher dose is required to achieve the anti-proliferative and anti-survival effects of IFN on tumor and benign cells (Jaitin et al, 2006).", [["tumor", "ANATOMY", 189, 194], ["benign cells", "ANATOMY", 199, 211], ["IFN", "CHEMICAL", 41, 44], ["IFN", "CHEMICAL", 182, 185], ["tumor", "DISEASE", 189, 194], ["IFN", "GENE_OR_GENE_PRODUCT", 41, 44], ["IFN", "GENE_OR_GENE_PRODUCT", 182, 185], ["tumor", "CANCER", 189, 194], ["benign cells", "CELL", 199, 211], ["IFN", "PROTEIN", 41, 44], ["IFN", "PROTEIN", 182, 185], ["tumor and benign cells", "CELL_TYPE", 189, 211], ["IFN action", "TREATMENT", 41, 51], ["the anti-proliferative and anti-survival effects", "TREATMENT", 130, 178], ["IFN on tumor", "PROBLEM", 182, 194], ["benign cells", "PROBLEM", 199, 211], ["tumor", "OBSERVATION", 189, 194]]], ["Furthermore, the toxic effects of IFN correlate with its affinity for IFNAR1 (Jaitin et al, 2006; Kalie et al, 2007; Thomas et al, 2011; de Weerd et al, 2013) and require a much higher cell surface density of its receptor (Moraga et al, 2009; Levin et al, 2011; Piehler et al, 2012).", [["cell surface", "ANATOMY", 185, 197], ["IFN", "CHEMICAL", 34, 37], ["IFN", "GENE_OR_GENE_PRODUCT", 34, 37], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 70, 76], ["cell surface", "CELLULAR_COMPONENT", 185, 197], ["IFN", "PROTEIN", 34, 37], ["IFNAR1", "PROTEIN", 70, 76], ["toxic", "OBSERVATION_MODIFIER", 17, 22]]], ["The cell surface levels of IFN receptor and ensuing sensitivity of cells to IFN are negatively regulated by the ubiquitination, endocytosis and degradation of IFNAR1 facilitated by the \u03b2-Trcp E3 ubiquitin ligase (Kumar et al, 2003, 2007).", [["cell surface", "ANATOMY", 4, 16], ["cells", "ANATOMY", 67, 72], ["cell", "CELL", 4, 8], ["IFN receptor", "GENE_OR_GENE_PRODUCT", 27, 39], ["cells", "CELL", 67, 72], ["IFN", "GENE_OR_GENE_PRODUCT", 76, 79], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 159, 165], ["\u03b2-Trcp E3", "GENE_OR_GENE_PRODUCT", 185, 194], ["IFN receptor", "PROTEIN", 27, 39], ["IFN", "PROTEIN", 76, 79], ["IFNAR1", "PROTEIN", 159, 165], ["\u03b2-Trcp E3 ubiquitin ligase", "PROTEIN", 185, 211], ["The cell surface levels", "TEST", 0, 23], ["IFN receptor", "TREATMENT", 27, 39], ["ensuing sensitivity of cells", "PROBLEM", 44, 72], ["IFN", "TEST", 76, 79], ["cell", "OBSERVATION_MODIFIER", 4, 8], ["surface", "OBSERVATION_MODIFIER", 9, 16]]], ["The ability of \u03b2-Trcp to interact with IFNAR1 and to ubiquitinate this protein requires phosphorylation on specific serine residues (Ser526 in mouse IFNAR1 or Ser535 in human receptor) within a conserved degron motif located in the intracellular domain of IFNAR1 (Kumar et al, 2003, 2004).IntroductionThis IFNAR1 phosphorylation triggered by IFN (Kumar et al, 2004; Marijanovic et al, 2006) through JAK-mediated activation of protein kinase D2 (PKD2) attenuates IFN signaling by ubiquitination-driven downregulation and degradation of IFNAR1 (Zheng et al, 2011a,c2011c).", [["intracellular", "ANATOMY", 232, 245], ["serine", "CHEMICAL", 116, 122], ["\u03b2-Trcp", "GENE_OR_GENE_PRODUCT", 15, 21], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 39, 45], ["mouse", "ORGANISM", 143, 148], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 149, 155], ["Ser535", "GENE_OR_GENE_PRODUCT", 159, 165], ["human", "ORGANISM", 169, 174], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 232, 245], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 256, 262], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 306, 312], ["JAK", "GENE_OR_GENE_PRODUCT", 399, 402], ["protein kinase D2", "GENE_OR_GENE_PRODUCT", 426, 443], ["PKD2", "GENE_OR_GENE_PRODUCT", 445, 449], ["IFN", "GENE_OR_GENE_PRODUCT", 462, 465], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 535, 541], ["c2011c", "GENE_OR_GENE_PRODUCT", 562, 568], ["\u03b2-Trcp", "PROTEIN", 15, 21], ["IFNAR1", "PROTEIN", 39, 45], ["mouse IFNAR1", "PROTEIN", 143, 155], ["Ser535", "PROTEIN", 159, 165], ["human receptor", "PROTEIN", 169, 183], ["conserved degron motif", "PROTEIN", 194, 216], ["intracellular domain", "PROTEIN", 232, 252], ["IFNAR1", "PROTEIN", 256, 262], ["IFNAR1", "PROTEIN", 306, 312], ["IFN", "PROTEIN", 342, 345], ["JAK", "PROTEIN", 399, 402], ["protein kinase D2", "PROTEIN", 426, 443], ["PKD2", "PROTEIN", 445, 449], ["IFN", "PROTEIN", 462, 465], ["IFNAR1", "PROTEIN", 535, 541], ["mouse", "SPECIES", 143, 148], ["human", "SPECIES", 169, 174], ["mouse", "SPECIES", 143, 148], ["human", "SPECIES", 169, 174], ["IFNAR1", "TREATMENT", 39, 45], ["phosphorylation", "TREATMENT", 88, 103], ["specific serine residues", "TREATMENT", 107, 131], ["a conserved degron motif", "PROBLEM", 192, 216], ["IFNAR1 phosphorylation", "PROBLEM", 306, 328], ["Marijanovic et al", "TREATMENT", 366, 383], ["JAK", "TREATMENT", 399, 402], ["protein kinase D2", "TREATMENT", 426, 443], ["IFN signaling", "PROBLEM", 462, 475], ["ubiquitination", "TEST", 479, 493]]], ["Importantly, this phosphorylation of IFNAR1 can be induced by ligand-unrelated stimuli that altogether desensitize cells to IFN (reviewed in (Fuchs, 2013).", [["cells", "ANATOMY", 115, 120], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 37, 43], ["cells", "CELL", 115, 120], ["IFN", "GENE_OR_GENE_PRODUCT", 124, 127], ["IFNAR1", "PROTEIN", 37, 43], ["IFN", "PROTEIN", 124, 127], ["this phosphorylation of IFNAR1", "TREATMENT", 13, 43]]], ["For example, PKD2-activating vascular endothelial growth factor (VEGF) can trigger ubiquitination and downregulation of IFNAR1 and blunt the cellular responses to IFN (Zheng et al, 2011b).", [["cellular", "ANATOMY", 141, 149], ["PKD2", "GENE_OR_GENE_PRODUCT", 13, 17], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 29, 63], ["VEGF", "GENE_OR_GENE_PRODUCT", 65, 69], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 120, 126], ["cellular", "CELL", 141, 149], ["PKD2", "PROTEIN", 13, 17], ["vascular endothelial growth factor", "PROTEIN", 29, 63], ["VEGF", "PROTEIN", 65, 69], ["IFNAR1", "PROTEIN", 120, 126], ["IFN", "PROTEIN", 163, 166], ["PKD2", "PROBLEM", 13, 17], ["activating vascular endothelial growth factor", "PROBLEM", 18, 63], ["ubiquitination", "PROBLEM", 83, 97], ["downregulation of IFNAR1", "PROBLEM", 102, 126], ["blunt the cellular responses", "PROBLEM", 131, 159], ["PKD2", "OBSERVATION", 13, 17], ["vascular endothelial", "ANATOMY", 29, 49]]], ["Other stimuli capable of IFN-independent phosphorylation of IFNAR1 utilize a different pathway (Liu et al, 2008, 2009b) that involves IFNAR1 Ser526/535 phosphorylation by casein kinase 1\u03b1 (Liu et al, 2009a) amplified by an adjacent priming phosphorylation (Bhattacharya et al, 2010), which is mediated by the p38 stress-activated protein kinase (Bhattacharya et al, 2011).", [["IFN", "GENE_OR_GENE_PRODUCT", 25, 28], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 60, 66], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 134, 140], ["casein kinase 1", "GENE_OR_GENE_PRODUCT", 171, 186], ["p38 stress-activated protein kinase", "GENE_OR_GENE_PRODUCT", 309, 344], ["IFN", "PROTEIN", 25, 28], ["IFNAR1", "PROTEIN", 60, 66], ["IFNAR1", "PROTEIN", 134, 140], ["casein kinase 1\u03b1", "PROTEIN", 171, 187], ["p38 stress-activated protein kinase", "PROTEIN", 309, 344], ["Other stimuli", "TEST", 0, 13]]], ["These stimuli include inflammatory cytokines such as interleukin-1\u03b2 and tumor necrosis factor-\u03b1 [IL1\u03b2 and TNF\u03b1 (Huangfu et al, 2012)], and bacterial lipopolysaccharide [LPS, (Qian et al, 2011)].IntroductionThe inflammatory stimuli trigger IFNAR1 phosphorylation, ubiquitination and degradation and, as a result, largely deprive cells from ability to respond to their future encounter with IFN in vitro (Qian et al, 2011; Zheng et al, 2011b; Huangfu et al, 2012).", [["cells", "ANATOMY", 328, 333], ["necrosis", "DISEASE", 78, 86], ["lipopolysaccharide", "CHEMICAL", 149, 167], ["LPS", "CHEMICAL", 169, 172], ["interleukin-1\u03b2", "GENE_OR_GENE_PRODUCT", 53, 67], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 72, 95], ["IL1\u03b2", "GENE_OR_GENE_PRODUCT", 97, 101], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 106, 110], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 149, 167], ["LPS", "SIMPLE_CHEMICAL", 169, 172], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 239, 245], ["cells", "CELL", 328, 333], ["IFN", "GENE_OR_GENE_PRODUCT", 389, 392], ["inflammatory cytokines", "PROTEIN", 22, 44], ["interleukin-1\u03b2", "PROTEIN", 53, 67], ["tumor necrosis factor-\u03b1", "PROTEIN", 72, 95], ["IL1\u03b2", "PROTEIN", 97, 101], ["TNF", "PROTEIN", 106, 109], ["IFNAR1", "PROTEIN", 239, 245], ["IFN", "PROTEIN", 389, 392], ["These stimuli", "TEST", 0, 13], ["inflammatory cytokines", "PROBLEM", 22, 44], ["interleukin", "TEST", 53, 64], ["tumor necrosis factor", "PROBLEM", 72, 93], ["TNF", "PROBLEM", 106, 109], ["bacterial lipopolysaccharide [LPS", "TEST", 139, 172], ["The inflammatory stimuli", "TEST", 206, 230], ["IFNAR1 phosphorylation", "PROBLEM", 239, 261], ["inflammatory", "OBSERVATION_MODIFIER", 22, 34], ["tumor", "OBSERVATION_MODIFIER", 72, 77], ["necrosis", "OBSERVATION", 78, 86], ["inflammatory", "OBSERVATION_MODIFIER", 210, 222]]], ["Should this regulation occur in vivo, it might pose a medical problem of reduced efficacy of pharmaceutical IFN in inflamed tissues.", [["tissues", "ANATOMY", 124, 131], ["IFN", "CHEMICAL", 108, 111], ["inflamed tissues", "TISSUE", 115, 131], ["IFN", "PROTEIN", 108, 111], ["pharmaceutical IFN in inflamed tissues", "PROBLEM", 93, 131], ["pharmaceutical IFN", "OBSERVATION", 93, 111], ["inflamed tissues", "OBSERVATION", 115, 131]]], ["Furthermore, the very existence of such mechanism is somewhat counterintuitive for the host defense as it may limit the anti-viral and anti-tumorigenic benefits of endogenously produced IFN within the regions of inflammation.IntroductionHence, we sought to investigate the manifestation and biological significance of inflammation-induced IFNAR1 ubiquitination and downregulation in vivo.", [["inflammation", "DISEASE", 212, 224], ["inflammation", "DISEASE", 318, 330], ["IFN", "GENE_OR_GENE_PRODUCT", 186, 189], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 339, 345], ["IFN", "PROTEIN", 186, 189], ["IFNAR1", "PROTEIN", 339, 345], ["endogenously produced IFN", "PROBLEM", 164, 189], ["inflammation", "PROBLEM", 212, 224], ["inflammation", "PROBLEM", 318, 330], ["IFNAR1 ubiquitination", "PROBLEM", 339, 360], ["downregulation in vivo", "TREATMENT", 365, 387], ["inflammation", "OBSERVATION", 212, 224], ["inflammation", "OBSERVATION", 318, 330], ["IFNAR1 ubiquitination", "OBSERVATION", 339, 360]]], ["We initially focused on the role of IFN signaling and IFNAR1 stability in development of acute pancreatitis, a deadly disease affecting millions of people worldwide [reviewed in (Pandol, 2006)].", [["acute pancreatitis", "DISEASE", 89, 107], ["IFN", "GENE_OR_GENE_PRODUCT", 36, 39], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 54, 60], ["people", "ORGANISM", 148, 154], ["IFN", "PROTEIN", 36, 39], ["IFNAR1", "PROTEIN", 54, 60], ["people", "SPECIES", 148, 154], ["IFN signaling", "PROBLEM", 36, 49], ["IFNAR1 stability", "PROBLEM", 54, 70], ["acute pancreatitis", "PROBLEM", 89, 107], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["pancreatitis", "OBSERVATION", 95, 107]]], ["Whereas the etiology of this disease is complex, common pathogenetic mechanisms include food/alcohol-induced pancreatic hyperstimulation and pancreatic duct obstruction leading to increased pancreatic duct pressure and reflux of active trypsin.", [["pancreatic", "ANATOMY", 109, 119], ["pancreatic duct", "ANATOMY", 141, 156], ["pancreatic duct", "ANATOMY", 190, 205], ["alcohol", "CHEMICAL", 93, 100], ["pancreatic hyperstimulation", "DISEASE", 109, 136], ["pancreatic duct obstruction", "DISEASE", 141, 168], ["alcohol", "CHEMICAL", 93, 100], ["alcohol", "SIMPLE_CHEMICAL", 93, 100], ["pancreatic", "ORGAN", 109, 119], ["pancreatic duct", "MULTI-TISSUE_STRUCTURE", 141, 156], ["pancreatic duct", "MULTI-TISSUE_STRUCTURE", 190, 205], ["trypsin", "GENE_OR_GENE_PRODUCT", 236, 243], ["trypsin", "PROTEIN", 236, 243], ["this disease", "PROBLEM", 24, 36], ["common pathogenetic mechanisms", "PROBLEM", 49, 79], ["pancreatic hyperstimulation", "PROBLEM", 109, 136], ["pancreatic duct obstruction", "PROBLEM", 141, 168], ["increased pancreatic duct pressure", "PROBLEM", 180, 214], ["reflux of active trypsin", "PROBLEM", 219, 243], ["disease", "OBSERVATION", 29, 36], ["pancreatic", "ANATOMY", 109, 119], ["hyperstimulation", "OBSERVATION", 120, 136], ["pancreatic duct", "ANATOMY", 141, 156], ["obstruction", "OBSERVATION", 157, 168], ["increased", "OBSERVATION_MODIFIER", 180, 189], ["pancreatic duct", "ANATOMY", 190, 205], ["pressure", "OBSERVATION_MODIFIER", 206, 214], ["reflux", "OBSERVATION", 219, 225], ["active", "OBSERVATION_MODIFIER", 229, 235], ["trypsin", "OBSERVATION_MODIFIER", 236, 243]]], ["As a result, trypsin and other proteolytic enzymes become activated within pancreatic acinar cells resulting in their autolysis and induction of local inflammation [reviewed in (Pandol, 2006; Reichert ' Rustgi, 2011)].", [["pancreatic acinar cells", "ANATOMY", 75, 98], ["inflammation", "DISEASE", 151, 163], ["trypsin", "GENE_OR_GENE_PRODUCT", 13, 20], ["pancreatic acinar cells", "CELL", 75, 98], ["trypsin", "PROTEIN", 13, 20], ["proteolytic enzymes", "PROTEIN", 31, 50], ["pancreatic acinar cells", "CELL_TYPE", 75, 98], ["trypsin", "TREATMENT", 13, 20], ["other proteolytic enzymes", "TEST", 25, 50], ["their autolysis", "PROBLEM", 112, 127], ["local inflammation", "PROBLEM", 145, 163], ["pancreatic", "ANATOMY", 75, 85], ["acinar cells", "OBSERVATION", 86, 98]]], ["Intriguingly, pancreatitis induces many pathways known to downregulate IFNAR1 such as VEGF (Kuehn et al, 1999), unfolded protein response (Kubisch ' Logsdon, 2007), and pathogen recognition receptors (Pastor et al, 2004; Li et al, 2005).", [["pancreatitis", "DISEASE", 14, 26], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 71, 77], ["VEGF", "GENE_OR_GENE_PRODUCT", 86, 90], ["pathogen recognition receptors", "GENE_OR_GENE_PRODUCT", 169, 199], ["IFNAR1", "PROTEIN", 71, 77], ["VEGF", "PROTEIN", 86, 90], ["pathogen recognition receptors", "PROTEIN", 169, 199], ["pancreatitis", "PROBLEM", 14, 26], ["unfolded protein response", "PROBLEM", 112, 137], ["pancreatitis", "OBSERVATION", 14, 26]]], ["Furthermore, a number of reported cases of iatrogenic pancreatitis have been attributed to the IFN-based drugs (Trivedi ' Pitchumoni, 2005), and IFN-induced pancreatic inflammation was observed in mice injected with poly I:C (Hayashi et al, 2011).IntroductionOur current data suggest that stimulation of IFNAR1 downregulation during pancreatitis functions as a protective mechanism that limits the extent of tissue damage and promotes the transition of inflammatory process to the stages of tissue regeneration.", [["pancreatic", "ANATOMY", 157, 167], ["tissue", "ANATOMY", 408, 414], ["tissue", "ANATOMY", 491, 497], ["pancreatitis", "DISEASE", 54, 66], ["IFN", "CHEMICAL", 95, 98], ["IFN", "CHEMICAL", 145, 148], ["pancreatic inflammation", "DISEASE", 157, 180], ["poly I:C", "CHEMICAL", 216, 224], ["pancreatitis", "DISEASE", 333, 345], ["IFN", "GENE_OR_GENE_PRODUCT", 145, 148], ["pancreatic", "ORGAN", 157, 167], ["mice", "ORGANISM", 197, 201], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 304, 310], ["tissue", "TISSUE", 408, 414], ["tissue", "TISSUE", 491, 497], ["IFN", "PROTEIN", 95, 98], ["IFN", "PROTEIN", 145, 148], ["IFNAR1", "PROTEIN", 304, 310], ["mice", "SPECIES", 197, 201], ["mice", "SPECIES", 197, 201], ["iatrogenic pancreatitis", "PROBLEM", 43, 66], ["the IFN-based drugs", "TREATMENT", 91, 110], ["Trivedi ' Pitchumoni", "TREATMENT", 112, 132], ["IFN", "TREATMENT", 145, 148], ["pancreatic inflammation", "PROBLEM", 157, 180], ["IFNAR1 downregulation", "PROBLEM", 304, 325], ["pancreatitis functions", "PROBLEM", 333, 355], ["a protective mechanism", "TREATMENT", 359, 381], ["tissue damage", "PROBLEM", 408, 421], ["inflammatory process", "PROBLEM", 453, 473], ["tissue regeneration", "PROBLEM", 491, 510], ["iatrogenic", "OBSERVATION_MODIFIER", 43, 53], ["pancreatitis", "OBSERVATION", 54, 66], ["pancreatic", "ANATOMY", 157, 167], ["inflammation", "OBSERVATION", 168, 180], ["pancreatitis", "OBSERVATION", 333, 345], ["tissue", "ANATOMY", 408, 414], ["damage", "OBSERVATION", 415, 421], ["inflammatory", "OBSERVATION", 453, 465], ["tissue", "ANATOMY", 491, 497], ["regeneration", "OBSERVATION", 498, 510]]], ["This mechanism also plays an important role in hepatic and generalized inflammatory syndromes.", [["hepatic", "ANATOMY", 47, 54], ["hepatic", "MULTI-TISSUE_STRUCTURE", 47, 54], ["generalized inflammatory syndromes", "PROBLEM", 59, 93], ["hepatic", "ANATOMY", 47, 54], ["generalized", "OBSERVATION_MODIFIER", 59, 70], ["inflammatory syndromes", "OBSERVATION", 71, 93]]], ["We further demonstrate that pharmacologic induction of PKD2 and p38 kinases aimed to preemptively accelerate downregulation of IFNAR1 reduces the severity of inflammatory tissue injury and may prove useful in treatment of acute inflammatory conditions.Important role of IFN in pathogenesis of acute pancreatitis ::: ResultsTo delineate the role of IFN in pancreatitis we used a clinically relevant model involving injections of caerulein peptide that mimics the effects of cholecystokinin and induces key pathogenetic elements of acute pancreatitis including pancreatic duct obstruction and premature activation of trypsin (Pandol, 2006; Reichert et al, 2013).", [["tissue", "ANATOMY", 171, 177], ["pancreatic duct", "ANATOMY", 559, 574], ["tissue injury", "DISEASE", 171, 184], ["pancreatitis", "DISEASE", 299, 311], ["pancreatitis", "DISEASE", 355, 367], ["caerulein", "CHEMICAL", 428, 437], ["cholecystokinin", "CHEMICAL", 473, 488], ["pancreatitis", "DISEASE", 536, 548], ["pancreatic duct obstruction", "DISEASE", 559, 586], ["PKD2", "GENE_OR_GENE_PRODUCT", 55, 59], ["p38 kinases", "GENE_OR_GENE_PRODUCT", 64, 75], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 127, 133], ["tissue", "TISSUE", 171, 177], ["IFN", "GENE_OR_GENE_PRODUCT", 270, 273], ["IFN", "GENE_OR_GENE_PRODUCT", 348, 351], ["caerulein peptide", "SIMPLE_CHEMICAL", 428, 445], ["cholecystokinin", "GENE_OR_GENE_PRODUCT", 473, 488], ["pancreatic duct", "MULTI-TISSUE_STRUCTURE", 559, 574], ["trypsin", "GENE_OR_GENE_PRODUCT", 615, 622], ["PKD2", "PROTEIN", 55, 59], ["p38 kinases", "PROTEIN", 64, 75], ["IFNAR1", "PROTEIN", 127, 133], ["IFN", "PROTEIN", 270, 273], ["IFN", "PROTEIN", 348, 351], ["trypsin", "PROTEIN", 615, 622], ["pharmacologic induction", "TREATMENT", 28, 51], ["PKD2 and p38 kinases", "TREATMENT", 55, 75], ["IFNAR1", "PROBLEM", 127, 133], ["inflammatory tissue injury", "PROBLEM", 158, 184], ["acute inflammatory conditions", "PROBLEM", 222, 251], ["acute pancreatitis", "PROBLEM", 293, 311], ["IFN", "PROBLEM", 348, 351], ["pancreatitis", "PROBLEM", 355, 367], ["caerulein peptide", "TREATMENT", 428, 445], ["cholecystokinin", "TREATMENT", 473, 488], ["acute pancreatitis", "PROBLEM", 530, 548], ["pancreatic duct obstruction", "PROBLEM", 559, 586], ["premature activation of trypsin", "PROBLEM", 591, 622], ["inflammatory tissue", "OBSERVATION", 158, 177], ["acute", "OBSERVATION_MODIFIER", 222, 227], ["inflammatory", "OBSERVATION", 228, 240], ["acute", "OBSERVATION_MODIFIER", 293, 298], ["pancreatitis", "OBSERVATION", 299, 311], ["pancreatitis", "OBSERVATION", 355, 367], ["acute", "OBSERVATION_MODIFIER", 530, 535], ["pancreatitis", "OBSERVATION", 536, 548], ["pancreatic duct", "ANATOMY", 559, 574], ["obstruction", "OBSERVATION", 575, 586]]], ["Caerulein injections triggered elevated plasma levels of IFN\u03b2 (Supplementary Fig 1) and pancreatic mRNA levels of IFN-stimulated genes such as Isg15, Irf7 and Stat1 (Supplementary Fig 2).", [["plasma", "ANATOMY", 40, 46], ["pancreatic", "ANATOMY", 88, 98], ["Caerulein", "CHEMICAL", 0, 9], ["Caerulein", "CHEMICAL", 0, 9], ["Caerulein", "SIMPLE_CHEMICAL", 0, 9], ["plasma", "ORGANISM_SUBSTANCE", 40, 46], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 57, 61], ["pancreatic", "ORGAN", 88, 98], ["IFN", "GENE_OR_GENE_PRODUCT", 114, 117], ["Isg15", "GENE_OR_GENE_PRODUCT", 143, 148], ["Irf7", "GENE_OR_GENE_PRODUCT", 150, 154], ["Stat1", "GENE_OR_GENE_PRODUCT", 159, 164], ["IFN", "PROTEIN", 57, 60], ["pancreatic mRNA", "RNA", 88, 103], ["IFN", "PROTEIN", 114, 117], ["Isg15", "DNA", 143, 148], ["Irf7", "DNA", 150, 154], ["Stat1", "PROTEIN", 159, 164], ["Caerulein injections", "TREATMENT", 0, 20], ["elevated plasma levels of IFN", "PROBLEM", 31, 60], ["Supplementary Fig", "TREATMENT", 63, 80], ["pancreatic mRNA levels", "TEST", 88, 110], ["IFN-stimulated genes", "TREATMENT", 114, 134], ["Irf7 and Stat1 (Supplementary Fig", "TREATMENT", 150, 183], ["pancreatic", "ANATOMY", 88, 98]]], ["Furthermore, this treatment led to a noticeable increase in the levels of amylase in blood plasma (Fig 1A) and in characteristic histopathologic alterations in the pancreas such as primary pancreatic tissue autodigestive injury (manifested by the loss of acinar cells) and evidence of secondary inflammation including activation of p38 kinase, tissue edema and immune cell infiltration (Fig 1B\u2013D, Supplementary Figs 3\u20135).Important role of IFN in pathogenesis of acute pancreatitis ::: ResultsRemarkably, wild type (Ifnar1+/+) and Ifnar1\u2212/\u2212 mice displayed a similar severity of these alterations (Fig 1, Supplementary Figs 3\u20135) suggesting that either IFN signaling plays no role in pathogenesis of acute pancreatitis or IFNAR1 is inactivated under these conditions in wild type tissues.", [["blood plasma", "ANATOMY", 85, 97], ["pancreas", "ANATOMY", 164, 172], ["pancreatic tissue", "ANATOMY", 189, 206], ["acinar cells", "ANATOMY", 255, 267], ["tissue", "ANATOMY", 344, 350], ["immune cell", "ANATOMY", 361, 372], ["tissues", "ANATOMY", 777, 784], ["autodigestive injury", "DISEASE", 207, 227], ["inflammation", "DISEASE", 295, 307], ["edema", "DISEASE", 351, 356], ["pancreatitis", "DISEASE", 468, 480], ["pancreatitis", "DISEASE", 703, 715], ["amylase", "GENE_OR_GENE_PRODUCT", 74, 81], ["blood plasma", "ORGANISM_SUBSTANCE", 85, 97], ["pancreas", "ORGAN", 164, 172], ["pancreatic tissue", "TISSUE", 189, 206], ["acinar cells", "CELL", 255, 267], ["p38 kinase", "GENE_OR_GENE_PRODUCT", 332, 342], ["tissue", "TISSUE", 344, 350], ["immune cell", "CELL", 361, 372], ["IFN", "GENE_OR_GENE_PRODUCT", 439, 442], ["Ifnar1", "GENE_OR_GENE_PRODUCT", 515, 521], ["Ifnar1\u2212", "GENE_OR_GENE_PRODUCT", 530, 537], ["IFN", "GENE_OR_GENE_PRODUCT", 650, 653], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 719, 725], ["tissues", "TISSUE", 777, 784], ["amylase", "PROTEIN", 74, 81], ["blood plasma", "CELL_TYPE", 85, 97], ["acinar cells", "CELL_TYPE", 255, 267], ["p38 kinase", "PROTEIN", 332, 342], ["IFN", "PROTEIN", 439, 442], ["Ifnar1", "PROTEIN", 515, 521], ["IFN", "PROTEIN", 650, 653], ["IFNAR1", "PROTEIN", 719, 725], ["mice", "SPECIES", 540, 544], ["mice", "SPECIES", 540, 544], ["this treatment", "TREATMENT", 13, 27], ["a noticeable increase", "PROBLEM", 35, 56], ["amylase", "TEST", 74, 81], ["blood plasma", "TEST", 85, 97], ["characteristic histopathologic alterations in the pancreas", "PROBLEM", 114, 172], ["primary pancreatic tissue autodigestive injury", "PROBLEM", 181, 227], ["the loss of acinar cells", "PROBLEM", 243, 267], ["secondary inflammation", "PROBLEM", 285, 307], ["activation of p38 kinase", "PROBLEM", 318, 342], ["tissue edema", "PROBLEM", 344, 356], ["immune cell infiltration", "PROBLEM", 361, 385], ["acute pancreatitis", "PROBLEM", 462, 480], ["Ifnar1", "TEST", 515, 521], ["these alterations", "PROBLEM", 577, 594], ["acute pancreatitis", "PROBLEM", 697, 715], ["IFNAR1", "PROBLEM", 719, 725], ["noticeable", "OBSERVATION_MODIFIER", 37, 47], ["increase", "OBSERVATION_MODIFIER", 48, 56], ["histopathologic alterations", "OBSERVATION", 129, 156], ["pancreas", "ANATOMY", 164, 172], ["primary", "OBSERVATION_MODIFIER", 181, 188], ["pancreatic tissue", "ANATOMY", 189, 206], ["autodigestive injury", "OBSERVATION", 207, 227], ["acinar cells", "OBSERVATION", 255, 267], ["evidence of", "UNCERTAINTY", 273, 284], ["secondary", "OBSERVATION_MODIFIER", 285, 294], ["inflammation", "OBSERVATION", 295, 307], ["p38 kinase", "OBSERVATION", 332, 342], ["tissue", "ANATOMY", 344, 350], ["edema", "OBSERVATION", 351, 356], ["immune cell infiltration", "OBSERVATION", 361, 385], ["acute", "OBSERVATION_MODIFIER", 462, 467], ["pancreatitis", "OBSERVATION", 468, 480], ["no role", "UNCERTAINTY", 670, 677], ["acute", "OBSERVATION_MODIFIER", 697, 702], ["pancreatitis", "OBSERVATION", 703, 715]]], ["Levels of IFNAR1 protein in the pancreas were indeed decreased after caerulein treatment (Fig 1D).", [["pancreas", "ANATOMY", 32, 40], ["caerulein", "CHEMICAL", 69, 78], ["caerulein", "CHEMICAL", 69, 78], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 10, 16], ["pancreas", "ORGAN", 32, 40], ["caerulein", "SIMPLE_CHEMICAL", 69, 78], ["IFNAR1 protein", "PROTEIN", 10, 24], ["IFNAR1 protein in the pancreas", "PROBLEM", 10, 40], ["caerulein treatment", "TREATMENT", 69, 88], ["IFNAR1 protein", "OBSERVATION", 10, 24], ["pancreas", "ANATOMY", 32, 40], ["decreased", "OBSERVATION_MODIFIER", 53, 62]]], ["Given that trypsin (activated in the inflamed pancreas) can cleave the extracellular domain of IFNAR1 in vitro (Supplementary Fig 6) and diverse inflammatory stimuli can induce ubiquitination of the intracellular domain of IFNAR1 leading to its endocytosis and degradation in cultured mammalian cells (Qian et al, 2011; Zheng et al, 2011b; Huangfu et al, 2012), it is plausible that a similar proteolytic inactivation of IFNAR1 could occur in vivo.Important role of IFN in pathogenesis of acute pancreatitis ::: ResultsIndeed, we observed that induction of pancreatitis robustly increased plasma concentration of several inflammatory cytokines including IL1\u03b1 (2.6-fold), IL1\u03b2 (12.8-fold), VEGF (70.5-fold) TNF\u03b1 (4.5-fold), and IL6 (585.2-fold) as well as stimulated p38 kinase activation in pancreatic tissue (Fig 1C,D).", [["pancreas", "ANATOMY", 46, 54], ["extracellular", "ANATOMY", 71, 84], ["intracellular", "ANATOMY", 199, 212], ["cells", "ANATOMY", 295, 300], ["plasma", "ANATOMY", 589, 595], ["pancreatic tissue", "ANATOMY", 791, 808], ["pancreatitis", "DISEASE", 495, 507], ["pancreatitis", "DISEASE", 557, 569], ["trypsin", "GENE_OR_GENE_PRODUCT", 11, 18], ["pancreas", "ORGAN", 46, 54], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 71, 84], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 95, 101], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 199, 212], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 223, 229], ["mammalian cells", "CELL", 285, 300], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 421, 427], ["IFN", "GENE_OR_GENE_PRODUCT", 466, 469], ["plasma", "ORGANISM_SUBSTANCE", 589, 595], ["IL1\u03b1", "GENE_OR_GENE_PRODUCT", 654, 658], ["IL1\u03b2", "GENE_OR_GENE_PRODUCT", 671, 675], ["VEGF", "GENE_OR_GENE_PRODUCT", 689, 693], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 706, 710], ["IL6", "GENE_OR_GENE_PRODUCT", 727, 730], ["p38 kinase", "GENE_OR_GENE_PRODUCT", 766, 776], ["pancreatic tissue", "TISSUE", 791, 808], ["trypsin", "PROTEIN", 11, 18], ["extracellular domain", "PROTEIN", 71, 91], ["IFNAR1", "PROTEIN", 95, 101], ["intracellular domain", "PROTEIN", 199, 219], ["IFNAR1", "PROTEIN", 223, 229], ["cultured mammalian cells", "CELL_LINE", 276, 300], ["IFNAR1", "PROTEIN", 421, 427], ["IFN", "PROTEIN", 466, 469], ["inflammatory cytokines", "PROTEIN", 621, 643], ["IL1\u03b1", "PROTEIN", 654, 658], ["IL1\u03b2", "PROTEIN", 671, 675], ["VEGF", "PROTEIN", 689, 693], ["TNF\u03b1", "PROTEIN", 706, 710], ["IL6", "PROTEIN", 727, 730], ["p38 kinase", "PROTEIN", 766, 776], ["trypsin (activated in the inflamed pancreas", "TREATMENT", 11, 54], ["IFNAR1 in vitro (Supplementary Fig", "TREATMENT", 95, 129], ["diverse inflammatory stimuli", "TREATMENT", 137, 165], ["the intracellular domain of IFNAR1", "PROBLEM", 195, 229], ["its endocytosis", "PROBLEM", 241, 256], ["a similar proteolytic inactivation of IFNAR1", "PROBLEM", 383, 427], ["acute pancreatitis", "PROBLEM", 489, 507], ["pancreatitis", "PROBLEM", 557, 569], ["several inflammatory cytokines", "PROBLEM", 613, 643], ["IL1\u03b1", "TEST", 654, 658], ["IL1\u03b2", "TEST", 671, 675], ["VEGF", "TEST", 689, 693], ["TNF\u03b1", "TEST", 706, 710], ["IL6", "TEST", 727, 730], ["stimulated p38 kinase activation in pancreatic tissue", "PROBLEM", 755, 808], ["pancreas", "ANATOMY", 46, 54], ["inflammatory stimuli", "OBSERVATION", 145, 165], ["acute", "OBSERVATION_MODIFIER", 489, 494], ["pancreatitis", "OBSERVATION", 495, 507], ["pancreatitis", "OBSERVATION", 557, 569], ["several", "OBSERVATION_MODIFIER", 613, 620], ["inflammatory", "OBSERVATION_MODIFIER", 621, 633], ["VEGF", "ANATOMY", 689, 693], ["IL6", "ANATOMY", 727, 730], ["pancreatic tissue", "ANATOMY", 791, 808]]], ["Furthermore, analysis of lysates from pancreatic tissues from wild type mice revealed an increase in ubiquitination of IFNAR1 in response to caerulein injections (Fig 1D).", [["lysates", "ANATOMY", 25, 32], ["pancreatic tissues", "ANATOMY", 38, 56], ["caerulein", "CHEMICAL", 141, 150], ["caerulein", "CHEMICAL", 141, 150], ["lysates", "ORGANISM_SUBSTANCE", 25, 32], ["pancreatic tissues", "TISSUE", 38, 56], ["mice", "ORGANISM", 72, 76], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 119, 125], ["caerulein", "SIMPLE_CHEMICAL", 141, 150], ["IFNAR1", "PROTEIN", 119, 125], ["mice", "SPECIES", 72, 76], ["lysates", "TEST", 25, 32], ["pancreatic tissues", "PROBLEM", 38, 56], ["ubiquitination of IFNAR1", "PROBLEM", 101, 125], ["caerulein injections", "TREATMENT", 141, 161], ["pancreatic", "ANATOMY", 38, 48], ["increase", "OBSERVATION_MODIFIER", 89, 97], ["ubiquitination of IFNAR1", "OBSERVATION", 101, 125]]], ["Given these data, it is plausible that the role of IFN in pathogenesis of pancreatitis is masked by rapid elimination of IFNAR1 protein in wild type animals.Important role of IFN in pathogenesis of acute pancreatitis ::: ResultsTo test this possibility, we took advantage of the fact that numerous pathways leading to ubiquitination of IFNAR1 in response to inflammatory stimuli converge on phosphorylation of IFNAR1 on Ser526/Ser535 that enables the recruitment of \u03b2-Trcp E3 ligase (Huangfu ' Fuchs, 2010; Fuchs, 2013).", [["IFN", "CHEMICAL", 51, 54], ["pancreatitis", "DISEASE", 74, 86], ["pancreatitis", "DISEASE", 204, 216], ["Ser", "CHEMICAL", 427, 430], ["IFN", "GENE_OR_GENE_PRODUCT", 51, 54], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 121, 127], ["IFN", "GENE_OR_GENE_PRODUCT", 175, 178], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 336, 342], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 410, 416], ["Ser526", "GENE_OR_GENE_PRODUCT", 420, 426], ["Ser535", "AMINO_ACID", 427, 433], ["\u03b2-Trcp E3", "GENE_OR_GENE_PRODUCT", 466, 475], ["IFN", "PROTEIN", 51, 54], ["IFNAR1 protein", "PROTEIN", 121, 135], ["IFN", "PROTEIN", 175, 178], ["IFNAR1", "PROTEIN", 336, 342], ["IFNAR1", "PROTEIN", 410, 416], ["Ser526", "PROTEIN", 420, 426], ["Ser535", "PROTEIN", 427, 433], ["\u03b2-Trcp E3 ligase", "PROTEIN", 466, 482], ["pancreatitis", "PROBLEM", 74, 86], ["IFNAR1 protein", "PROBLEM", 121, 135], ["acute pancreatitis", "PROBLEM", 198, 216], ["ubiquitination of IFNAR1", "PROBLEM", 318, 342], ["inflammatory stimuli", "PROBLEM", 358, 378], ["phosphorylation of IFNAR1", "TREATMENT", 391, 416], ["pancreatitis", "OBSERVATION", 74, 86], ["acute", "OBSERVATION_MODIFIER", 198, 203], ["pancreatitis", "OBSERVATION", 204, 216], ["inflammatory", "OBSERVATION_MODIFIER", 358, 370]]], ["We previously developed the knock-in mice harboring a single Ifnar1S526A allele (Liu et al, 2009b; Zheng et al, 2011b); all tissues of these animals expressed the IFNAR1S526A mutant protein resistant to ubiquitination induced by VEGF or LPS in vitro (Qian et al, 2011; Zheng et al, 2011b).", [["tissues", "ANATOMY", 124, 131], ["LPS", "CHEMICAL", 237, 240], ["mice", "ORGANISM", 37, 41], ["tissues", "TISSUE", 124, 131], ["animals", "ORGANISM", 141, 148], ["IFNAR", "GENE_OR_GENE_PRODUCT", 163, 168], ["VEGF", "GENE_OR_GENE_PRODUCT", 229, 233], ["LPS", "SIMPLE_CHEMICAL", 237, 240], ["Ifnar1S526A allele", "DNA", 61, 79], ["IFNAR1S526A mutant protein", "PROTEIN", 163, 189], ["VEGF", "PROTEIN", 229, 233], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41], ["mutant protein", "PROBLEM", 175, 189]]], ["Here we used animals homozygous for this mutant allele (Ifnar1SA mice).", [["Ifnar1SA mice", "ORGANISM", 56, 69], ["mutant allele", "DNA", 41, 54], ["mice", "SPECIES", 65, 69], ["animals homozygous", "TREATMENT", 13, 31], ["this mutant allele (Ifnar1SA mice", "TREATMENT", 36, 69]]], ["Importantly, na\u00efve Ifnar1SA mice developed normally and exhibit neither any signs of growth retardation nor gross abnormalities (Supplementary Fig 7), nor hallmarks of constitutive pancreatic inflammation (Fig 1B,C).", [["pancreatic", "ANATOMY", 181, 191], ["growth retardation", "DISEASE", 85, 103], ["pancreatic inflammation", "DISEASE", 181, 204], ["Ifnar1SA mice", "ORGANISM", 19, 32], ["pancreatic", "ORGAN", 181, 191], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 28, 32], ["growth retardation", "PROBLEM", 85, 103], ["gross abnormalities", "PROBLEM", 108, 127], ["constitutive pancreatic inflammation", "PROBLEM", 168, 204], ["constitutive", "OBSERVATION_MODIFIER", 168, 180], ["pancreatic", "ANATOMY", 181, 191], ["inflammation", "OBSERVATION", 192, 204]]], ["Cells from these animals exhibited a slower rate of IFNAR1 degradation yet did not display a hyper-reactive IFN signaling as evident from the lack of constitutive activation of STAT1 (Supplementary Fig 8), sustained ability of their hematopoietic cells to engraft and reconstitute bone marrow in lethally irradiated mice (Material and Methods and experiments described below), normal blood cell counts and serum chemistry profiles as well mitochondrial activities in the peripheral tissues similar to that of wild type mice (Supplemental Table 1).Important role of IFN in pathogenesis of acute pancreatitis ::: ResultsHowever, under conditions of experimental pancreatitis, Ifnar1SA mice exhibited noticeably higher pancreatic tissue levels of IFN-stimulated proteins (STAT1 and PKR, Fig 1D) and IFN-stimulated genes such as Irf7 (Supplementary Fig 2) compared with wild type animals.", [["Cells", "ANATOMY", 0, 5], ["hematopoietic cells", "ANATOMY", 233, 252], ["bone marrow", "ANATOMY", 281, 292], ["blood cell", "ANATOMY", 384, 394], ["serum", "ANATOMY", 406, 411], ["mitochondrial", "ANATOMY", 439, 452], ["peripheral tissues", "ANATOMY", 471, 489], ["pancreatic tissue", "ANATOMY", 716, 733], ["pancreatitis", "DISEASE", 594, 606], ["pancreatitis", "DISEASE", 660, 672], ["Cells", "CELL", 0, 5], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 52, 58], ["IFN", "GENE_OR_GENE_PRODUCT", 108, 111], ["STAT1", "GENE_OR_GENE_PRODUCT", 177, 182], ["hematopoietic cells", "CELL", 233, 252], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 281, 292], ["mice", "ORGANISM", 316, 320], ["blood cell", "CELL", 384, 394], ["serum", "ORGANISM_SUBSTANCE", 406, 411], ["mitochondrial", "CELLULAR_COMPONENT", 439, 452], ["peripheral tissues", "TISSUE", 471, 489], ["mice", "ORGANISM", 519, 523], ["IFN", "GENE_OR_GENE_PRODUCT", 565, 568], ["Ifnar1SA mice", "ORGANISM", 674, 687], ["pancreatic tissue", "TISSUE", 716, 733], ["IFN-stimulated proteins", "GENE_OR_GENE_PRODUCT", 744, 767], ["STAT1", "GENE_OR_GENE_PRODUCT", 769, 774], ["PKR", "GENE_OR_GENE_PRODUCT", 779, 782], ["Fig 1D", "GENE_OR_GENE_PRODUCT", 784, 790], ["IFN-stimulated genes", "GENE_OR_GENE_PRODUCT", 796, 816], ["Irf7", "GENE_OR_GENE_PRODUCT", 825, 829], ["IFNAR1", "PROTEIN", 52, 58], ["IFN", "PROTEIN", 108, 111], ["STAT1", "PROTEIN", 177, 182], ["hematopoietic cells", "CELL_TYPE", 233, 252], ["IFN", "PROTEIN", 565, 568], ["IFN-stimulated proteins", "PROTEIN", 744, 767], ["STAT1", "PROTEIN", 769, 774], ["PKR", "PROTEIN", 779, 782], ["Fig 1D", "PROTEIN", 784, 790], ["IFN", "PROTEIN", 796, 799], ["Irf7", "DNA", 825, 829], ["mice", "SPECIES", 316, 320], ["mice", "SPECIES", 519, 523], ["mice", "SPECIES", 683, 687], ["mice", "SPECIES", 316, 320], ["mice", "SPECIES", 519, 523], ["mice", "SPECIES", 683, 687], ["IFNAR1 degradation", "PROBLEM", 52, 70], ["a hyper-reactive IFN signaling", "PROBLEM", 91, 121], ["STAT1 (Supplementary Fig", "TREATMENT", 177, 201], ["their hematopoietic cells to engraft", "TREATMENT", 227, 263], ["blood cell counts", "TEST", 384, 401], ["serum chemistry profiles", "TEST", 406, 430], ["acute pancreatitis", "PROBLEM", 588, 606], ["experimental pancreatitis", "PROBLEM", 647, 672], ["noticeably higher pancreatic tissue levels of IFN", "PROBLEM", 698, 747], ["stimulated proteins", "PROBLEM", 748, 767], ["STAT1", "TEST", 769, 774], ["PKR", "TEST", 779, 782], ["IFN-stimulated genes", "TREATMENT", 796, 816], ["Irf7 (Supplementary Fig", "TREATMENT", 825, 848], ["hematopoietic cells", "OBSERVATION", 233, 252], ["bone marrow", "ANATOMY", 281, 292], ["peripheral tissues", "ANATOMY", 471, 489], ["acute", "OBSERVATION_MODIFIER", 588, 593], ["pancreatitis", "OBSERVATION", 594, 606], ["experimental", "OBSERVATION_MODIFIER", 647, 659], ["pancreatitis", "OBSERVATION", 660, 672], ["pancreatic tissue", "ANATOMY", 716, 733]]], ["Consistent with the key role of Irf7 in subsequent IFN induction (Platanias, 2005; Uze et al, 2007; Stark ' Darnell, 2012), levels of IFN\u03b2 in plasma of caerulein-treated Ifnar1SA mice were also elevated (Supplementary Fig 1).", [["plasma", "ANATOMY", 142, 148], ["caerulein", "CHEMICAL", 152, 161], ["caerulein", "CHEMICAL", 152, 161], ["Irf7", "GENE_OR_GENE_PRODUCT", 32, 36], ["IFN", "GENE_OR_GENE_PRODUCT", 51, 54], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 134, 138], ["plasma", "ORGANISM_SUBSTANCE", 142, 148], ["caerulein", "SIMPLE_CHEMICAL", 152, 161], ["Ifnar1SA", "ORGANISM", 170, 178], ["mice", "ORGANISM", 179, 183], ["Irf7", "PROTEIN", 32, 36], ["IFN", "PROTEIN", 51, 54], ["IFN\u03b2", "PROTEIN", 134, 138], ["mice", "SPECIES", 179, 183], ["mice", "SPECIES", 179, 183], ["subsequent IFN induction", "TREATMENT", 40, 64], ["Platanias", "TEST", 66, 75], ["levels", "TEST", 124, 130], ["IFN", "TEST", 134, 137], ["caerulein", "TEST", 152, 161]]], ["Importantly, while the IFNAR1S526A mutant receptor remained sensitive to the proteolytic effects of extracellular trypsin in vitro (Supplementary Fig 6), we did not observe its ubiquitination and downregulation in response to the caerulein-induced pancreatitis in vivo (Fig 1D).", [["extracellular", "ANATOMY", 100, 113], ["caerulein", "CHEMICAL", 230, 239], ["pancreatitis", "DISEASE", 248, 260], ["caerulein", "CHEMICAL", 230, 239], ["IFNAR1S526A", "GENE_OR_GENE_PRODUCT", 23, 34], ["extracellular trypsin", "GENE_OR_GENE_PRODUCT", 100, 121], ["caerulein", "SIMPLE_CHEMICAL", 230, 239], ["IFNAR1S526A mutant receptor", "PROTEIN", 23, 50], ["extracellular trypsin", "PROTEIN", 100, 121], ["extracellular trypsin", "TREATMENT", 100, 121], ["vitro (Supplementary Fig", "TREATMENT", 125, 149], ["its ubiquitination", "PROBLEM", 173, 191], ["downregulation", "PROBLEM", 196, 210], ["the caerulein", "TREATMENT", 226, 239], ["pancreatitis", "PROBLEM", 248, 260], ["pancreatitis", "OBSERVATION", 248, 260]]], ["These results demonstrate that analysis of inflammation in Ifnar1SA mice can provide us with a tool to differentiate between IFNAR1 ubiquitination-dependent and \u2013independent mechanisms.Important role of IFN in pathogenesis of acute pancreatitis ::: ResultsTo determine whether induction of IFNAR1 ubiquitination/downregulation is common under diverse inflammatory conditions, we utilized the LPS treatment to stimulate generalized inflammation in vivo.", [["inflammation", "DISEASE", 43, 55], ["pancreatitis", "DISEASE", 232, 244], ["LPS", "CHEMICAL", 392, 395], ["inflammation", "DISEASE", 431, 443], ["Ifnar1SA mice", "ORGANISM", 59, 72], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 125, 131], ["IFN", "GENE_OR_GENE_PRODUCT", 203, 206], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 290, 296], ["LPS", "SIMPLE_CHEMICAL", 392, 395], ["IFNAR1", "PROTEIN", 125, 131], ["IFN", "PROTEIN", 203, 206], ["IFNAR1", "PROTEIN", 290, 296], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 68, 72], ["inflammation", "PROBLEM", 43, 55], ["acute pancreatitis", "PROBLEM", 226, 244], ["IFNAR1 ubiquitination", "PROBLEM", 290, 311], ["downregulation", "PROBLEM", 312, 326], ["diverse inflammatory conditions", "PROBLEM", 343, 374], ["the LPS treatment", "TREATMENT", 388, 405], ["generalized inflammation in vivo", "PROBLEM", 419, 451], ["inflammation", "OBSERVATION", 43, 55], ["acute", "OBSERVATION_MODIFIER", 226, 231], ["pancreatitis", "OBSERVATION", 232, 244], ["diverse", "OBSERVATION_MODIFIER", 343, 350], ["inflammatory", "OBSERVATION", 351, 363], ["generalized", "OBSERVATION_MODIFIER", 419, 430], ["inflammation", "OBSERVATION", 431, 443]]], ["Injection of LPS decreased the cell surface IFNAR1 protein levels in leukocytes from wild type but not Ifnar1SA mice (Fig 2A).", [["cell surface", "ANATOMY", 31, 43], ["leukocytes", "ANATOMY", 69, 79], ["LPS", "CHEMICAL", 13, 16], ["LPS", "SIMPLE_CHEMICAL", 13, 16], ["cell", "CELL", 31, 35], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 44, 50], ["leukocytes", "CELL", 69, 79], ["Ifnar1SA mice", "ORGANISM", 103, 116], ["IFNAR1", "PROTEIN", 44, 50], ["leukocytes", "CELL_TYPE", 69, 79], ["mice", "SPECIES", 112, 116], ["mice", "SPECIES", 112, 116], ["Injection of LPS", "TREATMENT", 0, 16], ["the cell surface IFNAR1 protein levels", "TEST", 27, 65], ["leukocytes", "TEST", 69, 79], ["leukocytes", "ANATOMY", 69, 79]]], ["Given that mRNA levels of Ifnar1 were not dramatically affected (Fig 2B), this result suggests that either inflammation-induced downregulation of IFNAR1 in vivo is ubiquitination-dependent or Ifnar1SA mice do not efficiently produce inflammatory cytokines or IFN in response to LPS.", [["inflammation", "DISEASE", 107, 119], ["LPS", "CHEMICAL", 278, 281], ["Ifnar1", "GENE_OR_GENE_PRODUCT", 26, 32], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 146, 152], ["Ifnar1SA mice", "ORGANISM", 192, 205], ["IFN", "GENE_OR_GENE_PRODUCT", 259, 262], ["LPS", "SIMPLE_CHEMICAL", 278, 281], ["Ifnar1", "PROTEIN", 26, 32], ["IFNAR1", "PROTEIN", 146, 152], ["inflammatory cytokines", "PROTEIN", 233, 255], ["IFN", "PROTEIN", 259, 262], ["mice", "SPECIES", 201, 205], ["mice", "SPECIES", 201, 205], ["mRNA levels", "TEST", 11, 22], ["Ifnar1", "PROBLEM", 26, 32], ["inflammation", "PROBLEM", 107, 119], ["inflammatory cytokines", "PROBLEM", 233, 255], ["IFN", "PROBLEM", 259, 262], ["LPS", "TEST", 278, 281], ["inflammation", "OBSERVATION", 107, 119], ["inflammatory", "OBSERVATION_MODIFIER", 233, 245]]], ["Contrary to the latter hypothesis, much higher levels of IL1\u03b2, TNF\u03b1, IL6 and IFN\u03b2 were detected in plasma from Ifnar1SA than from wild type animals treated with LPS (Fig 2C, Supplementary Fig 9).", [["plasma", "ANATOMY", 99, 105], ["Ifnar1SA", "ANATOMY", 111, 119], ["LPS", "CHEMICAL", 161, 164], ["IL1\u03b2", "GENE_OR_GENE_PRODUCT", 57, 61], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 63, 67], ["IL6", "GENE_OR_GENE_PRODUCT", 69, 72], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 77, 81], ["plasma", "ORGANISM_SUBSTANCE", 99, 105], ["Ifnar1SA", "GENE_OR_GENE_PRODUCT", 111, 119], ["LPS", "SIMPLE_CHEMICAL", 161, 164], ["IL1\u03b2", "PROTEIN", 57, 61], ["TNF\u03b1", "PROTEIN", 63, 67], ["IL6", "PROTEIN", 69, 72], ["IFN\u03b2", "PROTEIN", 77, 81], ["the latter hypothesis", "PROBLEM", 12, 33], ["IL1\u03b2", "TEST", 57, 61], ["TNF", "TEST", 63, 66], ["IL6", "PROBLEM", 69, 72], ["IFN", "PROBLEM", 77, 80], ["LPS (Fig 2C", "TREATMENT", 161, 172]]], ["These data collectively indicate that promoting the ubiquitination of IFNAR1 is important for the downregulation of this receptor in response to local and systemic inflammatory stimuli in vivo.Important role of IFN in pathogenesis of acute pancreatitis ::: ResultsRemarkably, in the context of acute pancreatic inflammation, Ifnar1SA mice exhibited an increased amylase levels compared to the wild type animals (Fig 1A).", [["pancreatic", "ANATOMY", 300, 310], ["pancreatitis", "DISEASE", 240, 252], ["pancreatic inflammation", "DISEASE", 300, 323], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 70, 76], ["IFN", "GENE_OR_GENE_PRODUCT", 211, 214], ["pancreatic", "ORGAN", 300, 310], ["Ifnar1SA mice", "ORGANISM", 325, 338], ["amylase", "GENE_OR_GENE_PRODUCT", 362, 369], ["IFNAR1", "PROTEIN", 70, 76], ["IFN", "PROTEIN", 211, 214], ["amylase", "PROTEIN", 362, 369], ["mice", "SPECIES", 334, 338], ["mice", "SPECIES", 334, 338], ["this receptor", "TREATMENT", 116, 129], ["local and systemic inflammatory stimuli", "TREATMENT", 145, 184], ["acute pancreatitis", "PROBLEM", 234, 252], ["acute pancreatic inflammation", "PROBLEM", 294, 323], ["Ifnar1SA mice", "PROBLEM", 325, 338], ["an increased amylase levels", "PROBLEM", 349, 376], ["systemic", "OBSERVATION_MODIFIER", 155, 163], ["inflammatory stimuli", "OBSERVATION", 164, 184], ["acute", "OBSERVATION_MODIFIER", 234, 239], ["pancreatitis", "OBSERVATION", 240, 252], ["acute", "OBSERVATION_MODIFIER", 294, 299], ["pancreatic", "ANATOMY", 300, 310], ["inflammation", "OBSERVATION", 311, 323], ["increased", "OBSERVATION_MODIFIER", 352, 361], ["amylase levels", "OBSERVATION", 362, 376]]], ["A greater severity of pancreatitis in these mice was also manifested by an extensive acinar cell loss, pronounced leukocyte infiltration and robust activation of p38 kinase (Fig 1B,C and Supplementary Figs 3\u20135).", [["acinar cell", "ANATOMY", 85, 96], ["leukocyte", "ANATOMY", 114, 123], ["pancreatitis", "DISEASE", 22, 34], ["mice", "ORGANISM", 44, 48], ["acinar cell", "CELL", 85, 96], ["leukocyte", "CELL", 114, 123], ["p38 kinase", "GENE_OR_GENE_PRODUCT", 162, 172], ["p38 kinase", "PROTEIN", 162, 172], ["Fig 1B,C and Supplementary Figs 3\u20135", "PROTEIN", 174, 209], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 44, 48], ["pancreatitis", "PROBLEM", 22, 34], ["an extensive acinar cell loss", "PROBLEM", 72, 101], ["pronounced leukocyte infiltration", "PROBLEM", 103, 136], ["p38 kinase", "TEST", 162, 172], ["greater", "OBSERVATION_MODIFIER", 2, 9], ["severity", "OBSERVATION_MODIFIER", 10, 18], ["pancreatitis", "OBSERVATION", 22, 34], ["extensive", "OBSERVATION_MODIFIER", 75, 84], ["acinar cell loss", "OBSERVATION", 85, 101], ["pronounced", "OBSERVATION_MODIFIER", 103, 113], ["leukocyte infiltration", "OBSERVATION", 114, 136]]], ["Together with a greater expression of IFN-stimulated genes mRNA and proteins (Supplementary Fig 2, Fig 1D) these results indicate that stimulating IFNAR1 ubiquitination and attenuating IFN signaling may have a protective function to curb pancreatic inflammation.", [["pancreatic", "ANATOMY", 238, 248], ["pancreatic inflammation", "DISEASE", 238, 261], ["IFN", "GENE_OR_GENE_PRODUCT", 38, 41], ["Fig 1D", "GENE_OR_GENE_PRODUCT", 99, 105], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 147, 153], ["IFN", "GENE_OR_GENE_PRODUCT", 185, 188], ["pancreatic", "ORGAN", 238, 248], ["IFN", "PROTEIN", 38, 41], ["IFNAR1", "PROTEIN", 147, 153], ["IFN", "PROTEIN", 185, 188], ["IFN", "TREATMENT", 38, 41], ["proteins (Supplementary Fig", "TREATMENT", 68, 95], ["stimulating IFNAR1 ubiquitination", "PROBLEM", 135, 168], ["attenuating IFN signaling", "PROBLEM", 173, 198], ["pancreatic inflammation", "PROBLEM", 238, 261], ["pancreatic", "ANATOMY", 238, 248], ["inflammation", "OBSERVATION", 249, 261]]], ["They also argue that IFN signaling plays an important role in development of acute pancreatitis.Stimulation of IFNAR1 ubiquitination modulates specific leukocyte recruitment and enables pancreatic tissue repair ::: ResultsWe next aimed to investigate the mechanisms by which the inflammation-stimulated ubiquitination of IFNAR1 may contribute to protection of pancreatic tissues from excessive injury.", [["leukocyte", "ANATOMY", 152, 161], ["pancreatic tissue", "ANATOMY", 186, 203], ["pancreatic tissues", "ANATOMY", 360, 378], ["pancreatitis", "DISEASE", 83, 95], ["inflammation", "DISEASE", 279, 291], ["excessive injury", "DISEASE", 384, 400], ["IFN", "GENE_OR_GENE_PRODUCT", 21, 24], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 111, 117], ["leukocyte", "CELL", 152, 161], ["pancreatic tissue", "TISSUE", 186, 203], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 321, 327], ["pancreatic tissues", "TISSUE", 360, 378], ["IFN", "PROTEIN", 21, 24], ["IFNAR1", "PROTEIN", 111, 117], ["IFNAR1", "PROTEIN", 321, 327], ["acute pancreatitis", "PROBLEM", 77, 95], ["Stimulation of IFNAR1 ubiquitination", "TREATMENT", 96, 132], ["specific leukocyte recruitment", "TREATMENT", 143, 173], ["pancreatic tissue repair", "TREATMENT", 186, 210], ["the inflammation", "PROBLEM", 275, 291], ["IFNAR1", "PROBLEM", 321, 327], ["pancreatic tissues", "PROBLEM", 360, 378], ["excessive injury", "PROBLEM", 384, 400], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["pancreatitis", "OBSERVATION", 83, 95], ["IFNAR1 ubiquitination", "OBSERVATION", 111, 132], ["leukocyte recruitment", "OBSERVATION", 152, 173], ["pancreatic", "ANATOMY", 186, 196], ["inflammation", "OBSERVATION", 279, 291], ["pancreatic tissues", "ANATOMY", 360, 378], ["excessive", "OBSERVATION_MODIFIER", 384, 393], ["injury", "OBSERVATION", 394, 400]]], ["We first focused on a balance between inflammatory cytokines (e.g. TNF\u03b1) and anti-inflammatory cytokines (e.g. IL10).", [["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 67, 71], ["IL10", "GENE_OR_GENE_PRODUCT", 111, 115], ["inflammatory cytokines", "PROTEIN", 38, 60], ["TNF\u03b1", "PROTEIN", 67, 71], ["anti-inflammatory cytokines", "PROTEIN", 77, 104], ["IL10", "PROTEIN", 111, 115], ["inflammatory cytokines", "TREATMENT", 38, 60], ["TNF\u03b1", "TREATMENT", 67, 71], ["anti-inflammatory cytokines", "TREATMENT", 77, 104]]], ["Noticeably higher TNF\u03b1 mRNA levels were found in pancreatic tissues from Ifnar1SA mice than in their wild type counterparts (Fig 3A).", [["pancreatic tissues", "ANATOMY", 49, 67], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 18, 22], ["pancreatic tissues", "TISSUE", 49, 67], ["Ifnar1SA mice", "ORGANISM", 73, 86], ["TNF\u03b1 mRNA", "RNA", 18, 27], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 82, 86], ["mRNA levels", "TEST", 23, 34], ["pancreatic tissues", "PROBLEM", 49, 67], ["higher", "OBSERVATION_MODIFIER", 11, 17], ["TNF", "OBSERVATION", 18, 21], ["pancreatic tissues", "ANATOMY", 49, 67]]], ["In addition, the pancreatitis-induced increase in blood plasma TNF\u03b1 levels were also greater in Ifnar1SA (7.89 fold) than in Ifnar1+/+ (4.50-fold) mice.", [["blood plasma", "ANATOMY", 50, 62], ["pancreatitis", "DISEASE", 17, 29], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["plasma", "ORGANISM_SUBSTANCE", 56, 62], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 63, 67], ["Ifnar1", "GENE_OR_GENE_PRODUCT", 125, 131], ["mice", "ORGANISM", 147, 151], ["TNF", "PROTEIN", 63, 66], ["Ifnar1", "PROTEIN", 125, 131], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 147, 151], ["the pancreatitis", "PROBLEM", 13, 29], ["induced increase", "PROBLEM", 30, 46], ["blood plasma TNF\u03b1 levels", "TEST", 50, 74], ["Ifnar1SA", "TEST", 96, 104], ["Ifnar1", "TEST", 125, 131], ["pancreatitis", "OBSERVATION", 17, 29], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["greater", "OBSERVATION_MODIFIER", 85, 92]]], ["Levels of IL10 protein in blood plasma were higher in caerulein-treated Ifnar1SA animals (251 \u00b1 2 versus 114 \u00b1 2 pg/ml in wild type mice) indicative of systemic anti-inflammatory response and consistent with reported increase of this cytokine in caerulein-treated mice (Zhou et al, 2012) and documented ability of IFN to induce IL10 production in leukocytes in vitro (Aman et al, 1996; Rudick et al, 1996).", [["blood plasma", "ANATOMY", 26, 38], ["leukocytes", "ANATOMY", 347, 357], ["caerulein", "CHEMICAL", 54, 63], ["caerulein", "CHEMICAL", 246, 255], ["caerulein", "CHEMICAL", 54, 63], ["IL10", "GENE_OR_GENE_PRODUCT", 10, 14], ["blood plasma", "ORGANISM_SUBSTANCE", 26, 38], ["caerulein", "SIMPLE_CHEMICAL", 54, 63], ["Ifnar1SA animals", "ORGANISM", 72, 88], ["mice", "ORGANISM", 132, 136], ["caerulein", "SIMPLE_CHEMICAL", 246, 255], ["mice", "ORGANISM", 264, 268], ["IFN", "GENE_OR_GENE_PRODUCT", 314, 317], ["IL10", "GENE_OR_GENE_PRODUCT", 328, 332], ["leukocytes", "CELL", 347, 357], ["IL10 protein", "PROTEIN", 10, 22], ["cytokine", "PROTEIN", 234, 242], ["IFN", "PROTEIN", 314, 317], ["IL10", "PROTEIN", 328, 332], ["leukocytes", "CELL_TYPE", 347, 357], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 264, 268], ["Levels", "TEST", 0, 6], ["IL10 protein", "TEST", 10, 22], ["blood plasma", "TEST", 26, 38], ["caerulein", "TEST", 54, 63], ["systemic anti-inflammatory response", "PROBLEM", 152, 187], ["this cytokine in caerulein", "TREATMENT", 229, 255], ["IFN", "TREATMENT", 314, 317], ["IL10 production", "PROBLEM", 328, 343], ["indicative of", "UNCERTAINTY", 138, 151], ["systemic", "OBSERVATION", 152, 160], ["anti-inflammatory response", "OBSERVATION", 161, 187], ["leukocytes", "ANATOMY", 347, 357]]], ["However, unexpectedly low IL10 mRNA levels were found in the pancreatic tissues from Ifnar1SA animals (Fig 3A).", [["pancreatic tissues", "ANATOMY", 61, 79], ["IL10", "GENE_OR_GENE_PRODUCT", 26, 30], ["pancreatic tissues", "TISSUE", 61, 79], ["IL10 mRNA", "RNA", 26, 35], ["unexpectedly low IL10 mRNA levels", "PROBLEM", 9, 42], ["low", "OBSERVATION_MODIFIER", 22, 25], ["pancreatic tissues", "ANATOMY", 61, 79]]], ["This result suggests that downregulation of IFNAR1 in cells localized in the focus of inflammation restrains production of inflammatory TNF\u03b1 while promoting the expression of anti-inflammatory IL10.Stimulation of IFNAR1 ubiquitination modulates specific leukocyte recruitment and enables pancreatic tissue repair ::: ResultsGiven that inflammatory cytokines in the pancreas can be produced by infiltrating leukocytes, we then assessed the recruitment of these cells to the inflamed tissues in wild type and Ifnar1SA mice.", [["cells", "ANATOMY", 54, 59], ["leukocyte", "ANATOMY", 254, 263], ["pancreatic tissue", "ANATOMY", 288, 305], ["pancreas", "ANATOMY", 365, 373], ["infiltrating leukocytes", "ANATOMY", 393, 416], ["cells", "ANATOMY", 460, 465], ["inflamed tissues", "ANATOMY", 473, 489], ["inflammation", "DISEASE", 86, 98], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 44, 50], ["cells", "CELL", 54, 59], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 136, 140], ["IL10", "GENE_OR_GENE_PRODUCT", 193, 197], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 213, 219], ["leukocyte", "CELL", 254, 263], ["pancreatic tissue", "TISSUE", 288, 305], ["pancreas", "ORGAN", 365, 373], ["leukocytes", "CELL", 406, 416], ["cells", "CELL", 460, 465], ["inflamed tissues", "TISSUE", 473, 489], ["Ifnar1SA mice", "ORGANISM", 507, 520], ["IFNAR1", "PROTEIN", 44, 50], ["inflammatory TNF\u03b1", "PROTEIN", 123, 140], ["anti-inflammatory IL10", "PROTEIN", 175, 197], ["IFNAR1", "PROTEIN", 213, 219], ["inflammatory cytokines", "PROTEIN", 335, 357], ["infiltrating leukocytes", "CELL_TYPE", 393, 416], ["mice", "SPECIES", 516, 520], ["mice", "SPECIES", 516, 520], ["downregulation of IFNAR1 in cells", "PROBLEM", 26, 59], ["inflammation", "PROBLEM", 86, 98], ["inflammatory TNF", "PROBLEM", 123, 139], ["anti-inflammatory IL10", "TREATMENT", 175, 197], ["Stimulation of IFNAR1 ubiquitination", "TREATMENT", 198, 234], ["specific leukocyte recruitment", "TREATMENT", 245, 275], ["pancreatic tissue repair", "TREATMENT", 288, 312], ["inflammatory cytokines in the pancreas", "PROBLEM", 335, 373], ["infiltrating leukocytes", "PROBLEM", 393, 416], ["downregulation", "OBSERVATION_MODIFIER", 26, 40], ["IFNAR1", "OBSERVATION_MODIFIER", 44, 50], ["focus", "OBSERVATION_MODIFIER", 77, 82], ["inflammation", "OBSERVATION", 86, 98], ["inflammatory", "OBSERVATION_MODIFIER", 123, 135], ["anti-inflammatory IL10", "OBSERVATION", 175, 197], ["IFNAR1 ubiquitination", "OBSERVATION", 213, 234], ["leukocyte recruitment", "OBSERVATION", 254, 275], ["pancreatic", "ANATOMY", 288, 298], ["inflammatory", "OBSERVATION_MODIFIER", 335, 347], ["cytokines", "OBSERVATION", 348, 357], ["pancreas", "ANATOMY", 365, 373], ["infiltrating leukocytes", "OBSERVATION", 393, 416], ["inflamed tissues", "OBSERVATION", 473, 489]]], ["Upon caerulein injections, the pancreata from Ifnar1SA animals displayed a greater extent of infiltration by leukocytes as seen from histologic analysis (Fig 1B and Supplementary Fig 3) and immunofluorescent analysis of CD45+ cells (Fig 3B).", [["pancreata", "ANATOMY", 31, 40], ["leukocytes", "ANATOMY", 109, 119], ["CD45+ cells", "ANATOMY", 220, 231], ["caerulein", "CHEMICAL", 5, 14], ["caerulein", "SIMPLE_CHEMICAL", 5, 14], ["pancreata", "ORGAN", 31, 40], ["leukocytes", "CELL", 109, 119], ["CD45", "GENE_OR_GENE_PRODUCT", 220, 224], ["leukocytes", "CELL_TYPE", 109, 119], ["CD45", "PROTEIN", 220, 224], ["caerulein injections", "TREATMENT", 5, 25], ["infiltration", "PROBLEM", 93, 105], ["leukocytes", "PROBLEM", 109, 119], ["histologic analysis", "TEST", 133, 152], ["Supplementary Fig", "TEST", 165, 182], ["immunofluorescent analysis", "TEST", 190, 216], ["CD45", "TEST", 220, 224], ["pancreata", "ANATOMY", 31, 40], ["greater extent", "OBSERVATION_MODIFIER", 75, 89], ["infiltration", "OBSERVATION", 93, 105], ["leukocytes", "OBSERVATION", 109, 119]]], ["Among these leukocytes, the CD11b+ myeloid cells displayed a prominent preference for the diffuse pancreatic infiltration in the Ifnar1SA mice (Fig 3C and control staining in Supplementary Fig 10A).", [["leukocytes", "ANATOMY", 12, 22], ["CD11b+ myeloid cells", "ANATOMY", 28, 48], ["pancreatic", "ANATOMY", 98, 108], ["pancreatic infiltration", "DISEASE", 98, 121], ["leukocytes", "CELL", 12, 22], ["CD11b", "GENE_OR_GENE_PRODUCT", 28, 33], ["myeloid cells", "CELL", 35, 48], ["pancreatic", "ORGAN", 98, 108], ["Ifnar1SA mice", "ORGANISM", 129, 142], ["leukocytes", "CELL_TYPE", 12, 22], ["CD11b", "PROTEIN", 28, 33], ["myeloid cells", "CELL_TYPE", 35, 48], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 138, 142], ["these leukocytes", "TEST", 6, 22], ["the CD11b", "TEST", 24, 33], ["myeloid cells", "PROBLEM", 35, 48], ["the diffuse pancreatic infiltration", "PROBLEM", 86, 121], ["the Ifnar1SA mice", "TREATMENT", 125, 142], ["Fig 3C", "TREATMENT", 144, 150], ["leukocytes", "ANATOMY", 12, 22], ["myeloid cells", "OBSERVATION", 35, 48], ["prominent", "OBSERVATION_MODIFIER", 61, 70], ["diffuse", "OBSERVATION_MODIFIER", 90, 97], ["pancreatic", "ANATOMY", 98, 108], ["infiltration", "OBSERVATION", 109, 121]]], ["In addition, CD11b+/F4/80+ cells represented a majority of leukocytes in the highly infiltrated areas in these mice (Supplementary Fig 10B).", [["CD11b+/F4/80+ cells", "ANATOMY", 13, 32], ["leukocytes", "ANATOMY", 59, 69], ["CD11b", "GENE_OR_GENE_PRODUCT", 13, 18], ["leukocytes", "CELL", 59, 69], ["mice", "ORGANISM", 111, 115], ["CD11b+/F4/80+ cells", "CELL_LINE", 13, 32], ["leukocytes", "CELL_TYPE", 59, 69], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["CD11", "TEST", 13, 17], ["leukocytes", "PROBLEM", 59, 69], ["Supplementary Fig 10B", "TREATMENT", 117, 138], ["leukocytes", "OBSERVATION", 59, 69], ["highly", "OBSERVATION_MODIFIER", 77, 83], ["infiltrated", "OBSERVATION", 84, 95]]], ["Pancreata of these mice also exhibited a low expression of mRNA for RANTES/CCL5) chemotactic for T cells (Fig 3A) and, accordingly, noticeably fewer CD3+ T cells (Fig 3C).", [["T cells", "ANATOMY", 97, 104], ["CD3+ T cells", "ANATOMY", 149, 161], ["mice", "ORGANISM", 19, 23], ["RANTES", "GENE_OR_GENE_PRODUCT", 68, 74], ["CCL5", "GENE_OR_GENE_PRODUCT", 75, 79], ["T cells", "CELL", 97, 104], ["Fig 3A", "CELL", 106, 112], ["CD3", "GENE_OR_GENE_PRODUCT", 149, 152], ["mRNA", "RNA", 59, 63], ["RANTES", "PROTEIN", 68, 74], ["CCL5", "PROTEIN", 75, 79], ["T cells", "CELL_TYPE", 97, 104], ["CD3", "PROTEIN", 149, 152], ["T cells", "CELL_TYPE", 154, 161], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 19, 23], ["RANTES/CCL5", "TEST", 68, 79], ["T cells", "TEST", 97, 104], ["low expression", "OBSERVATION_MODIFIER", 41, 55]]], ["Conversely, a robust increase in expression of a monocyte-attracting chemokine MCP-1/CCL2 and relatively low levels of neutrophil chemoattractant CXCL1 (Fig 3A) was consistent with predominant pancreatic infiltration with monocytes/maturing macrophages (CD11b+; F4/80+; Ly6Glow) in Ifnar1SA mice (Fig 3C,D, Supplementary Figs 10B and 11).Stimulation of IFNAR1 ubiquitination modulates specific leukocyte recruitment and enables pancreatic tissue repair ::: ResultsA careful analysis of kinetics of acute pancreatitis in wild type mice shows that tissue damage peaks at Day 3 after caerulein injection whereas pancreatic glands collected at Day 7 shows the signs of subsided inflammation and reestablishment of tissue integrity.", [["monocyte", "ANATOMY", 49, 57], ["pancreatic", "ANATOMY", 193, 203], ["monocytes", "ANATOMY", 222, 231], ["macrophages", "ANATOMY", 241, 252], ["leukocyte", "ANATOMY", 394, 403], ["pancreatic tissue", "ANATOMY", 428, 445], ["tissue", "ANATOMY", 546, 552], ["pancreatic glands", "ANATOMY", 609, 626], ["tissue", "ANATOMY", 710, 716], ["pancreatitis", "DISEASE", 504, 516], ["tissue damage", "DISEASE", 546, 559], ["caerulein", "CHEMICAL", 581, 590], ["inflammation", "DISEASE", 674, 686], ["monocyte", "CELL", 49, 57], ["MCP-1", "GENE_OR_GENE_PRODUCT", 79, 84], ["CCL2", "GENE_OR_GENE_PRODUCT", 85, 89], ["neutrophil", "CELL", 119, 129], ["CXCL1", "GENE_OR_GENE_PRODUCT", 146, 151], ["Fig 3A", "GENE_OR_GENE_PRODUCT", 153, 159], ["pancreatic", "ORGAN", 193, 203], ["monocytes", "CELL", 222, 231], ["macrophages", "CELL", 241, 252], ["CD11b", "GENE_OR_GENE_PRODUCT", 254, 259], ["Ly6Glow", "GENE_OR_GENE_PRODUCT", 270, 277], ["Ifnar1SA mice", "ORGANISM", 282, 295], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 353, 359], ["leukocyte", "CELL", 394, 403], ["pancreatic tissue", "TISSUE", 428, 445], ["mice", "ORGANISM", 530, 534], ["tissue", "TISSUE", 546, 552], ["caerulein", "SIMPLE_CHEMICAL", 581, 590], ["pancreatic glands", "ORGAN", 609, 626], ["tissue", "TISSUE", 710, 716], ["chemokine", "PROTEIN", 69, 78], ["MCP-1", "PROTEIN", 79, 84], ["CCL2", "PROTEIN", 85, 89], ["neutrophil chemoattractant", "PROTEIN", 119, 145], ["CXCL1", "PROTEIN", 146, 151], ["Fig 3A", "PROTEIN", 153, 159], ["monocytes", "CELL_TYPE", 222, 231], ["maturing macrophages", "CELL_TYPE", 232, 252], ["CD11b", "PROTEIN", 254, 259], ["IFNAR1", "PROTEIN", 353, 359], ["mice", "SPECIES", 291, 295], ["mice", "SPECIES", 530, 534], ["mice", "SPECIES", 291, 295], ["mice", "SPECIES", 530, 534], ["a monocyte", "TEST", 47, 57], ["chemokine MCP", "TEST", 69, 82], ["CCL2", "PROBLEM", 85, 89], ["neutrophil chemoattractant CXCL1", "TEST", 119, 151], ["predominant pancreatic infiltration", "PROBLEM", 181, 216], ["monocytes", "TEST", 222, 231], ["maturing macrophages", "PROBLEM", 232, 252], ["CD11", "TEST", 254, 258], ["b", "TEST", 258, 259], ["F4", "TEST", 262, 264], ["Ly6Glow", "TEST", 270, 277], ["Stimulation of IFNAR1 ubiquitination", "TREATMENT", 338, 374], ["specific leukocyte recruitment", "TREATMENT", 385, 415], ["pancreatic tissue repair", "TREATMENT", 428, 452], ["careful analysis", "TEST", 466, 482], ["acute pancreatitis", "PROBLEM", 498, 516], ["tissue damage peaks", "PROBLEM", 546, 565], ["caerulein injection", "TREATMENT", 581, 600], ["pancreatic glands", "PROBLEM", 609, 626], ["subsided inflammation", "PROBLEM", 665, 686], ["robust", "OBSERVATION_MODIFIER", 14, 20], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["low levels", "OBSERVATION_MODIFIER", 105, 115], ["consistent with", "UNCERTAINTY", 165, 180], ["predominant", "OBSERVATION_MODIFIER", 181, 192], ["pancreatic", "ANATOMY", 193, 203], ["infiltration", "OBSERVATION", 204, 216], ["monocytes", "OBSERVATION", 222, 231], ["maturing macrophages", "OBSERVATION", 232, 252], ["IFNAR1 ubiquitination", "OBSERVATION", 353, 374], ["leukocyte recruitment", "OBSERVATION", 394, 415], ["pancreatic", "ANATOMY", 428, 438], ["acute", "OBSERVATION_MODIFIER", 498, 503], ["pancreatitis", "OBSERVATION", 504, 516], ["tissue", "ANATOMY", 546, 552], ["damage", "OBSERVATION", 553, 559], ["pancreatic glands", "ANATOMY", 609, 626], ["subsided", "OBSERVATION_MODIFIER", 665, 673], ["inflammation", "OBSERVATION", 674, 686], ["reestablishment of tissue integrity", "OBSERVATION", 691, 726]]], ["Yet, pancreata from Ifnar1SA mice exhibited very few sings of acinar cell restoration and displayed a persistent immune infiltration (Fig 1B and Supplementary Fig 3).", [["pancreata", "ANATOMY", 5, 14], ["acinar cell", "ANATOMY", 62, 73], ["pancreata", "ORGAN", 5, 14], ["Ifnar1SA mice", "ORGANISM", 20, 33], ["acinar cell", "CELL", 62, 73], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["acinar cell restoration", "TREATMENT", 62, 85], ["a persistent immune infiltration", "PROBLEM", 100, 132], ["pancreata", "ANATOMY", 5, 14], ["very", "OBSERVATION_MODIFIER", 44, 48], ["few", "OBSERVATION_MODIFIER", 49, 52], ["acinar cell restoration", "OBSERVATION", 62, 85], ["persistent", "OBSERVATION_MODIFIER", 102, 112], ["immune infiltration", "OBSERVATION", 113, 132]]], ["An even greater increase in pancreatic inflammation and damage was observed in Ifnar1SA mice receiving multiple injections of caerulein to model chronic pancreatits (Fig 4A\u2013D and Supplementary Fig 12).", [["pancreatic", "ANATOMY", 28, 38], ["pancreatic inflammation", "DISEASE", 28, 51], ["caerulein", "CHEMICAL", 126, 135], ["pancreatits", "DISEASE", 153, 164], ["pancreatic", "ORGAN", 28, 38], ["Ifnar1SA mice", "ORGANISM", 79, 92], ["caerulein", "SIMPLE_CHEMICAL", 126, 135], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 88, 92], ["pancreatic inflammation", "PROBLEM", 28, 51], ["damage", "PROBLEM", 56, 62], ["caerulein", "TREATMENT", 126, 135], ["model chronic pancreatits", "TREATMENT", 139, 164], ["Supplementary Fig", "TREATMENT", 179, 196], ["greater", "OBSERVATION_MODIFIER", 8, 15], ["increase", "OBSERVATION_MODIFIER", 16, 24], ["pancreatic", "ANATOMY", 28, 38], ["inflammation", "OBSERVATION", 39, 51], ["chronic", "OBSERVATION_MODIFIER", 145, 152], ["pancreatits", "OBSERVATION", 153, 164]]], ["Unlike wild type mice that displayed both signs of inflammation (including edema and leukocytic infiltration) and restored tissue (Fig 4B), pancreata from Ifnar1SA animals remained highly inflamed (Fig 4B,D and Supplementary Fig 12) and exhibited pronounced signs of tissue damage, degeneration and fibrosis (Fig 4B\u2013D).", [["edema", "ANATOMY", 75, 80], ["leukocytic", "ANATOMY", 85, 95], ["tissue", "ANATOMY", 123, 129], ["pancreata", "ANATOMY", 140, 149], ["tissue", "ANATOMY", 267, 273], ["inflammation", "DISEASE", 51, 63], ["edema", "DISEASE", 75, 80], ["tissue damage", "DISEASE", 267, 280], ["fibrosis", "DISEASE", 299, 307], ["mice", "ORGANISM", 17, 21], ["edema", "PATHOLOGICAL_FORMATION", 75, 80], ["tissue", "TISSUE", 123, 129], ["pancreata", "ORGAN", 140, 149], ["Ifnar1SA", "GENE_OR_GENE_PRODUCT", 155, 163], ["tissue", "TISSUE", 267, 273], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["inflammation", "PROBLEM", 51, 63], ["edema", "PROBLEM", 75, 80], ["leukocytic infiltration", "PROBLEM", 85, 108], ["restored tissue", "PROBLEM", 114, 129], ["pancreata from Ifnar1SA animals", "TEST", 140, 171], ["highly inflamed", "PROBLEM", 181, 196], ["Supplementary Fig", "TEST", 211, 228], ["tissue damage", "PROBLEM", 267, 280], ["degeneration", "PROBLEM", 282, 294], ["fibrosis", "PROBLEM", 299, 307], ["inflammation", "OBSERVATION", 51, 63], ["edema", "OBSERVATION", 75, 80], ["leukocytic infiltration", "OBSERVATION", 85, 108], ["pancreata", "ANATOMY", 140, 149], ["tissue damage", "OBSERVATION", 267, 280], ["degeneration", "OBSERVATION", 282, 294], ["fibrosis", "OBSERVATION", 299, 307]]], ["These data strongly suggest that induction of IFNAR1 ubiquitination restricts the extent of inflammation and tissue injury and enables pancreatic tissue regeneration in chronic pancreatitis.Autoimmune and toxic hepatitis is exacerbated by inefficient ubiquitination of IFNAR1 ::: ResultsWe sought to further examine whether ubiquitin-mediated downregulation of IFNAR1 could be important for limiting the damage to other inflamed tissues.", [["tissue", "ANATOMY", 109, 115], ["pancreatic tissue", "ANATOMY", 135, 152], ["tissues", "ANATOMY", 429, 436], ["inflammation", "DISEASE", 92, 104], ["tissue injury", "DISEASE", 109, 122], ["pancreatitis", "DISEASE", 177, 189], ["Autoimmune and toxic hepatitis", "DISEASE", 190, 220], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 46, 52], ["tissue", "TISSUE", 109, 115], ["pancreatic tissue", "TISSUE", 135, 152], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 269, 275], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 324, 333], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 361, 367], ["tissues", "TISSUE", 429, 436], ["IFNAR1", "PROTEIN", 46, 52], ["IFNAR1", "PROTEIN", 269, 275], ["ubiquitin", "PROTEIN", 324, 333], ["IFNAR1", "PROTEIN", 361, 367], ["IFNAR1 ubiquitination", "TREATMENT", 46, 67], ["inflammation", "PROBLEM", 92, 104], ["tissue injury", "PROBLEM", 109, 122], ["pancreatic tissue regeneration", "PROBLEM", 135, 165], ["chronic pancreatitis", "PROBLEM", 169, 189], ["Autoimmune", "PROBLEM", 190, 200], ["toxic hepatitis", "PROBLEM", 205, 220], ["ubiquitin-mediated downregulation of IFNAR1", "TREATMENT", 324, 367], ["the damage to other inflamed tissues", "PROBLEM", 400, 436], ["inflammation", "OBSERVATION", 92, 104], ["tissue injury", "OBSERVATION", 109, 122], ["pancreatic tissue", "ANATOMY", 135, 152], ["regeneration", "OBSERVATION_MODIFIER", 153, 165], ["chronic", "OBSERVATION_MODIFIER", 169, 176], ["pancreatitis", "OBSERVATION", 177, 189], ["toxic", "OBSERVATION_MODIFIER", 205, 210], ["hepatitis", "OBSERVATION", 211, 220], ["inflamed tissues", "ANATOMY", 420, 436]]], ["To this end, we utilized two independent models of experimental hepatitis induced either by concanavalin A [ConA, that triggers autoimmune hepatitis (Tiegs et al, 1992)] or carbon tetrachloride [CCl4, that causes hepatic necrosis and reactive hepatitis (Luster et al, 2001)].", [["hepatic", "ANATOMY", 213, 220], ["hepatitis", "DISEASE", 64, 73], ["concanavalin A", "CHEMICAL", 92, 106], ["autoimmune hepatitis", "DISEASE", 128, 148], ["carbon tetrachloride", "CHEMICAL", 173, 193], ["CCl4", "CHEMICAL", 195, 199], ["hepatic necrosis", "DISEASE", 213, 229], ["reactive hepatitis", "DISEASE", 234, 252], ["carbon tetrachloride", "CHEMICAL", 173, 193], ["CCl4", "CHEMICAL", 195, 199], ["concanavalin A", "SIMPLE_CHEMICAL", 92, 106], ["ConA", "SIMPLE_CHEMICAL", 108, 112], ["carbon tetrachloride", "SIMPLE_CHEMICAL", 173, 193], ["CCl4", "SIMPLE_CHEMICAL", 195, 199], ["hepatic", "ORGAN", 213, 220], ["experimental hepatitis", "PROBLEM", 51, 73], ["autoimmune hepatitis", "PROBLEM", 128, 148], ["carbon tetrachloride [CCl4", "TREATMENT", 173, 199], ["hepatic necrosis", "PROBLEM", 213, 229], ["reactive hepatitis", "PROBLEM", 234, 252], ["hepatitis", "OBSERVATION", 64, 73], ["autoimmune hepatitis", "OBSERVATION", 128, 148], ["hepatic", "ANATOMY", 213, 220], ["necrosis", "OBSERVATION", 221, 229], ["reactive hepatitis", "OBSERVATION", 234, 252]]], ["Remarkably, in both of these models we observed a robust induction of IFNAR1 ubiquitination and downregulation of this protein (but not mRNA) in liver tissues from wild type but not Ifnar1SA mice (Fig 5A, Supplementary Fig 13).", [["liver tissues", "ANATOMY", 145, 158], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 70, 76], ["liver tissues", "TISSUE", 145, 158], ["Ifnar1SA mice", "ORGANISM", 182, 195], ["IFNAR1", "PROTEIN", 70, 76], ["mRNA", "RNA", 136, 140], ["mice", "SPECIES", 191, 195], ["mice", "SPECIES", 191, 195], ["IFNAR1 ubiquitination", "PROBLEM", 70, 91], ["this protein", "PROBLEM", 114, 126], ["mRNA) in liver tissues", "PROBLEM", 136, 158], ["IFNAR1 ubiquitination", "OBSERVATION", 70, 91], ["liver", "ANATOMY", 145, 150]]], ["Conversely, the latter animals exhibited a noticeably higher expression of STAT1 and PKR proteins (Fig 5A), expression of TNF\u03b1 mRNA (Supplementary Fig 14) and levels of plasma IFN\u03b2 (Supplementary Fig 15 and data not shown).", [["plasma", "ANATOMY", 169, 175], ["STAT1", "GENE_OR_GENE_PRODUCT", 75, 80], ["PKR", "GENE_OR_GENE_PRODUCT", 85, 88], ["Fig 5A", "GENE_OR_GENE_PRODUCT", 99, 105], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 122, 126], ["plasma", "ORGANISM_SUBSTANCE", 169, 175], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 176, 180], ["STAT1", "PROTEIN", 75, 80], ["PKR proteins", "PROTEIN", 85, 97], ["Fig 5A", "PROTEIN", 99, 105], ["TNF", "PROTEIN", 122, 125], ["mRNA", "RNA", 127, 131], ["plasma IFN\u03b2", "PROTEIN", 169, 180], ["mRNA (Supplementary Fig", "TREATMENT", 127, 150], ["Supplementary Fig", "TREATMENT", 182, 199]]], ["In parallel, the severity of hepatic inflammation was prominently greater in Ifnar1SA mice compared to the wild type animals as judged by increased release of liver aminotransferases from hepatocytes into the bloodstream (serum AST and ALT, Fig 5B).Autoimmune and toxic hepatitis is exacerbated by inefficient ubiquitination of IFNAR1 ::: ResultsFurthermore, livers harvested from Ifnar1SA mice exhibited dramatic histopathologic alterations (Fig 5C and Supplementary Fig 16) along with robust activation of p38 kinase (Fig 5D), greater number of hepatic lesions and consistently higher hepatitis grade (Table 1).", [["hepatic", "ANATOMY", 29, 36], ["liver", "ANATOMY", 159, 164], ["hepatocytes", "ANATOMY", 188, 199], ["bloodstream", "ANATOMY", 209, 220], ["serum", "ANATOMY", 222, 227], ["livers", "ANATOMY", 359, 365], ["hepatic lesions", "ANATOMY", 547, 562], ["hepatic inflammation", "DISEASE", 29, 49], ["Autoimmune and toxic hepatitis", "DISEASE", 249, 279], ["hepatic lesions", "DISEASE", 547, 562], ["hepatitis", "DISEASE", 587, 596], ["hepatic", "ORGAN", 29, 36], ["Ifnar1SA mice", "ORGANISM", 77, 90], ["liver", "ORGAN", 159, 164], ["aminotransferases", "GENE_OR_GENE_PRODUCT", 165, 182], ["hepatocytes", "CELL", 188, 199], ["bloodstream", "ORGANISM_SUBSTANCE", 209, 220], ["serum", "ORGANISM_SUBSTANCE", 222, 227], ["AST", "SIMPLE_CHEMICAL", 228, 231], ["ALT", "SIMPLE_CHEMICAL", 236, 239], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 328, 334], ["livers", "ORGAN", 359, 365], ["Ifnar1SA mice", "ORGANISM", 381, 394], ["p38 kinase", "GENE_OR_GENE_PRODUCT", 508, 518], ["Fig 5D", "GENE_OR_GENE_PRODUCT", 520, 526], ["hepatic lesions", "CANCER", 547, 562], ["liver aminotransferases", "PROTEIN", 159, 182], ["hepatocytes", "CELL_TYPE", 188, 199], ["serum AST", "PROTEIN", 222, 231], ["ALT", "PROTEIN", 236, 239], ["IFNAR1", "PROTEIN", 328, 334], ["p38 kinase", "PROTEIN", 508, 518], ["Fig 5D", "PROTEIN", 520, 526], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 390, 394], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 390, 394], ["hepatic inflammation", "PROBLEM", 29, 49], ["liver aminotransferases", "TEST", 159, 182], ["the bloodstream", "TEST", 205, 220], ["serum AST", "TEST", 222, 231], ["ALT", "TEST", 236, 239], ["Fig 5B", "TEST", 241, 247], ["Autoimmune", "PROBLEM", 249, 259], ["toxic hepatitis", "PROBLEM", 264, 279], ["dramatic histopathologic alterations", "PROBLEM", 405, 441], ["Fig 5C", "TREATMENT", 443, 449], ["Supplementary Fig", "TREATMENT", 454, 471], ["robust activation of p38 kinase (Fig 5D", "TREATMENT", 487, 526], ["hepatic lesions", "PROBLEM", 547, 562], ["consistently higher hepatitis grade", "PROBLEM", 567, 602], ["parallel", "OBSERVATION_MODIFIER", 3, 11], ["severity", "OBSERVATION_MODIFIER", 17, 25], ["hepatic", "ANATOMY", 29, 36], ["inflammation", "OBSERVATION", 37, 49], ["prominently", "OBSERVATION_MODIFIER", 54, 65], ["greater", "OBSERVATION_MODIFIER", 66, 73], ["increased", "OBSERVATION_MODIFIER", 138, 147], ["liver", "ANATOMY", 159, 164], ["bloodstream", "ANATOMY", 209, 220], ["toxic", "OBSERVATION_MODIFIER", 264, 269], ["hepatitis", "OBSERVATION", 270, 279], ["livers", "ANATOMY", 359, 365], ["harvested", "OBSERVATION", 366, 375], ["dramatic", "OBSERVATION_MODIFIER", 405, 413], ["greater", "OBSERVATION_MODIFIER", 529, 536], ["number", "OBSERVATION_MODIFIER", 537, 543], ["hepatic", "ANATOMY", 547, 554], ["lesions", "OBSERVATION", 555, 562], ["higher", "OBSERVATION_MODIFIER", 580, 586], ["hepatitis", "OBSERVATION", 587, 596]]], ["These alterations in Ifnar1SA mice together with a more pronounced leukocyte infiltration (Supplementary Fig 17) strongly suggest that ubiquitination of IFNAR1 plays a protective role during hepatitis of either autoimmune or toxic etiology.", [["leukocyte", "ANATOMY", 67, 76], ["hepatitis of either autoimmune or toxic etiology", "DISEASE", 191, 239], ["Ifnar1SA mice", "ORGANISM", 21, 34], ["leukocyte", "CELL", 67, 76], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 153, 159], ["IFNAR1", "PROTEIN", 153, 159], ["mice", "SPECIES", 30, 34], ["a more pronounced leukocyte infiltration", "PROBLEM", 49, 89], ["more pronounced", "OBSERVATION_MODIFIER", 51, 66], ["leukocyte infiltration", "OBSERVATION", 67, 89], ["autoimmune", "OBSERVATION", 211, 221], ["toxic", "OBSERVATION_MODIFIER", 225, 230]]], ["Collectively, these data implicate ubiquitination and degradation of IFNAR1 as an important common mechanism that limits the extent of inflammatory liver injury.Downregulation of IFNAR1 on bone marrow-derived cells determines the severity of inflammatory syndromes ::: ResultsWithin the foci of inflammation, an accelerated ubiquitin-dependent turnover of IFNAR1 may occur on diverse type of cells including parenchymal, endothelial and stromal cells as well as on immune cells recruited to the target organs.", [["liver", "ANATOMY", 148, 153], ["bone marrow-derived cells", "ANATOMY", 189, 214], ["foci", "ANATOMY", 287, 291], ["cells", "ANATOMY", 392, 397], ["parenchymal", "ANATOMY", 408, 419], ["endothelial", "ANATOMY", 421, 432], ["stromal cells", "ANATOMY", 437, 450], ["immune cells", "ANATOMY", 465, 477], ["organs", "ANATOMY", 502, 508], ["liver injury", "DISEASE", 148, 160], ["inflammation", "DISEASE", 295, 307], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 69, 75], ["liver", "ORGAN", 148, 153], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 179, 185], ["bone marrow-derived cells", "CELL", 189, 214], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 324, 333], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 356, 362], ["cells", "CELL", 392, 397], ["parenchymal", "CELL", 408, 419], ["endothelial", "CELL", 421, 432], ["stromal cells", "CELL", 437, 450], ["immune cells", "CELL", 465, 477], ["organs", "ORGAN", 502, 508], ["IFNAR1", "PROTEIN", 69, 75], ["IFNAR1", "PROTEIN", 179, 185], ["bone marrow-derived cells", "CELL_TYPE", 189, 214], ["ubiquitin", "PROTEIN", 324, 333], ["IFNAR1", "PROTEIN", 356, 362], ["parenchymal, endothelial and stromal cells", "CELL_TYPE", 408, 450], ["immune cells", "CELL_TYPE", 465, 477], ["ubiquitination", "PROBLEM", 35, 49], ["IFNAR1", "TREATMENT", 69, 75], ["inflammatory liver injury", "PROBLEM", 135, 160], ["bone marrow", "TEST", 189, 200], ["inflammatory syndromes", "PROBLEM", 242, 264], ["inflammation", "PROBLEM", 295, 307], ["an accelerated ubiquitin-dependent turnover of IFNAR1", "PROBLEM", 309, 362], ["parenchymal, endothelial and stromal cells", "PROBLEM", 408, 450], ["immune cells", "PROBLEM", 465, 477], ["inflammatory", "OBSERVATION_MODIFIER", 135, 147], ["liver", "ANATOMY", 148, 153], ["injury", "OBSERVATION", 154, 160], ["IFNAR1", "OBSERVATION", 179, 185], ["bone", "ANATOMY", 189, 193], ["marrow", "OBSERVATION", 194, 200], ["inflammatory syndromes", "OBSERVATION", 242, 264], ["foci", "OBSERVATION_MODIFIER", 287, 291], ["inflammation", "OBSERVATION", 295, 307], ["accelerated", "OBSERVATION_MODIFIER", 312, 323], ["ubiquitin", "OBSERVATION_MODIFIER", 324, 333], ["-dependent", "OBSERVATION_MODIFIER", 333, 343], ["diverse type", "OBSERVATION_MODIFIER", 376, 388], ["parenchymal", "ANATOMY_MODIFIER", 408, 419], ["endothelial", "ANATOMY", 421, 432], ["stromal cells", "OBSERVATION", 437, 450]]], ["To differentiate between the roles of IFNAR1 ubiquitination in hematopoietic/immune compartment versus peripheral tissues, the bone marrow transfer (BMT) approach was utilized.", [["hematopoietic", "ANATOMY", 63, 76], ["immune compartment", "ANATOMY", 77, 95], ["peripheral tissues", "ANATOMY", 103, 121], ["bone marrow", "ANATOMY", 127, 138], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 38, 44], ["hematopoietic", "CELL", 63, 76], ["immune compartment", "MULTI-TISSUE_STRUCTURE", 77, 95], ["peripheral tissues", "TISSUE", 103, 121], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 127, 138], ["IFNAR1", "PROTEIN", 38, 44], ["IFNAR1 ubiquitination", "PROBLEM", 38, 59], ["hematopoietic/immune compartment", "TREATMENT", 63, 95], ["peripheral tissues", "PROBLEM", 103, 121], ["the bone marrow transfer (BMT) approach", "TREATMENT", 123, 162], ["IFNAR1 ubiquitination", "OBSERVATION", 38, 59], ["hematopoietic", "ANATOMY", 63, 76], ["immune compartment", "OBSERVATION", 77, 95], ["peripheral tissues", "ANATOMY", 103, 121], ["bone", "ANATOMY", 127, 131]]], ["We initially compared the severity of acute pancreatitis in Ifnar1SA animals that received BMT from either mice of the same genotype or from wild type animals.", [["pancreatitis", "DISEASE", 44, 56], ["mice", "ORGANISM", 107, 111], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 107, 111], ["acute pancreatitis", "PROBLEM", 38, 56], ["BMT", "TREATMENT", 91, 94], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["pancreatitis", "OBSERVATION", 44, 56]]], ["The latter chimeric mice challenged with caerulein exhibited a lesser increase in the levels of serum amylase activity (Fig 6A, blue bars v. red bars).", [["serum", "ANATOMY", 96, 101], ["caerulein", "CHEMICAL", 41, 50], ["caerulein", "CHEMICAL", 41, 50], ["mice", "ORGANISM", 20, 24], ["caerulein", "SIMPLE_CHEMICAL", 41, 50], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["amylase", "GENE_OR_GENE_PRODUCT", 102, 109], ["serum amylase", "PROTEIN", 96, 109], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["caerulein", "TREATMENT", 41, 50], ["a lesser increase", "PROBLEM", 61, 78], ["serum amylase activity", "TEST", 96, 118], ["lesser", "OBSERVATION_MODIFIER", 63, 69], ["increase", "OBSERVATION_MODIFIER", 70, 78]]], ["Conversely, the replacement of bone marrow in wild type mice by that from Ifnar1SA animals augmented the induction of serum amylase (Fig 6A, white bars v. black bars).", [["bone marrow", "ANATOMY", 31, 42], ["serum", "ANATOMY", 118, 123], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 31, 42], ["mice", "ORGANISM", 56, 60], ["Ifnar1SA animals", "ORGANISM", 74, 90], ["serum", "ORGANISM_SUBSTANCE", 118, 123], ["amylase", "GENE_OR_GENE_PRODUCT", 124, 131], ["serum amylase", "PROTEIN", 118, 131], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 56, 60], ["white bars v. black bars", "SPECIES", 141, 165], ["the replacement of bone marrow", "TREATMENT", 12, 42], ["serum amylase", "TEST", 118, 131], ["Fig", "TEST", 133, 136], ["bone marrow", "ANATOMY", 31, 42]]], ["These data were further corroborated by the histopathologic analyses (Fig 6B and Supplementary Fig 18) demonstrating that severity of pancreatitis correlated with expression of ubiquitination-deficient Ifnar1SA mutant in the bone marrow-derived cells but not in the peripheral tissues.Downregulation of IFNAR1 on bone marrow-derived cells determines the severity of inflammatory syndromes ::: ResultsThe importance of IFNAR1 ubiquitination within the central immune compartment for tissue protection was next investigated in the hepatitis model induced by CCl4.", [["bone marrow-derived cells", "ANATOMY", 225, 250], ["peripheral tissues", "ANATOMY", 266, 284], ["bone marrow-derived cells", "ANATOMY", 313, 338], ["immune compartment", "ANATOMY", 459, 477], ["tissue", "ANATOMY", 482, 488], ["pancreatitis", "DISEASE", 134, 146], ["hepatitis", "DISEASE", 529, 538], ["CCl4", "CHEMICAL", 556, 560], ["CCl4", "CHEMICAL", 556, 560], ["Ifnar1SA", "GENE_OR_GENE_PRODUCT", 202, 210], ["bone marrow-derived cells", "CELL", 225, 250], ["peripheral tissues", "TISSUE", 266, 284], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 303, 309], ["bone marrow-derived cells", "CELL", 313, 338], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 418, 424], ["central immune compartment", "TISSUE", 451, 477], ["tissue", "TISSUE", 482, 488], ["CCl4", "SIMPLE_CHEMICAL", 556, 560], ["Ifnar1SA mutant", "PROTEIN", 202, 217], ["bone marrow-derived cells", "CELL_TYPE", 225, 250], ["IFNAR1", "PROTEIN", 303, 309], ["bone marrow-derived cells", "CELL_TYPE", 313, 338], ["IFNAR1", "PROTEIN", 418, 424], ["the histopathologic analyses", "TEST", 40, 68], ["pancreatitis", "PROBLEM", 134, 146], ["ubiquitination-deficient Ifnar1SA mutant in the bone marrow", "PROBLEM", 177, 236], ["bone marrow", "TEST", 313, 324], ["inflammatory syndromes", "PROBLEM", 366, 388], ["IFNAR1 ubiquitination", "PROBLEM", 418, 439], ["tissue protection", "TREATMENT", 482, 499], ["pancreatitis", "OBSERVATION", 134, 146], ["bone marrow", "ANATOMY", 225, 236], ["peripheral tissues", "ANATOMY", 266, 284], ["IFNAR1", "OBSERVATION", 303, 309], ["bone", "ANATOMY", 313, 317], ["marrow", "OBSERVATION", 318, 324], ["inflammatory syndromes", "OBSERVATION", 366, 388], ["IFNAR1 ubiquitination", "OBSERVATION", 418, 439], ["central", "ANATOMY_MODIFIER", 451, 458], ["hepatitis", "OBSERVATION", 529, 538], ["CCl4", "OBSERVATION", 556, 560]]], ["Chimeric animals that received BMT from wild type mice consistently exhibited a lesser serum level of liver aminotransferases (Fig 6C), fewer hepatic lesions and overall lower hepatitis scores (Fig 6D, Supplementary Fig 19 and Table 1).", [["serum", "ANATOMY", 87, 92], ["liver", "ANATOMY", 102, 107], ["hepatic lesions", "ANATOMY", 142, 157], ["hepatic lesions", "DISEASE", 142, 157], ["hepatitis", "DISEASE", 176, 185], ["mice", "ORGANISM", 50, 54], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["liver", "ORGAN", 102, 107], ["hepatic lesions", "PATHOLOGICAL_FORMATION", 142, 157], ["liver aminotransferases", "PROTEIN", 102, 125], ["mice", "SPECIES", 50, 54], ["mice", "SPECIES", 50, 54], ["BMT", "TREATMENT", 31, 34], ["liver aminotransferases", "TEST", 102, 125], ["fewer hepatic lesions", "PROBLEM", 136, 157], ["overall lower hepatitis scores", "PROBLEM", 162, 192], ["liver", "ANATOMY", 102, 107], ["fewer", "OBSERVATION_MODIFIER", 136, 141], ["hepatic", "ANATOMY", 142, 149], ["lesions", "OBSERVATION", 150, 157], ["overall", "OBSERVATION_MODIFIER", 162, 169], ["lower", "OBSERVATION_MODIFIER", 170, 175], ["hepatitis", "OBSERVATION", 176, 185]]], ["On the other hand, experiments using the reverse approach (BMT from Ifnar1SA animals into the wild type mice) revealed a robustly augmented liver tissue damage and inflammatory phenotype (Fig 6C,D, Supplementary Fig 19 and Table 1).", [["liver tissue", "ANATOMY", 140, 152], ["liver tissue damage", "DISEASE", 140, 159], ["mice", "ORGANISM", 104, 108], ["liver tissue", "TISSUE", 140, 152], ["mice", "SPECIES", 104, 108], ["the reverse approach", "TREATMENT", 37, 57], ["BMT from Ifnar1SA animals", "TREATMENT", 59, 84], ["a robustly augmented liver tissue damage", "PROBLEM", 119, 159], ["inflammatory phenotype", "PROBLEM", 164, 186], ["robustly", "OBSERVATION_MODIFIER", 121, 129], ["augmented", "OBSERVATION", 130, 139], ["liver tissue", "ANATOMY", 140, 152], ["damage", "OBSERVATION", 153, 159], ["inflammatory", "OBSERVATION_MODIFIER", 164, 176]]], ["These data indicate that ubiquitination and degradation of IFNAR1 in the bone marrow-derived cells recruited to the foci of inflammation plays a common major tissue protective role.Pharmacologically induced ubiquitination and downregulation of IFNAR1 protects from toxic hepatitis and fulminant generalized inflammation ::: ResultsIf downregulation of IFNAR1 as a byproduct of inflammation limits tissue injury, a preemptive pharmacologic elimination of this receptor might be used as a tissue protective approach.", [["bone marrow-derived cells", "ANATOMY", 73, 98], ["foci", "ANATOMY", 116, 120], ["tissue", "ANATOMY", 158, 164], ["tissue", "ANATOMY", 397, 403], ["tissue", "ANATOMY", 487, 493], ["inflammation", "DISEASE", 124, 136], ["toxic hepatitis", "DISEASE", 265, 280], ["inflammation", "DISEASE", 307, 319], ["inflammation", "DISEASE", 377, 389], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 59, 65], ["bone marrow-derived cells", "CELL", 73, 98], ["tissue", "TISSUE", 158, 164], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 244, 250], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 352, 358], ["tissue", "TISSUE", 397, 403], ["tissue", "TISSUE", 487, 493], ["IFNAR1", "PROTEIN", 59, 65], ["bone marrow-derived cells", "CELL_TYPE", 73, 98], ["IFNAR1", "PROTEIN", 244, 250], ["IFNAR1", "PROTEIN", 352, 358], ["These data", "TEST", 0, 10], ["ubiquitination", "PROBLEM", 25, 39], ["IFNAR1 in the bone marrow", "PROBLEM", 59, 84], ["derived cells", "PROBLEM", 85, 98], ["inflammation", "PROBLEM", 124, 136], ["Pharmacologically induced ubiquitination", "PROBLEM", 181, 221], ["IFNAR1 protects", "TREATMENT", 244, 259], ["toxic hepatitis", "PROBLEM", 265, 280], ["fulminant generalized inflammation", "PROBLEM", 285, 319], ["IFNAR1", "PROBLEM", 352, 358], ["inflammation", "PROBLEM", 377, 389], ["tissue injury", "PROBLEM", 397, 410], ["a preemptive pharmacologic elimination", "TREATMENT", 412, 450], ["this receptor", "TREATMENT", 454, 467], ["a tissue protective approach", "TREATMENT", 485, 513], ["ubiquitination", "OBSERVATION", 25, 39], ["bone", "ANATOMY", 73, 77], ["foci", "OBSERVATION_MODIFIER", 116, 120], ["inflammation", "OBSERVATION", 124, 136], ["ubiquitination", "OBSERVATION", 207, 221], ["toxic", "OBSERVATION_MODIFIER", 265, 270], ["hepatitis", "OBSERVATION", 271, 280], ["fulminant", "OBSERVATION_MODIFIER", 285, 294], ["generalized", "OBSERVATION_MODIFIER", 295, 306], ["inflammation", "OBSERVATION", 307, 319], ["inflammation", "OBSERVATION_MODIFIER", 377, 389], ["limits tissue", "OBSERVATION_MODIFIER", 390, 403], ["injury", "OBSERVATION", 404, 410]]], ["Agents triggering this elimination should theoretically be capable of inducing IFNAR1 serine phosphorylation and subsequent ubiquitination.", [["serine", "CHEMICAL", 86, 92], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 79, 85], ["IFNAR1", "PROTEIN", 79, 85], ["Agents", "TREATMENT", 0, 6], ["IFNAR1 serine phosphorylation", "TREATMENT", 79, 108]]], ["An endogenous lipid mediator, lysophosphatidic acid (LPA) was previously shown to act on immune cells (Graler ' Goetzl, 2002) and activate both PKD2 and p38 kinases (Chiu et al, 2007).", [["immune cells", "ANATOMY", 89, 101], ["lysophosphatidic acid", "CHEMICAL", 30, 51], ["LPA", "CHEMICAL", 53, 56], ["lysophosphatidic acid", "CHEMICAL", 30, 51], ["LPA", "CHEMICAL", 53, 56], ["lipid", "SIMPLE_CHEMICAL", 14, 19], ["lysophosphatidic acid", "SIMPLE_CHEMICAL", 30, 51], ["LPA", "SIMPLE_CHEMICAL", 53, 56], ["immune cells", "CELL", 89, 101], ["Graler ' Goetzl, 2002", "CELL", 103, 124], ["PKD2", "GENE_OR_GENE_PRODUCT", 144, 148], ["p38 kinases", "GENE_OR_GENE_PRODUCT", 153, 164], ["immune cells", "CELL_TYPE", 89, 101], ["PKD2", "PROTEIN", 144, 148], ["p38 kinases", "PROTEIN", 153, 164], ["An endogenous lipid mediator", "TEST", 0, 28], ["lysophosphatidic acid (LPA", "TEST", 30, 56], ["p38 kinases", "TEST", 153, 164], ["endogenous lipid", "OBSERVATION", 3, 19]]], ["Thus, we tested the effects of LPA on IFNAR1 ubiquitination and related inflammatory conditions.Pharmacologically induced ubiquitination and downregulation of IFNAR1 protects from toxic hepatitis and fulminant generalized inflammation ::: ResultsTo this end, the in vivo signaling experiments utilizing the intravenous injection of mice with LPA followed by analysis of IFNAR1 in the splenic tissues were used.", [["intravenous", "ANATOMY", 307, 318], ["splenic tissues", "ANATOMY", 384, 399], ["LPA", "CHEMICAL", 31, 34], ["toxic hepatitis", "DISEASE", 180, 195], ["inflammation", "DISEASE", 222, 234], ["LPA", "CHEMICAL", 342, 345], ["LPA", "CHEMICAL", 31, 34], ["LPA", "CHEMICAL", 342, 345], ["LPA", "SIMPLE_CHEMICAL", 31, 34], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 38, 44], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 159, 165], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 307, 318], ["mice", "ORGANISM", 332, 336], ["LPA", "SIMPLE_CHEMICAL", 342, 345], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 370, 376], ["splenic tissues", "TISSUE", 384, 399], ["IFNAR1", "PROTEIN", 38, 44], ["IFNAR1", "PROTEIN", 159, 165], ["IFNAR1", "PROTEIN", 370, 376], ["mice", "SPECIES", 332, 336], ["mice", "SPECIES", 332, 336], ["LPA", "PROBLEM", 31, 34], ["IFNAR1 ubiquitination", "TREATMENT", 38, 59], ["inflammatory conditions", "PROBLEM", 72, 95], ["Pharmacologically induced ubiquitination", "PROBLEM", 96, 136], ["IFNAR1 protects", "TREATMENT", 159, 174], ["toxic hepatitis", "PROBLEM", 180, 195], ["fulminant generalized inflammation", "PROBLEM", 200, 234], ["the intravenous injection of mice with LPA", "TREATMENT", 303, 345], ["IFNAR1 in the splenic tissues", "TREATMENT", 370, 399], ["LPA", "OBSERVATION_MODIFIER", 31, 34], ["IFNAR1 ubiquitination", "OBSERVATION", 38, 59], ["inflammatory conditions", "OBSERVATION", 72, 95], ["ubiquitination", "OBSERVATION", 122, 136], ["toxic", "OBSERVATION_MODIFIER", 180, 185], ["hepatitis", "OBSERVATION", 186, 195], ["fulminant", "OBSERVATION_MODIFIER", 200, 209], ["generalized", "OBSERVATION_MODIFIER", 210, 221], ["inflammation", "OBSERVATION", 222, 234], ["splenic tissues", "ANATOMY", 384, 399]]], ["LPA treatment induced phosphorylation of IFNAR1 on Ser526 in wild type mice (Fig 7A).", [["LPA", "CHEMICAL", 0, 3], ["LPA", "CHEMICAL", 0, 3], ["LPA", "SIMPLE_CHEMICAL", 0, 3], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 41, 47], ["Ser526", "GENE_OR_GENE_PRODUCT", 51, 57], ["wild type mice", "ORGANISM", 61, 75], ["IFNAR1", "PROTEIN", 41, 47], ["Ser526", "PROTEIN", 51, 57], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 71, 75], ["LPA treatment", "TREATMENT", 0, 13], ["phosphorylation of IFNAR1", "TREATMENT", 22, 47]]], ["As expected, this effect was not seen in Ifnar1SA animals whose receptor contains the alanine residue in this position.", [["alanine", "CHEMICAL", 86, 93], ["alanine", "CHEMICAL", 86, 93], ["alanine", "AMINO_ACID", 86, 93], ["the alanine residue", "PROBLEM", 82, 101], ["not seen", "UNCERTAINTY", 29, 37], ["alanine residue", "OBSERVATION", 86, 101]]], ["Importantly, wild type but not Ifnar1SA tissues exhibited an increase in ubiquitination of IFNAR1 (Fig 7A).", [["Ifnar1SA tissues", "ANATOMY", 31, 47], ["Ifnar1SA tissues", "TISSUE", 31, 47], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 91, 97], ["Fig 7A", "GENE_OR_GENE_PRODUCT", 99, 105], ["IFNAR1", "PROTEIN", 91, 97], ["Fig 7A", "PROTEIN", 99, 105], ["Ifnar1SA tissues", "PROBLEM", 31, 47], ["increase", "OBSERVATION_MODIFIER", 61, 69], ["ubiquitination", "OBSERVATION_MODIFIER", 73, 87]]], ["Furthermore, injection of wild type mice with LPA led to a noticeable downregulation of IFNAR1 protein (but not mRNA) on splenocytes (Fig 7B) and attenuated the sensitivity of these cells to IFN in vitro as assessed by IFN-induced activation of STAT1 (Fig 7C).", [["splenocytes", "ANATOMY", 121, 132], ["cells", "ANATOMY", 182, 187], ["LPA", "CHEMICAL", 46, 49], ["LPA", "CHEMICAL", 46, 49], ["mice", "ORGANISM", 36, 40], ["LPA", "SIMPLE_CHEMICAL", 46, 49], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 88, 94], ["splenocytes", "CELL", 121, 132], ["cells", "CELL", 182, 187], ["IFN", "GENE_OR_GENE_PRODUCT", 191, 194], ["IFN", "GENE_OR_GENE_PRODUCT", 219, 222], ["STAT1", "GENE_OR_GENE_PRODUCT", 245, 250], ["IFNAR1 protein", "PROTEIN", 88, 102], ["mRNA", "RNA", 112, 116], ["splenocytes", "CELL_TYPE", 121, 132], ["IFN", "PROTEIN", 191, 194], ["IFN", "PROTEIN", 219, 222], ["STAT1", "PROTEIN", 245, 250], ["Fig 7C", "PROTEIN", 252, 258], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 36, 40], ["a noticeable downregulation of IFNAR1 protein", "PROBLEM", 57, 102], ["splenocytes", "TEST", 121, 132], ["these cells", "PROBLEM", 176, 187], ["STAT1 (Fig 7C", "TREATMENT", 245, 258], ["IFNAR1 protein", "OBSERVATION", 88, 102], ["splenocytes", "ANATOMY", 121, 132]]], ["Importantly, neither of these events was observed in Ifnar1SA tissues (Fig 7B,C).", [["Ifnar1SA tissues", "ANATOMY", 53, 69], ["Ifnar1SA tissues", "TISSUE", 53, 69], ["these events", "PROBLEM", 24, 36]]], ["These data indicate that LPA can be utilized to trigger IFNAR1 ubiquitination and degradation and to attenuate IFN signaling in vivo.", [["LPA", "CHEMICAL", 25, 28], ["LPA", "CHEMICAL", 25, 28], ["LPA", "SIMPLE_CHEMICAL", 25, 28], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 56, 62], ["IFN", "GENE_OR_GENE_PRODUCT", 111, 114], ["IFNAR1", "PROTEIN", 56, 62], ["IFN", "PROTEIN", 111, 114], ["These data", "TEST", 0, 10], ["LPA", "TEST", 25, 28], ["IFNAR1 ubiquitination", "PROBLEM", 56, 77]]], ["Moreover, the Ifnar1SA mice deficient in IFNAR1 ubiquitination yet competent in LPA-induced activation of PKD2 and p38 kinases (Fig 7A) serve as a critical control that allows to distinguish the role of LPA-induced IFNAR1 elimination from IFNAR1-independent pleiotropic effects of LPA.Pharmacologically induced ubiquitination and downregulation of IFNAR1 protects from toxic hepatitis and fulminant generalized inflammation ::: ResultsWe tested the effects of LPA in a clinically relevant model of toxic hepatitis induced by analgesic agent Acetaminophen (APAP), whose overdose causes severe liver damage and greatly contributes to acute liver failure of non-viral etiology in human patients (Ostapowicz ' Lee, 2000; Bernal et al, 2010).", [["liver", "ANATOMY", 592, 597], ["liver", "ANATOMY", 638, 643], ["LPA", "CHEMICAL", 80, 83], ["LPA", "CHEMICAL", 203, 206], ["LPA", "CHEMICAL", 281, 284], ["toxic hepatitis", "DISEASE", 369, 384], ["inflammation", "DISEASE", 411, 423], ["LPA", "CHEMICAL", 460, 463], ["toxic hepatitis", "DISEASE", 498, 513], ["Acetaminophen", "CHEMICAL", 541, 554], ["APAP", "CHEMICAL", 556, 560], ["overdose", "DISEASE", 569, 577], ["liver damage", "DISEASE", 592, 604], ["acute liver failure", "DISEASE", 632, 651], ["LPA", "CHEMICAL", 80, 83], ["LPA", "CHEMICAL", 203, 206], ["LPA", "CHEMICAL", 281, 284], ["LPA", "CHEMICAL", 460, 463], ["Acetaminophen", "CHEMICAL", 541, 554], ["APAP", "CHEMICAL", 556, 560], ["Ifnar1SA mice", "ORGANISM", 14, 27], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 41, 47], ["LPA", "SIMPLE_CHEMICAL", 80, 83], ["PKD2", "GENE_OR_GENE_PRODUCT", 106, 110], ["p38 kinases", "GENE_OR_GENE_PRODUCT", 115, 126], ["Fig 7A", "GENE_OR_GENE_PRODUCT", 128, 134], ["LPA", "SIMPLE_CHEMICAL", 203, 206], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 215, 221], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 239, 245], ["LPA", "SIMPLE_CHEMICAL", 281, 284], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 348, 354], ["LPA", "SIMPLE_CHEMICAL", 460, 463], ["Acetaminophen", "SIMPLE_CHEMICAL", 541, 554], ["APAP", "SIMPLE_CHEMICAL", 556, 560], ["liver", "ORGAN", 592, 597], ["liver", "ORGAN", 638, 643], ["human", "ORGANISM", 677, 682], ["patients", "ORGANISM", 683, 691], ["Ifnar1SA", "PROTEIN", 14, 22], ["IFNAR1", "PROTEIN", 41, 47], ["PKD2", "PROTEIN", 106, 110], ["p38 kinases", "PROTEIN", 115, 126], ["Fig 7A", "PROTEIN", 128, 134], ["IFNAR1", "PROTEIN", 215, 221], ["IFNAR1", "PROTEIN", 239, 245], ["IFNAR1", "PROTEIN", 348, 354], ["mice", "SPECIES", 23, 27], ["human", "SPECIES", 677, 682], ["patients", "SPECIES", 683, 691], ["mice", "SPECIES", 23, 27], ["human", "SPECIES", 677, 682], ["the Ifnar1SA mice deficient", "PROBLEM", 10, 37], ["IFNAR1 ubiquitination", "PROBLEM", 41, 62], ["PKD2 and p38 kinases", "TREATMENT", 106, 126], ["a critical control", "TREATMENT", 145, 163], ["LPA", "TEST", 203, 206], ["IFNAR1 elimination", "PROBLEM", 215, 233], ["IFNAR1", "PROBLEM", 239, 245], ["Pharmacologically induced ubiquitination", "PROBLEM", 285, 325], ["IFNAR1 protects", "TREATMENT", 348, 363], ["toxic hepatitis", "PROBLEM", 369, 384], ["fulminant generalized inflammation", "PROBLEM", 389, 423], ["LPA", "PROBLEM", 460, 463], ["toxic hepatitis", "PROBLEM", 498, 513], ["analgesic agent", "TREATMENT", 525, 540], ["Acetaminophen (APAP)", "TREATMENT", 541, 561], ["severe liver damage", "PROBLEM", 585, 604], ["acute liver failure", "PROBLEM", 632, 651], ["ubiquitination", "OBSERVATION", 311, 325], ["toxic", "OBSERVATION_MODIFIER", 369, 374], ["hepatitis", "OBSERVATION", 375, 384], ["fulminant", "OBSERVATION_MODIFIER", 389, 398], ["generalized", "OBSERVATION_MODIFIER", 399, 410], ["inflammation", "OBSERVATION", 411, 423], ["toxic", "OBSERVATION_MODIFIER", 498, 503], ["hepatitis", "OBSERVATION", 504, 513], ["severe", "OBSERVATION_MODIFIER", 585, 591], ["liver", "ANATOMY", 592, 597], ["damage", "OBSERVATION", 598, 604], ["acute", "OBSERVATION_MODIFIER", 632, 637], ["liver", "ANATOMY", 638, 643], ["failure", "OBSERVATION", 644, 651]]], ["A greater extent of APAP-induced liver damage (assessed by the plasma aminotransferase levels) was detected in Ifnar1SA mice compared to wild type animals.", [["liver", "ANATOMY", 33, 38], ["plasma", "ANATOMY", 63, 69], ["APAP", "CHEMICAL", 20, 24], ["liver damage", "DISEASE", 33, 45], ["APAP", "CHEMICAL", 20, 24], ["APAP", "SIMPLE_CHEMICAL", 20, 24], ["liver", "ORGAN", 33, 38], ["plasma", "ORGANISM_SUBSTANCE", 63, 69], ["aminotransferase", "SIMPLE_CHEMICAL", 70, 86], ["Ifnar1SA mice", "ORGANISM", 111, 124], ["plasma aminotransferase", "PROTEIN", 63, 86], ["mice", "SPECIES", 120, 124], ["mice", "SPECIES", 120, 124], ["APAP", "TEST", 20, 24], ["liver damage", "PROBLEM", 33, 45], ["the plasma aminotransferase levels", "TEST", 59, 93], ["greater", "OBSERVATION_MODIFIER", 2, 9], ["extent", "OBSERVATION_MODIFIER", 10, 16], ["APAP", "OBSERVATION", 20, 24], ["liver", "ANATOMY", 33, 38], ["damage", "OBSERVATION", 39, 45]]], ["While AST/ALT levels in APAP-treated wild type were significantly decreased upon treatment with LPA, we did not observe this effect in Ifnar1SA mice (Fig 7D and Supplementary Fig 20).", [["APAP", "CHEMICAL", 24, 28], ["LPA", "CHEMICAL", 96, 99], ["APAP", "CHEMICAL", 24, 28], ["LPA", "CHEMICAL", 96, 99], ["AST", "SIMPLE_CHEMICAL", 6, 9], ["ALT", "SIMPLE_CHEMICAL", 10, 13], ["APAP", "SIMPLE_CHEMICAL", 24, 28], ["LPA", "SIMPLE_CHEMICAL", 96, 99], ["Ifnar1SA mice", "ORGANISM", 135, 148], ["AST", "PROTEIN", 6, 9], ["ALT", "PROTEIN", 10, 13], ["mice", "SPECIES", 144, 148], ["mice", "SPECIES", 144, 148], ["AST", "TEST", 6, 9], ["ALT levels", "TEST", 10, 20], ["APAP", "TEST", 24, 28], ["wild type", "PROBLEM", 37, 46], ["LPA", "TREATMENT", 96, 99]]], ["Given that the latter mice express receptor whose ubiquitination and levels are not affected by LPA (Fig 7A,B), this result specifically suggests that LPA-induced ubiquitination and degradation of IFNAR1 can protect hepatic tissues from toxic injury.Pharmacologically induced ubiquitination and downregulation of IFNAR1 protects from toxic hepatitis and fulminant generalized inflammation ::: ResultsTo further determine the benefit of targeting IFNAR1 in inflammation, we used a neutralizing antibody against IFNAR1 that binds to its extracellular domain (Sheehan et al, 2006) and, therefore, should block signaling from both wild type and ubiquitination-deficient receptor.", [["hepatic tissues", "ANATOMY", 216, 231], ["extracellular", "ANATOMY", 535, 548], ["LPA", "CHEMICAL", 151, 154], ["toxic injury", "DISEASE", 237, 249], ["toxic hepatitis", "DISEASE", 334, 349], ["inflammation", "DISEASE", 376, 388], ["inflammation", "DISEASE", 456, 468], ["LPA", "CHEMICAL", 96, 99], ["LPA", "CHEMICAL", 151, 154], ["mice", "ORGANISM", 22, 26], ["LPA", "SIMPLE_CHEMICAL", 96, 99], ["B", "GENE_OR_GENE_PRODUCT", 108, 109], ["LPA", "SIMPLE_CHEMICAL", 151, 154], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 197, 203], ["hepatic tissues", "TISSUE", 216, 231], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 313, 319], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 446, 452], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 510, 516], ["IFNAR1", "PROTEIN", 197, 203], ["IFNAR1", "PROTEIN", 313, 319], ["IFNAR1", "PROTEIN", 446, 452], ["IFNAR1", "PROTEIN", 510, 516], ["extracellular domain", "PROTEIN", 535, 555], ["ubiquitination-deficient receptor", "PROTEIN", 641, 674], ["mice", "SPECIES", 22, 26], ["LPA", "TEST", 151, 154], ["induced ubiquitination", "PROBLEM", 155, 177], ["IFNAR1", "PROBLEM", 197, 203], ["toxic injury", "PROBLEM", 237, 249], ["Pharmacologically induced ubiquitination", "PROBLEM", 250, 290], ["IFNAR1 protects", "TREATMENT", 313, 328], ["toxic hepatitis", "PROBLEM", 334, 349], ["fulminant generalized inflammation", "PROBLEM", 354, 388], ["targeting IFNAR1 in inflammation", "PROBLEM", 436, 468], ["a neutralizing antibody", "TREATMENT", 478, 501], ["hepatic", "ANATOMY", 216, 223], ["toxic", "OBSERVATION_MODIFIER", 237, 242], ["injury", "OBSERVATION", 243, 249], ["ubiquitination", "OBSERVATION", 276, 290], ["toxic", "OBSERVATION_MODIFIER", 334, 339], ["hepatitis", "OBSERVATION", 340, 349], ["fulminant", "OBSERVATION_MODIFIER", 354, 363], ["generalized", "OBSERVATION_MODIFIER", 364, 375], ["inflammation", "OBSERVATION", 376, 388], ["inflammation", "OBSERVATION", 456, 468]]], ["Indeed, injection of this antibody noticeably decreased APAP-induced hepatitis in all animals (Fig 7D and Supplementary Fig 21).", [["APAP", "CHEMICAL", 56, 60], ["hepatitis", "DISEASE", 69, 78], ["APAP", "CHEMICAL", 56, 60], ["APAP", "SIMPLE_CHEMICAL", 56, 60], ["this antibody", "PROBLEM", 21, 34], ["APAP", "TREATMENT", 56, 60], ["hepatitis", "PROBLEM", 69, 78], ["hepatitis", "OBSERVATION", 69, 78]]], ["Furthermore, similar results with either LPA or anti-IFNAR1 antibody were obtained when hepatotoxicity was induced using CCl4 (Supplementary Figs 22 and 23).", [["LPA", "CHEMICAL", 41, 44], ["hepatotoxicity", "DISEASE", 88, 102], ["CCl4", "CHEMICAL", 121, 125], ["LPA", "CHEMICAL", 41, 44], ["CCl4", "CHEMICAL", 121, 125], ["LPA", "SIMPLE_CHEMICAL", 41, 44], ["anti-IFNAR1 antibody", "GENE_OR_GENE_PRODUCT", 48, 68], ["CCl4", "SIMPLE_CHEMICAL", 121, 125], ["anti-IFNAR1 antibody", "PROTEIN", 48, 68], ["LPA or anti-IFNAR1 antibody", "TEST", 41, 68], ["hepatotoxicity", "PROBLEM", 88, 102]]], ["Collectively, these results suggest that targeting IFNAR1 via either blocking its extracellular domain (by antibody) or inducing ubiquitination of its intracellular domain (by LPA-like agents) can be used to protect liver against excessive inflammatory damage.Pharmacologically induced ubiquitination and downregulation of IFNAR1 protects from toxic hepatitis and fulminant generalized inflammation ::: ResultsIntriguingly, the ability of LPA to moderate generalized inflammation induced by LPS has been previously reported, although the mechanisms underlying these effects are yet to be understood (Fan et al, 2008; Zhao et al, 2011).", [["extracellular", "ANATOMY", 82, 95], ["intracellular", "ANATOMY", 151, 164], ["liver", "ANATOMY", 216, 221], ["LPA", "CHEMICAL", 176, 179], ["toxic hepatitis", "DISEASE", 344, 359], ["inflammation", "DISEASE", 386, 398], ["LPA", "CHEMICAL", 439, 442], ["inflammation", "DISEASE", 467, 479], ["LPS", "CHEMICAL", 491, 494], ["LPA", "CHEMICAL", 176, 179], ["LPA", "CHEMICAL", 439, 442], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 51, 57], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 82, 95], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 151, 164], ["LPA", "SIMPLE_CHEMICAL", 176, 179], ["liver", "ORGAN", 216, 221], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 323, 329], ["LPA", "SIMPLE_CHEMICAL", 439, 442], ["LPS", "SIMPLE_CHEMICAL", 491, 494], ["IFNAR1", "PROTEIN", 51, 57], ["extracellular domain", "PROTEIN", 82, 102], ["intracellular domain", "PROTEIN", 151, 171], ["IFNAR1", "PROTEIN", 323, 329], ["IFNAR1", "PROBLEM", 51, 57], ["its intracellular domain", "PROBLEM", 147, 171], ["LPA-like agents", "TREATMENT", 176, 191], ["excessive inflammatory damage", "PROBLEM", 230, 259], ["Pharmacologically induced ubiquitination", "PROBLEM", 260, 300], ["IFNAR1 protects", "TREATMENT", 323, 338], ["toxic hepatitis", "PROBLEM", 344, 359], ["fulminant generalized inflammation", "PROBLEM", 364, 398], ["moderate generalized inflammation", "PROBLEM", 446, 479], ["LPS", "PROBLEM", 491, 494], ["liver", "ANATOMY", 216, 221], ["excessive", "OBSERVATION_MODIFIER", 230, 239], ["inflammatory", "OBSERVATION", 240, 252], ["ubiquitination", "OBSERVATION", 286, 300], ["toxic", "OBSERVATION_MODIFIER", 344, 349], ["hepatitis", "OBSERVATION", 350, 359], ["fulminant", "OBSERVATION_MODIFIER", 364, 373], ["generalized", "OBSERVATION_MODIFIER", 374, 385], ["inflammation", "OBSERVATION", 386, 398], ["moderate", "OBSERVATION_MODIFIER", 446, 454], ["generalized", "OBSERVATION_MODIFIER", 455, 466], ["inflammation", "OBSERVATION", 467, 479]]], ["While toxicity of LPS was attenuated upon genetic ablation of Ifnar1 (Karaghiosoff et al, 2003), it remains unclear whether induction of IFNAR1 ubiquitination in wild type animals might function as a mechanism for reducing the LPS toxicity or/and a target for protective effects of LPA.", [["toxicity", "DISEASE", 6, 14], ["LPS", "CHEMICAL", 18, 21], ["LPS", "CHEMICAL", 227, 230], ["toxicity", "DISEASE", 231, 239], ["LPA", "CHEMICAL", 282, 285], ["LPA", "CHEMICAL", 282, 285], ["LPS", "SIMPLE_CHEMICAL", 18, 21], ["Ifnar1", "GENE_OR_GENE_PRODUCT", 62, 68], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 137, 143], ["wild type animals", "ORGANISM", 162, 179], ["LPS", "SIMPLE_CHEMICAL", 227, 230], ["LPA", "SIMPLE_CHEMICAL", 282, 285], ["IFNAR1", "PROTEIN", 137, 143], ["LPS", "PROBLEM", 18, 21], ["genetic ablation", "TREATMENT", 42, 58], ["Ifnar1", "PROBLEM", 62, 68], ["IFNAR1 ubiquitination", "PROBLEM", 137, 158], ["the LPS toxicity", "PROBLEM", 223, 239], ["LPA", "TEST", 282, 285]]], ["While conducting the experiments on LPS-induced cytokines (Fig 2) we were unable to compare the levels of these cytokines between wild type and Ifnar1SA mice past 24 h after LPS treatment because of early lethality in the Ifnar1SA group.", [["LPS", "CHEMICAL", 36, 39], ["LPS", "CHEMICAL", 174, 177], ["LPS", "SIMPLE_CHEMICAL", 36, 39], ["Ifnar1SA mice", "ORGANISM", 144, 157], ["LPS", "SIMPLE_CHEMICAL", 174, 177], ["Ifnar1SA", "CANCER", 222, 230], ["cytokines", "PROTEIN", 48, 57], ["cytokines", "PROTEIN", 112, 121], ["mice", "SPECIES", 153, 157], ["mice", "SPECIES", 153, 157], ["LPS", "TREATMENT", 36, 39], ["these cytokines", "PROBLEM", 106, 121], ["LPS treatment", "TREATMENT", 174, 187], ["early lethality", "PROBLEM", 199, 214], ["cytokines", "OBSERVATION", 112, 121], ["early", "OBSERVATION_MODIFIER", 199, 204], ["lethality", "OBSERVATION", 205, 214]]], ["This lethality was likely associated with a strikingly greater extent of lung injury including pronounced leukocyte infiltration of the interstitial and alveolar spaces, edema and alveolar distortion observed within 12 h after LPS injection (Fig 7E).", [["lung", "ANATOMY", 73, 77], ["leukocyte", "ANATOMY", 106, 115], ["interstitial", "ANATOMY", 136, 148], ["alveolar spaces", "ANATOMY", 153, 168], ["edema", "ANATOMY", 170, 175], ["alveolar", "ANATOMY", 180, 188], ["lung injury", "DISEASE", 73, 84], ["edema", "DISEASE", 170, 175], ["LPS", "CHEMICAL", 227, 230], ["lung", "ORGAN", 73, 77], ["leukocyte", "CELL", 106, 115], ["interstitial", "TISSUE", 136, 148], ["alveolar", "TISSUE", 153, 161], ["edema", "PATHOLOGICAL_FORMATION", 170, 175], ["alveolar", "TISSUE", 180, 188], ["LPS", "SIMPLE_CHEMICAL", 227, 230], ["This lethality", "PROBLEM", 0, 14], ["lung injury", "PROBLEM", 73, 84], ["pronounced leukocyte infiltration of the interstitial and alveolar spaces", "PROBLEM", 95, 168], ["edema", "PROBLEM", 170, 175], ["alveolar distortion", "PROBLEM", 180, 199], ["LPS injection", "TREATMENT", 227, 240], ["likely associated with", "UNCERTAINTY", 19, 41], ["strikingly", "OBSERVATION_MODIFIER", 44, 54], ["greater", "OBSERVATION_MODIFIER", 55, 62], ["extent", "OBSERVATION_MODIFIER", 63, 69], ["lung", "ANATOMY", 73, 77], ["injury", "OBSERVATION", 78, 84], ["pronounced", "OBSERVATION_MODIFIER", 95, 105], ["leukocyte infiltration", "OBSERVATION", 106, 128], ["interstitial", "ANATOMY_MODIFIER", 136, 148], ["alveolar", "ANATOMY_MODIFIER", 153, 161], ["edema", "OBSERVATION", 170, 175], ["alveolar distortion", "OBSERVATION", 180, 199]]], ["Remarkably, a detailed analysis of survival revealed a significant protective effect of LPA treatment in wild type but not in Ifnar1SA mice (Fig 7F).", [["LPA", "CHEMICAL", 88, 91], ["LPA", "CHEMICAL", 88, 91], ["LPA", "SIMPLE_CHEMICAL", 88, 91], ["Ifnar1SA mice", "ORGANISM", 126, 139], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 135, 139], ["a detailed analysis", "TEST", 12, 31], ["LPA treatment", "TREATMENT", 88, 101], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["protective effect", "OBSERVATION_MODIFIER", 67, 84], ["LPA", "OBSERVATION_MODIFIER", 88, 91]]], ["These results indicate that ubiquitination of IFNAR1 is an intrinsic mechanism that plays a critical role in preventing the fulminant course of LPS-induced septic shock.", [["LPS", "CHEMICAL", 144, 147], ["septic shock", "DISEASE", 156, 168], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 46, 52], ["LPS", "SIMPLE_CHEMICAL", 144, 147], ["IFNAR1", "PROTEIN", 46, 52], ["ubiquitination of IFNAR1", "PROBLEM", 28, 52], ["LPS", "PROBLEM", 144, 147], ["septic shock", "PROBLEM", 156, 168], ["fulminant", "OBSERVATION_MODIFIER", 124, 133], ["septic shock", "OBSERVATION", 156, 168]]], ["Furthermore, collectively these data provide a proof of principle for pharmacological stimulation of IFNAR1 ubiquitination as an effective strategy against acute local and generalized inflammatory syndromes.DiscussionData presented here indicate that stimulated ubiquitination and degradation of IFNAR1 in the bone marrow-derived cells recruited to the foci of inflammation plays a major protective role during inflammation.", [["bone marrow-derived cells", "ANATOMY", 310, 335], ["foci", "ANATOMY", 353, 357], ["inflammation", "DISEASE", 361, 373], ["inflammation", "DISEASE", 411, 423], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 101, 107], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 296, 302], ["bone marrow-derived cells", "CELL", 310, 335], ["IFNAR1", "PROTEIN", 101, 107], ["IFNAR1", "PROTEIN", 296, 302], ["bone marrow-derived cells", "CELL_TYPE", 310, 335], ["pharmacological stimulation", "TREATMENT", 70, 97], ["IFNAR1 ubiquitination", "TREATMENT", 101, 122], ["acute local and generalized inflammatory syndromes", "PROBLEM", 156, 206], ["stimulated ubiquitination", "PROBLEM", 251, 276], ["IFNAR1 in the bone marrow", "PROBLEM", 296, 321], ["derived cells", "PROBLEM", 322, 335], ["inflammation", "PROBLEM", 361, 373], ["inflammation", "PROBLEM", 411, 423], ["generalized", "OBSERVATION_MODIFIER", 172, 183], ["inflammatory syndromes", "OBSERVATION", 184, 206], ["bone marrow", "ANATOMY", 310, 321], ["foci", "OBSERVATION_MODIFIER", 353, 357], ["inflammation", "OBSERVATION", 361, 373], ["inflammation", "OBSERVATION", 411, 423]]], ["Striking systemic and local phenotypes observed in Ifnar1SA mice under etiologically and pathogenetically diverse types of inflammatory syndromes illustrate two important points.", [["Ifnar1SA mice", "ORGANISM", 51, 64], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 60, 64], ["Striking systemic and local phenotypes", "PROBLEM", 0, 38], ["inflammatory syndromes", "PROBLEM", 123, 145], ["systemic", "OBSERVATION_MODIFIER", 9, 17], ["local phenotypes", "OBSERVATION", 22, 38], ["pathogenetically", "OBSERVATION_MODIFIER", 89, 105], ["diverse", "OBSERVATION_MODIFIER", 106, 113], ["types", "OBSERVATION_MODIFIER", 114, 119], ["inflammatory syndromes", "OBSERVATION", 123, 145]]], ["First, the results suggest that accelerated ubiquitination and ensuing downregulation of IFNAR1 in response to numerous stimuli may (at least to some extent) functionally mimic the complete loss of this receptor via genetic ablation.", [["IFNAR1", "GENE_OR_GENE_PRODUCT", 89, 95], ["IFNAR1", "PROTEIN", 89, 95], ["accelerated ubiquitination", "PROBLEM", 32, 58], ["IFNAR1", "PROBLEM", 89, 95], ["numerous stimuli", "TEST", 111, 127], ["genetic ablation", "TREATMENT", 216, 232], ["accelerated", "OBSERVATION_MODIFIER", 32, 43], ["ubiquitination", "OBSERVATION", 44, 58]]], ["Under specific physiologic and pathologic scenarios, this accelerated degradation may result in a phenotypic equivalency between wild type and IFNAR1 knockout animals.", [["IFNAR1", "GENE_OR_GENE_PRODUCT", 143, 149], ["IFNAR1", "PROTEIN", 143, 149], ["this accelerated degradation", "PROBLEM", 53, 81], ["a phenotypic equivalency", "PROBLEM", 96, 120], ["pathologic scenarios", "OBSERVATION", 31, 51]]], ["Such equivalency should not be over-interpreted as the lack of role of IFN in a given physiologic process or a pathologic condition.DiscussionSecond, given that upregulation of Irf7 seen in Ifnar1SA mice can contribute to further increases in ligands production (Supplementary Figs 1, 2, 9 and 15), the inability to eliminate IFNAR1 may create a feed-forward signaling amplification mechanism.", [["IFN", "GENE_OR_GENE_PRODUCT", 71, 74], ["Irf7", "GENE_OR_GENE_PRODUCT", 177, 181], ["Ifnar1SA mice", "ORGANISM", 190, 203], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 326, 332], ["IFN", "PROTEIN", 71, 74], ["Irf7", "PROTEIN", 177, 181], ["IFNAR1", "PROTEIN", 326, 332], ["mice", "SPECIES", 199, 203], ["mice", "SPECIES", 199, 203], ["IFN", "TREATMENT", 71, 74], ["a pathologic condition", "PROBLEM", 109, 131], ["Irf7", "PROBLEM", 177, 181], ["further increases in ligands production", "PROBLEM", 222, 261], ["increases", "OBSERVATION_MODIFIER", 230, 239]]], ["Importantly, the augmented IFN signaling as well as phenotypes observed in Ifnar1SA mice are evident despite numerous negative regulators of IFN pathway that function downstream of receptor and include the expression of signaling and transcriptional inhibitors including tyrosine phosphatases, suppressors of cytokine signaling, Sprouty, Ubp43, protein inhibitors of STAT, etc. (Coccia et al, 2006; Zhang ' Zhang, 2011; Sharma et al, 2012).", [["tyrosine", "CHEMICAL", 271, 279], ["tyrosine", "CHEMICAL", 271, 279], ["IFN", "GENE_OR_GENE_PRODUCT", 27, 30], ["Ifnar1SA mice", "ORGANISM", 75, 88], ["IFN", "GENE_OR_GENE_PRODUCT", 141, 144], ["Sprouty", "GENE_OR_GENE_PRODUCT", 329, 336], ["Ubp43", "GENE_OR_GENE_PRODUCT", 338, 343], ["STAT", "GENE_OR_GENE_PRODUCT", 367, 371], ["etc", "GENE_OR_GENE_PRODUCT", 373, 376], ["IFN", "PROTEIN", 27, 30], ["IFN", "PROTEIN", 141, 144], ["tyrosine phosphatases", "PROTEIN", 271, 292], ["cytokine", "PROTEIN", 309, 317], ["Sprouty", "PROTEIN", 329, 336], ["Ubp43", "PROTEIN", 338, 343], ["STAT", "PROTEIN", 367, 371], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 84, 88], ["the augmented IFN signaling", "PROBLEM", 13, 40], ["phenotypes", "PROBLEM", 52, 62], ["IFN pathway", "TREATMENT", 141, 152], ["receptor", "TREATMENT", 181, 189], ["transcriptional inhibitors", "TREATMENT", 234, 260], ["tyrosine phosphatases", "TREATMENT", 271, 292], ["cytokine signaling", "PROBLEM", 309, 327], ["protein inhibitors", "TREATMENT", 345, 363]]], ["This fact suggests that ubiquitination-dependent downregulation of IFNAR1 represents a major and critically important mechanism that attenuates the sensitivity of cells and tissues to IFN and plays a key role in limiting IFN-mediated immunopathology.DiscussionThe mechanisms by which elimination of IFNAR1 in cells within inflamed tissues aids to restrict tissue damage and switch to recovery are likely to be complex.", [["cells", "ANATOMY", 163, 168], ["tissues", "ANATOMY", 173, 180], ["cells", "ANATOMY", 309, 314], ["tissues", "ANATOMY", 331, 338], ["tissue", "ANATOMY", 356, 362], ["IFN", "CHEMICAL", 184, 187], ["immunopathology", "DISEASE", 234, 249], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 67, 73], ["cells", "CELL", 163, 168], ["tissues", "TISSUE", 173, 180], ["IFN", "GENE_OR_GENE_PRODUCT", 184, 187], ["IFN", "GENE_OR_GENE_PRODUCT", 221, 224], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 299, 305], ["cells", "CELL", 309, 314], ["tissues", "TISSUE", 331, 338], ["tissue", "TISSUE", 356, 362], ["IFNAR1", "PROTEIN", 67, 73], ["IFN", "PROTEIN", 184, 187], ["IFN", "PROTEIN", 221, 224], ["IFNAR1", "PROTEIN", 299, 305], ["ubiquitination-dependent downregulation of IFNAR1", "PROBLEM", 24, 73], ["IFNAR1 in cells", "PROBLEM", 299, 314], ["inflamed tissues aids", "PROBLEM", 322, 343], ["tissue damage", "PROBLEM", 356, 369], ["ubiquitination", "OBSERVATION", 24, 38], ["dependent", "OBSERVATION_MODIFIER", 39, 48], ["downregulation", "OBSERVATION_MODIFIER", 49, 63], ["immunopathology", "OBSERVATION", 234, 249], ["likely to be", "UNCERTAINTY", 397, 409]]], ["Temporarily limiting the output of IFN signaling is expected to attenuate the direct detrimental effects of IFN on cell growth and viability and affect IFN-induced p38-dependent (Katsoulidis et al, 2005) and NF-\u03baB-regulated (Du et al, 2007) inflammatory pathways known to contribute to expression of additional inflammatory cytokines (Karin, 2005).", [["cell", "ANATOMY", 115, 119], ["IFN", "CHEMICAL", 108, 111], ["IFN", "GENE_OR_GENE_PRODUCT", 35, 38], ["IFN", "GENE_OR_GENE_PRODUCT", 108, 111], ["cell", "CELL", 115, 119], ["IFN", "GENE_OR_GENE_PRODUCT", 152, 155], ["p38", "GENE_OR_GENE_PRODUCT", 164, 167], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 208, 213], ["IFN", "PROTEIN", 35, 38], ["IFN", "PROTEIN", 108, 111], ["IFN", "PROTEIN", 152, 155], ["p38", "PROTEIN", 164, 167], ["inflammatory cytokines", "PROTEIN", 311, 333], ["IFN signaling", "PROBLEM", 35, 48], ["IFN on cell growth", "TREATMENT", 108, 126], ["viability", "TEST", 131, 140], ["IFN", "TEST", 152, 155], ["p38", "TEST", 164, 167], ["NF", "TEST", 208, 210], ["inflammatory pathways", "PROBLEM", 241, 262], ["additional inflammatory cytokines", "PROBLEM", 300, 333], ["inflammatory", "OBSERVATION_MODIFIER", 311, 323]]], ["Furthermore, previously published studies showed that IFNAR1 expression is essential for efficient IL6 signaling (Mitani et al, 2001).", [["IFNAR1", "GENE_OR_GENE_PRODUCT", 54, 60], ["IL6", "GENE_OR_GENE_PRODUCT", 99, 102], ["IFNAR1", "PROTEIN", 54, 60], ["IL6", "PROTEIN", 99, 102], ["previously published studies", "TEST", 13, 41], ["IFNAR1 expression", "PROBLEM", 54, 71], ["efficient IL6 signaling", "PROBLEM", 89, 112]]], ["The produced cytokines/chemokines either directly kill cells or contribute to subsequent waves of recruitment of immune cells that are capable of further damaging the inflamed tissue.", [["cells", "ANATOMY", 55, 60], ["immune cells", "ANATOMY", 113, 125], ["tissue", "ANATOMY", 176, 182], ["cells", "CELL", 55, 60], ["immune cells", "CELL", 113, 125], ["tissue", "TISSUE", 176, 182], ["cytokines", "PROTEIN", 13, 22], ["chemokines", "PROTEIN", 23, 33], ["immune cells", "CELL_TYPE", 113, 125], ["cytokines/chemokines", "TREATMENT", 13, 33], ["directly kill cells", "PROBLEM", 41, 60], ["recruitment of immune cells", "PROBLEM", 98, 125], ["further damaging the inflamed tissue", "PROBLEM", 146, 182], ["immune cells", "OBSERVATION", 113, 125], ["inflamed tissue", "OBSERVATION", 167, 182]]], ["Pancreatic inflammation in mice deficient in IFNAR1 ubiquitination was paralleled with an altered balance between pro-inflammatory and anti-inflammatory cytokines (e.g. TNF\u03b1 and IL10) and increased expression of CCL2 (Fig 3).", [["Pancreatic", "ANATOMY", 0, 10], ["Pancreatic inflammation", "DISEASE", 0, 23], ["Pancreatic", "ORGAN", 0, 10], ["mice", "ORGANISM", 27, 31], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 45, 51], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 169, 173], ["IL10", "GENE_OR_GENE_PRODUCT", 178, 182], ["CCL2", "GENE_OR_GENE_PRODUCT", 212, 216], ["Fig 3", "GENE_OR_GENE_PRODUCT", 218, 223], ["IFNAR1", "PROTEIN", 45, 51], ["anti-inflammatory cytokines", "PROTEIN", 135, 162], ["TNF\u03b1", "PROTEIN", 169, 173], ["IL10", "PROTEIN", 178, 182], ["CCL2", "PROTEIN", 212, 216], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31], ["Pancreatic inflammation in mice deficient in IFNAR1 ubiquitination", "PROBLEM", 0, 66], ["an altered balance", "PROBLEM", 87, 105], ["pro-inflammatory and anti-inflammatory cytokines", "TREATMENT", 114, 162], ["TNF\u03b1 and IL10)", "TREATMENT", 169, 183], ["inflammation", "OBSERVATION", 11, 23], ["mice deficient", "OBSERVATION", 27, 41], ["IFNAR1 ubiquitination", "OBSERVATION", 45, 66], ["altered", "OBSERVATION_MODIFIER", 90, 97], ["balance", "OBSERVATION", 98, 105], ["anti-inflammatory cytokines", "OBSERVATION", 135, 162]]], ["Given that IFN directly induces transcription of CCL2 (Buttmann et al, 2007) that mediates recruitment of inflammatory monocytes, which in turn produce TNF\u03b1 and other inflammatory cytokines (Guha ' Mackman, 2001), it is plausible that down-regulation of IFNAR1 may help to restrict this pathway.", [["inflammatory monocytes", "ANATOMY", 106, 128], ["IFN", "CHEMICAL", 11, 14], ["IFN", "GENE_OR_GENE_PRODUCT", 11, 14], ["CCL2", "GENE_OR_GENE_PRODUCT", 49, 53], ["monocytes", "CELL", 119, 128], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 152, 156], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 254, 260], ["IFN", "PROTEIN", 11, 14], ["CCL2", "PROTEIN", 49, 53], ["inflammatory monocytes", "CELL_TYPE", 106, 128], ["TNF\u03b1", "PROTEIN", 152, 156], ["inflammatory cytokines", "PROTEIN", 167, 189], ["IFNAR1", "PROTEIN", 254, 260], ["CCL2 (Buttmann et al", "TREATMENT", 49, 69], ["inflammatory monocytes", "PROBLEM", 106, 128], ["TNF", "TEST", 152, 155], ["this pathway", "TREATMENT", 282, 294], ["inflammatory monocytes", "OBSERVATION", 106, 128], ["inflammatory", "OBSERVATION_MODIFIER", 167, 179]]], ["Consistent with this possibility, a greater number of inflammatory monocytes/macrophages was observed in tissues from Ifnar1SA mice (Fig 3 and Supplementary Fig 11).DiscussionIn addition, a dramatic deficiency in tissue repair and regeneration seen in chronic pancreatitis model (Fig 4 and Supplementary Fig 12) suggests that other mechanisms affecting mesenchymal stem cells or/and endothelial progenitors might be involved as well.", [["monocytes", "ANATOMY", 67, 76], ["macrophages", "ANATOMY", 77, 88], ["tissues", "ANATOMY", 105, 112], ["tissue", "ANATOMY", 213, 219], ["mesenchymal stem cells", "ANATOMY", 353, 375], ["endothelial progenitors", "ANATOMY", 383, 406], ["pancreatitis", "DISEASE", 260, 272], ["monocytes", "CELL", 67, 76], ["macrophages", "CELL", 77, 88], ["tissues", "TISSUE", 105, 112], ["Ifnar1SA mice", "ORGANISM", 118, 131], ["tissue", "TISSUE", 213, 219], ["mesenchymal stem cells", "CELL", 353, 375], ["endothelial progenitors", "CELL", 383, 406], ["inflammatory monocytes", "CELL_TYPE", 54, 76], ["macrophages", "CELL_TYPE", 77, 88], ["mesenchymal stem cells", "CELL_TYPE", 353, 375], ["endothelial progenitors", "CELL_TYPE", 383, 406], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 127, 131], ["inflammatory monocytes/macrophages", "PROBLEM", 54, 88], ["Ifnar1SA mice (Fig", "TREATMENT", 118, 136], ["a dramatic deficiency", "PROBLEM", 188, 209], ["tissue repair", "TREATMENT", 213, 226], ["regeneration", "TREATMENT", 231, 243], ["chronic pancreatitis model", "PROBLEM", 252, 278], ["Supplementary Fig", "TREATMENT", 290, 307], ["mesenchymal stem cells", "PROBLEM", 353, 375], ["with this possibility", "UNCERTAINTY", 11, 32], ["greater", "OBSERVATION_MODIFIER", 36, 43], ["number", "OBSERVATION_MODIFIER", 44, 50], ["inflammatory monocytes", "OBSERVATION", 54, 76], ["macrophages", "OBSERVATION", 77, 88], ["dramatic", "OBSERVATION_MODIFIER", 190, 198], ["deficiency", "OBSERVATION", 199, 209], ["tissue repair", "OBSERVATION", 213, 226], ["chronic", "OBSERVATION_MODIFIER", 252, 259], ["pancreatitis", "OBSERVATION", 260, 272], ["mesenchymal stem cells", "OBSERVATION", 353, 375]]], ["In light of demonstrated resistance of endothelial cells from Ifnar1SA mice to VEGF-induced angiogenesis (Zheng et al, 2011b) along with observations that elevated levels of VEGF are protective against tissue injury in human patients with acute pancreatitis (Ueda et al, 2006), the role of efficient IFNAR1 ubiquitination in ensuring an adequate blood supply to the regenerating tissues might be important.", [["endothelial cells", "ANATOMY", 39, 56], ["tissue", "ANATOMY", 202, 208], ["blood", "ANATOMY", 346, 351], ["tissues", "ANATOMY", 379, 386], ["tissue injury", "DISEASE", 202, 215], ["acute pancreatitis", "DISEASE", 239, 257], ["endothelial cells", "CELL", 39, 56], ["Ifnar1SA mice", "ORGANISM", 62, 75], ["VEGF", "GENE_OR_GENE_PRODUCT", 79, 83], ["VEGF", "GENE_OR_GENE_PRODUCT", 174, 178], ["tissue", "TISSUE", 202, 208], ["human", "ORGANISM", 219, 224], ["patients", "ORGANISM", 225, 233], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 300, 306], ["blood", "ORGANISM_SUBSTANCE", 346, 351], ["tissues", "TISSUE", 379, 386], ["endothelial cells", "CELL_TYPE", 39, 56], ["VEGF", "PROTEIN", 79, 83], ["VEGF", "PROTEIN", 174, 178], ["IFNAR1", "PROTEIN", 300, 306], ["mice", "SPECIES", 71, 75], ["human", "SPECIES", 219, 224], ["patients", "SPECIES", 225, 233], ["human", "SPECIES", 219, 224], ["endothelial cells", "PROBLEM", 39, 56], ["VEGF", "TEST", 79, 83], ["induced angiogenesis", "PROBLEM", 84, 104], ["elevated levels of VEGF", "PROBLEM", 155, 178], ["tissue injury", "PROBLEM", 202, 215], ["acute pancreatitis", "PROBLEM", 239, 257], ["efficient IFNAR1 ubiquitination", "TREATMENT", 290, 321], ["resistance", "OBSERVATION", 25, 35], ["endothelial cells", "OBSERVATION", 39, 56], ["VEGF", "ANATOMY", 174, 178], ["protective", "OBSERVATION_MODIFIER", 183, 193], ["against tissue", "OBSERVATION_MODIFIER", 194, 208], ["injury", "OBSERVATION", 209, 215], ["acute", "OBSERVATION_MODIFIER", 239, 244], ["pancreatitis", "OBSERVATION", 245, 257], ["IFNAR1 ubiquitination", "OBSERVATION", 300, 321], ["regenerating tissues", "OBSERVATION", 366, 386]]], ["Future studies delineating the mechanisms by which elimination of IFNAR1 aids to tissue recovery are warranted.DiscussionThe practical relevance of the mechanisms utilizing IFNAR1 elimination to attenuate the responsiveness of tissues to IFN in hepatitis is underscored by several clinical observations.", [["tissue", "ANATOMY", 81, 87], ["tissues", "ANATOMY", 227, 234], ["IFN", "CHEMICAL", 238, 241], ["hepatitis", "DISEASE", 245, 254], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 66, 72], ["tissue", "TISSUE", 81, 87], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 173, 179], ["tissues", "TISSUE", 227, 234], ["IFN", "GENE_OR_GENE_PRODUCT", 238, 241], ["IFNAR1", "PROTEIN", 66, 72], ["IFNAR1", "PROTEIN", 173, 179], ["IFN", "PROTEIN", 238, 241], ["Future studies", "TEST", 0, 14], ["IFNAR1 aids", "TREATMENT", 66, 77], ["IFNAR1 elimination", "TREATMENT", 173, 191], ["hepatitis", "PROBLEM", 245, 254], ["hepatitis", "OBSERVATION", 245, 254]]], ["Despite the use of IFN in treatment of chronic viral hepatitis caused by hepatitis C and B viruses, the hepatic side effects including exacerbation of liver damage after IFN administration has been widely reported (Dusheiko, 1997).", [["hepatic", "ANATOMY", 104, 111], ["liver", "ANATOMY", 151, 156], ["IFN", "CHEMICAL", 19, 22], ["chronic viral hepatitis", "DISEASE", 39, 62], ["hepatitis C", "DISEASE", 73, 84], ["liver damage", "DISEASE", 151, 163], ["IFN", "CHEMICAL", 170, 173], ["IFN", "GENE_OR_GENE_PRODUCT", 19, 22], ["hepatitis C", "ORGANISM", 73, 84], ["B viruses", "ORGANISM", 89, 98], ["hepatic", "ORGAN", 104, 111], ["liver", "ORGAN", 151, 156], ["IFN", "PROTEIN", 19, 22], ["IFN", "PROTEIN", 170, 173], ["B viruses", "SPECIES", 89, 98], ["IFN", "TREATMENT", 19, 22], ["treatment", "TREATMENT", 26, 35], ["chronic viral hepatitis", "PROBLEM", 39, 62], ["hepatitis C", "PROBLEM", 73, 84], ["B viruses", "PROBLEM", 89, 98], ["the hepatic side effects", "PROBLEM", 100, 124], ["exacerbation of liver damage", "PROBLEM", 135, 163], ["IFN administration", "TREATMENT", 170, 188], ["chronic", "OBSERVATION_MODIFIER", 39, 46], ["viral hepatitis", "OBSERVATION", 47, 62], ["hepatitis", "OBSERVATION", 73, 82], ["viruses", "OBSERVATION", 91, 98], ["hepatic", "ANATOMY", 104, 111], ["liver", "ANATOMY", 151, 156], ["damage", "OBSERVATION", 157, 163]]], ["We proposed previously that the interventions aimed to enable IFNAR1 to withstand inflammatory elimination may increase the efficacy of IFN against tumors (Huangfu et al, 2012).", [["tumors", "ANATOMY", 148, 154], ["IFN", "CHEMICAL", 136, 139], ["tumors", "DISEASE", 148, 154], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 62, 68], ["IFN", "GENE_OR_GENE_PRODUCT", 136, 139], ["tumors", "CANCER", 148, 154], ["IFNAR1", "PROTEIN", 62, 68], ["IFN", "PROTEIN", 136, 139], ["the interventions", "TREATMENT", 28, 45], ["inflammatory elimination", "TREATMENT", 82, 106], ["IFN against tumors", "PROBLEM", 136, 154]]], ["Our current results argue to expand the clinical considerations for preventive stimulation of IFNAR1 turnover through PKD2/p38 induction in order to further limit the harmful effects of IFN.DiscussionIndeed, treatment with LPA capable of inducing IFNAR1 ubiquitination protected wild type but not Ifnar1SA animals from toxic hepatitis and fulminant generalized inflammation (Fig 7).", [["IFN", "CHEMICAL", 186, 189], ["LPA", "CHEMICAL", 223, 226], ["toxic hepatitis", "DISEASE", 319, 334], ["inflammation", "DISEASE", 361, 373], ["LPA", "CHEMICAL", 223, 226], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 94, 100], ["PKD2", "GENE_OR_GENE_PRODUCT", 118, 122], ["p38", "GENE_OR_GENE_PRODUCT", 123, 126], ["IFN", "GENE_OR_GENE_PRODUCT", 186, 189], ["LPA", "SIMPLE_CHEMICAL", 223, 226], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 247, 253], ["Ifnar1SA animals", "ORGANISM", 297, 313], ["IFNAR1", "PROTEIN", 94, 100], ["PKD2", "PROTEIN", 118, 122], ["p38", "PROTEIN", 123, 126], ["IFN", "PROTEIN", 186, 189], ["IFNAR1", "PROTEIN", 247, 253], ["preventive stimulation of IFNAR1 turnover", "TREATMENT", 68, 109], ["PKD2/p38 induction", "TREATMENT", 118, 136], ["IFN", "TREATMENT", 186, 189], ["treatment", "TREATMENT", 208, 217], ["IFNAR1 ubiquitination", "PROBLEM", 247, 268], ["toxic hepatitis", "PROBLEM", 319, 334], ["fulminant generalized inflammation", "PROBLEM", 339, 373], ["toxic", "OBSERVATION_MODIFIER", 319, 324], ["hepatitis", "OBSERVATION", 325, 334], ["fulminant", "OBSERVATION_MODIFIER", 339, 348], ["generalized", "OBSERVATION_MODIFIER", 349, 360], ["inflammation", "OBSERVATION", 361, 373]]], ["These data provide a proof of principle for pharmacologic downregulation of IFNAR1 to be used against acute life-threatening inflammatory conditions where the concerns for attenuated anti-viral or anti-tumor defenses are secondary.", [["anti-tumor", "ANATOMY", 197, 207], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 76, 82], ["anti-tumor", "CANCER", 197, 207], ["IFNAR1", "PROTEIN", 76, 82], ["pharmacologic downregulation of IFNAR1", "TREATMENT", 44, 82], ["acute life-threatening inflammatory conditions", "PROBLEM", 102, 148], ["attenuated anti-viral or anti-tumor defenses", "PROBLEM", 172, 216], ["inflammatory", "OBSERVATION", 125, 137]]], ["Similar to LPA, numerous natural and synthetic agonists of G-protein coupled receptors are capable of activating PKD2 and p38 kinases (Rosenbaum et al, 2009; Tilley, 2011).", [["LPA", "CHEMICAL", 11, 14], ["LPA", "CHEMICAL", 11, 14], ["LPA", "SIMPLE_CHEMICAL", 11, 14], ["G-protein coupled receptors", "GENE_OR_GENE_PRODUCT", 59, 86], ["PKD2", "GENE_OR_GENE_PRODUCT", 113, 117], ["p38 kinases", "GENE_OR_GENE_PRODUCT", 122, 133], ["G-protein coupled receptors", "PROTEIN", 59, 86], ["PKD2", "PROTEIN", 113, 117], ["p38 kinases", "PROTEIN", 122, 133], ["LPA", "TEST", 11, 14], ["numerous natural and synthetic agonists of G-protein coupled receptors", "TREATMENT", 16, 86], ["activating PKD2", "PROBLEM", 102, 117], ["p38 kinases", "TEST", 122, 133], ["LPA", "OBSERVATION_MODIFIER", 11, 14]]], ["Some of these agents and their receptors were already shown to play a role in regulating the severity of inflammation (Ohta ' Sitkovsky, 2001).", [["inflammation", "DISEASE", 105, 117], ["inflammation", "PROBLEM", 105, 117], ["inflammation", "OBSERVATION", 105, 117]]], ["The usefulness of these receptors' agonists may be helped by the fact that these receptors are expressed either ubiquitously or in a tissue-specific manner (Jacoby et al, 2006) thereby affording systemic or selective protective effects.DiscussionStudies described here uncovered an endogenous mechanism by which inflammatory process confines its harmful phase and enables the transition to tissue restoration through promoting IFNAR1 ubiquitination and degradation.", [["tissue", "ANATOMY", 133, 139], ["tissue", "ANATOMY", 390, 396], ["tissue", "TISSUE", 133, 139], ["tissue", "TISSUE", 390, 396], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 427, 433], ["IFNAR1", "PROTEIN", 427, 433], ["these receptors' agonists", "TREATMENT", 18, 43], ["selective protective effects", "TREATMENT", 207, 235], ["inflammatory process", "PROBLEM", 312, 332], ["tissue restoration", "TREATMENT", 390, 408], ["inflammatory", "OBSERVATION", 312, 324], ["harmful phase", "OBSERVATION_MODIFIER", 346, 359], ["IFNAR1 ubiquitination", "OBSERVATION", 427, 448]]], ["In addition, mimicking this natural mechanism by preemptive induction of p38 and PKD2 kinases that leads to stimulation of IFNAR1 ubiquitination elicits a tissue protective effect.", [["tissue", "ANATOMY", 155, 161], ["p38", "GENE_OR_GENE_PRODUCT", 73, 76], ["PKD2", "GENE_OR_GENE_PRODUCT", 81, 85], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 123, 129], ["tissue", "TISSUE", 155, 161], ["p38 and PKD2 kinases", "PROTEIN", 73, 93], ["IFNAR1", "PROTEIN", 123, 129], ["preemptive induction of p38", "TREATMENT", 49, 76], ["PKD2 kinases", "TREATMENT", 81, 93], ["stimulation of IFNAR1 ubiquitination", "TREATMENT", 108, 144], ["a tissue protective effect", "PROBLEM", 153, 179]]], ["Pharmacologic stimulation of IFNAR1 ubiquitination and degradation represents a fundamentally novel strategy to limit the extent of tissue damage and accelerate healing and restoration of the function.", [["tissue", "ANATOMY", 132, 138], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 29, 35], ["tissue", "TISSUE", 132, 138], ["IFNAR1", "PROTEIN", 29, 35], ["Pharmacologic stimulation of IFNAR1 ubiquitination", "TREATMENT", 0, 50], ["tissue damage", "PROBLEM", 132, 145], ["accelerate healing", "PROBLEM", 150, 168], ["IFNAR1 ubiquitination", "OBSERVATION", 29, 50], ["tissue", "ANATOMY", 132, 138], ["damage", "OBSERVATION", 139, 145], ["healing", "OBSERVATION_MODIFIER", 161, 168]]], ["Given that modulators of the G-protein coupled receptors comprise the most populous class of currently available drugs (Rosenbaum et al, 2009; Wang ' Lewis, 2013), the validation of this concept and practical applications to eliminate IFNAR1 in acute life-threatening inflammatory syndromes is likely to be imminent.Mice and inflammation modeling ::: Materials and MethodsThe Institutional Animal Care and Use Committee (IACUC) of the University of Pennsylvania approved all animal procedures of disease modeling, blood collection, euthanasia and tissue harvesting (protocols #802558, 803995, 802868, 803699, and 804209).", [["blood", "ANATOMY", 514, 519], ["tissue", "ANATOMY", 547, 553], ["inflammation", "DISEASE", 325, 337], ["G-protein coupled receptors", "GENE_OR_GENE_PRODUCT", 29, 56], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 235, 241], ["Mice", "ORGANISM", 316, 320], ["blood", "ORGANISM_SUBSTANCE", 514, 519], ["tissue", "TISSUE", 547, 553], ["G-protein coupled receptors", "PROTEIN", 29, 56], ["IFNAR1", "PROTEIN", 235, 241], ["Mice", "SPECIES", 316, 320], ["the G-protein coupled receptors", "TREATMENT", 25, 56], ["this concept", "TREATMENT", 182, 194], ["practical applications", "TREATMENT", 199, 221], ["IFNAR1 in acute life-threatening inflammatory syndromes", "PROBLEM", 235, 290], ["disease modeling", "PROBLEM", 496, 512], ["blood collection", "PROBLEM", 514, 530], ["euthanasia and tissue harvesting", "TREATMENT", 532, 564], ["acute", "OBSERVATION_MODIFIER", 245, 250], ["inflammatory syndromes", "OBSERVATION", 268, 290], ["likely to be", "UNCERTAINTY", 294, 306], ["inflammation", "OBSERVATION", 325, 337], ["disease", "OBSERVATION", 496, 503], ["blood collection", "OBSERVATION", 514, 530]]], ["Eight to 10 weeks old female littermate mice including wild type (Ifnar1+/+) mice, Ifnar1SA (Ifnar1tm1.1Syfu) mice (Zheng et al, 2011b) and Ifnar1\u2212/\u2212 mice (Roth-Cross et al, 2008; a generous gift of S. Weiss) were used in all experiments.", [["female", "ORGANISM", 22, 28], ["littermate", "ORGANISM", 29, 39], ["mice", "ORGANISM", 40, 44], ["Ifnar1", "GENE_OR_GENE_PRODUCT", 66, 72], ["Ifnar1\u2212", "GENE_OR_GENE_PRODUCT", 140, 147], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 150, 154], ["mice", "SPECIES", 40, 44], ["Ifnar1\u2212/\u2212 mice", "TREATMENT", 140, 154]]], ["We have previously described the generation of Ifnar1SA knock-in mice (Zheng et al, 2011b) from the C57Bl/6 ES cells previously targeted with the knock-in vector [described in (Liu et al, 2009b)] and then treated with Cre to remove the neo marker in vitro.", [["C57Bl/6 ES cells", "ANATOMY", 100, 116], ["Ifnar1SA", "GENE_OR_GENE_PRODUCT", 47, 55], ["mice", "ORGANISM", 65, 69], ["C57Bl/6 ES cells", "CELL", 100, 116], ["Cre", "GENE_OR_GENE_PRODUCT", 218, 221], ["neo", "GENE_OR_GENE_PRODUCT", 236, 239], ["Ifnar1SA", "PROTEIN", 47, 55], ["C57Bl/6 ES cells", "CELL_LINE", 100, 116], ["knock-in vector", "DNA", 146, 161], ["Cre", "PROTEIN", 218, 221], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 65, 69], ["Ifnar1SA knock", "TEST", 47, 61], ["the C57Bl/6 ES cells", "TREATMENT", 96, 116], ["Cre", "TREATMENT", 218, 221], ["the neo marker", "TREATMENT", 232, 246]]], ["Whereas cells from heterozygous mice (Ifnar1+/SA) were used in previous publications (Qian et al, 2011; Zheng et al, 2011b), all of our current experiments were carried out using animals/cells that had both wild type alleles replaced by homozygous Ifnar1SA.Mice and inflammation modeling ::: Materials and MethodsAll mice were on 100% C57Bl/6 background (Ifnar1SA were generated in C57Bl/6 embryonic stem cells (Liu et al, 2009b) and maintained in this background; Ifnar1\u2212/\u2212 mice were back-crossed into C57Bl/6 background for more than 20 generations) and were homozygous for indicated Ifnar1 alleles.", [["cells", "ANATOMY", 8, 13], ["cells", "ANATOMY", 187, 192], ["C57Bl/6 embryonic stem cells", "ANATOMY", 382, 410], ["inflammation", "DISEASE", 266, 278], ["cells", "CELL", 8, 13], ["mice", "ORGANISM", 32, 36], ["Ifnar1", "GENE_OR_GENE_PRODUCT", 38, 44], ["cells", "CELL", 187, 192], ["Mice", "ORGANISM", 257, 261], ["mice", "ORGANISM", 317, 321], ["C57Bl/6 background", "ORGANISM", 335, 353], ["C57Bl/6 embryonic stem cells", "CELL", 382, 410], ["Ifnar1\u2212", "GENE_OR_GENE_PRODUCT", 465, 472], ["C57Bl/6 background", "ORGANISM", 503, 521], ["Ifnar1", "GENE_OR_GENE_PRODUCT", 586, 592], ["wild type alleles", "DNA", 207, 224], ["Ifnar1SA", "PROTEIN", 248, 256], ["C57Bl/6 embryonic stem cells", "CELL_LINE", 382, 410], ["Ifnar1 alleles", "DNA", 586, 600], ["mice", "SPECIES", 32, 36], ["Mice", "SPECIES", 257, 261], ["mice", "SPECIES", 317, 321], ["mice", "SPECIES", 475, 479], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 317, 321], ["heterozygous mice", "PROBLEM", 19, 36], ["Ifnar1", "TEST", 38, 44], ["animals/cells", "PROBLEM", 179, 192], ["Ifnar1SA", "TEST", 355, 363], ["Ifnar1\u2212/\u2212 mice", "TREATMENT", 465, 479], ["Ifnar1 alleles", "PROBLEM", 586, 600], ["inflammation", "OBSERVATION", 266, 278]]], ["For generalized inflammation model, mice were treated with LPS (10.5 mg/kg, intraperitoneal injection) and sacrificed when they became moribund and displayed the loss of righting reflex, loss of >20% of body weight and non-responsiveness to footpad compression as previously described (Karaghiosoff et al, 2003).", [["intraperitoneal", "ANATOMY", 76, 91], ["body", "ANATOMY", 203, 207], ["inflammation", "DISEASE", 16, 28], ["LPS", "CHEMICAL", 59, 62], ["loss of righting reflex", "DISEASE", 162, 185], ["mice", "ORGANISM", 36, 40], ["LPS", "SIMPLE_CHEMICAL", 59, 62], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 76, 91], ["body", "ORGANISM_SUBDIVISION", 203, 207], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 36, 40], ["generalized inflammation model", "PROBLEM", 4, 34], ["LPS", "TREATMENT", 59, 62], ["intraperitoneal injection", "TREATMENT", 76, 101], ["moribund", "PROBLEM", 135, 143], ["the loss of righting reflex", "PROBLEM", 158, 185], ["body weight", "TEST", 203, 214], ["non-responsiveness to footpad compression", "PROBLEM", 219, 260], ["generalized", "OBSERVATION_MODIFIER", 4, 15], ["inflammation", "OBSERVATION", 16, 28], ["righting reflex", "OBSERVATION", 170, 185], ["footpad compression", "OBSERVATION", 241, 260]]], ["Bone marrow harvesting and transfers were carried out as described elsewhere (Pear et al, 1998).", [["Bone marrow", "ANATOMY", 0, 11], ["Bone marrow", "MULTI-TISSUE_STRUCTURE", 0, 11], ["Bone marrow harvesting", "TREATMENT", 0, 22], ["marrow harvesting", "OBSERVATION", 5, 22]]], ["Blood cell and plasma chemistry analyses (including AST/ALT assays) were carried out by at the Clinical Pathology Laboratory at the University of Pennsylvania Ryan Veterinary Hospital.Experimental pancreatitis ::: Materials and Methodswas induced as previously described (Reichert ' Rustgi, 2011; Reichert et al, 2013).", [["Blood cell", "ANATOMY", 0, 10], ["plasma", "ANATOMY", 15, 21], ["pancreatitis", "DISEASE", 197, 209], ["Blood cell", "CELL", 0, 10], ["plasma", "ORGANISM_SUBSTANCE", 15, 21], ["AST", "SIMPLE_CHEMICAL", 52, 55], ["AST", "PROTEIN", 52, 55], ["ALT", "PROTEIN", 56, 59], ["Blood cell", "TEST", 0, 10], ["plasma chemistry analyses", "TEST", 15, 40], ["AST/ALT assays", "TEST", 52, 66], ["Experimental pancreatitis", "PROBLEM", 184, 209], ["pancreatitis", "OBSERVATION", 197, 209]]], ["Briefly, acute pancreatitis was induced in by 8 hourly intraperitoneal injections of caerulein (50 \u03bcg/kg) for two consecutive days.", [["intraperitoneal", "ANATOMY", 55, 70], ["pancreatitis", "DISEASE", 15, 27], ["caerulein", "CHEMICAL", 85, 94], ["caerulein", "CHEMICAL", 85, 94], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 55, 70], ["caerulein", "SIMPLE_CHEMICAL", 85, 94], ["acute pancreatitis", "PROBLEM", 9, 27], ["caerulein", "TREATMENT", 85, 94], ["acute", "OBSERVATION_MODIFIER", 9, 14], ["pancreatitis", "OBSERVATION", 15, 27]]], ["Blood was collected from the tail vein at 3 or 7 days after the first injection.", [["Blood", "ANATOMY", 0, 5], ["tail vein", "ANATOMY", 29, 38], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["tail vein", "MULTI-TISSUE_STRUCTURE", 29, 38], ["Blood", "TEST", 0, 5], ["the first injection", "TREATMENT", 60, 79], ["tail vein", "ANATOMY", 29, 38]]], ["At this point, mice were sacrificed and pancreata were harvested and processed for mRNA isolation and either frozen section-immunohistochemistry or formalin-fixation and subsequent hematoxylin-eosin staining.", [["pancreata", "ANATOMY", 40, 49], ["formalin", "CHEMICAL", 148, 156], ["hematoxylin", "CHEMICAL", 181, 192], ["eosin", "CHEMICAL", 193, 198], ["mice", "ORGANISM", 15, 19], ["pancreata", "ORGAN", 40, 49], ["formalin", "SIMPLE_CHEMICAL", 148, 156], ["hematoxylin-eosin", "SIMPLE_CHEMICAL", 181, 198], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["pancreata", "TREATMENT", 40, 49], ["mRNA isolation", "TREATMENT", 83, 97], ["frozen section", "TEST", 109, 123], ["immunohistochemistry", "TEST", 124, 144], ["formalin", "TEST", 148, 156], ["fixation", "TREATMENT", 157, 165], ["pancreata", "ANATOMY", 40, 49]]], ["Amylase assays were carried out as per manufacturer instructions (QuantiChrom \u03b1-Amylase Assay Kit).", [["Amylase", "GENE_OR_GENE_PRODUCT", 0, 7], ["Amylase", "GENE_OR_GENE_PRODUCT", 80, 87], ["Amylase", "PROTEIN", 0, 7], ["Amylase", "PROTEIN", 80, 87], ["Amylase assays", "TEST", 0, 14], ["QuantiChrom", "TEST", 66, 77], ["Amylase Assay Kit", "TEST", 80, 97]]], ["Chronic pancreatitis was induced by injections of caerulein (50 \u03bcg/kg per day for 5 days a week for 4 weeks).", [["pancreatitis", "DISEASE", 8, 20], ["caerulein", "CHEMICAL", 50, 59], ["caerulein", "CHEMICAL", 50, 59], ["caerulein", "SIMPLE_CHEMICAL", 50, 59], ["Chronic pancreatitis", "PROBLEM", 0, 20], ["caerulein", "TREATMENT", 50, 59], ["pancreatitis", "OBSERVATION", 8, 20]]], ["At the end of every week (day 5) blood was collected from the tail vein.", [["blood", "ANATOMY", 33, 38], ["tail vein", "ANATOMY", 62, 71], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["tail vein", "MULTI-TISSUE_STRUCTURE", 62, 71], ["tail vein", "ANATOMY", 62, 71]]], ["Mice were sacrificed after 4 weeks and pancreata were harvested and analyzed as indicated above.Experimental hepatitis ::: Materials and MethodsTo induce autoimmune hepatitis, mice were injected intravenously with Concanavalin A (20 mg/kg) or vehicle (sterile saline) and sacrificed 10 h later for blood and tissues harvesting.", [["pancreata", "ANATOMY", 39, 48], ["intravenously", "ANATOMY", 195, 208], ["blood", "ANATOMY", 298, 303], ["tissues", "ANATOMY", 308, 315], ["hepatitis", "DISEASE", 109, 118], ["autoimmune hepatitis", "DISEASE", 154, 174], ["Concanavalin A", "CHEMICAL", 214, 228], ["Mice", "ORGANISM", 0, 4], ["pancreata", "ORGAN", 39, 48], ["mice", "ORGANISM", 176, 180], ["Concanavalin A", "SIMPLE_CHEMICAL", 214, 228], ["blood", "ORGANISM_SUBSTANCE", 298, 303], ["tissues", "TISSUE", 308, 315], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 176, 180], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 176, 180], ["pancreata", "TREATMENT", 39, 48], ["Materials", "TREATMENT", 123, 132], ["Methods", "TREATMENT", 137, 144], ["autoimmune hepatitis", "PROBLEM", 154, 174], ["Concanavalin A", "TREATMENT", 214, 228], ["vehicle (sterile saline)", "TREATMENT", 243, 267], ["blood and tissues harvesting", "TREATMENT", 298, 326], ["pancreata", "ANATOMY", 39, 48], ["hepatitis", "OBSERVATION", 109, 118], ["autoimmune hepatitis", "OBSERVATION", 154, 174], ["tissues", "ANATOMY", 308, 315], ["harvesting", "OBSERVATION", 316, 326]]], ["To induce toxic hepatitis, mice were injected intraperitoneally with CCl4 (0.5 ml/kg) or vehicle (olive oil) and sacrificed after 48 h.", [["intraperitoneally", "ANATOMY", 46, 63], ["olive oil", "ANATOMY", 98, 107], ["toxic hepatitis", "DISEASE", 10, 25], ["CCl4", "CHEMICAL", 69, 73], ["CCl4", "CHEMICAL", 69, 73], ["mice", "ORGANISM", 27, 31], ["CCl4", "SIMPLE_CHEMICAL", 69, 73], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31], ["toxic hepatitis", "PROBLEM", 10, 25], ["CCl4", "TREATMENT", 69, 73], ["vehicle (olive oil", "TREATMENT", 89, 107], ["toxic", "OBSERVATION_MODIFIER", 10, 15], ["hepatitis", "OBSERVATION", 16, 25]]], ["Alternatively, mice were injected with acetaminophen (APAP, 150 mg/kg, i.p.) and sacrificed after 24 h.", [["acetaminophen", "CHEMICAL", 39, 52], ["APAP", "CHEMICAL", 54, 58], ["acetaminophen", "CHEMICAL", 39, 52], ["APAP", "CHEMICAL", 54, 58], ["mice", "ORGANISM", 15, 19], ["acetaminophen", "SIMPLE_CHEMICAL", 39, 52], ["APAP", "SIMPLE_CHEMICAL", 54, 58], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["acetaminophen", "TREATMENT", 39, 52], ["APAP", "TREATMENT", 54, 58]]], ["Blood was processed for ALT/AST analyses.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["ALT", "SIMPLE_CHEMICAL", 24, 27], ["AST", "SIMPLE_CHEMICAL", 28, 31], ["ALT", "PROTEIN", 24, 27], ["AST", "PROTEIN", 28, 31], ["Blood", "TEST", 0, 5], ["ALT/AST analyses", "TEST", 24, 40]]], ["Livers were either flash frozen for extracting mRNA or fixed in 4% formalin for hematoxylin and eosin staining.", [["Livers", "ANATOMY", 0, 6], ["formalin", "CHEMICAL", 67, 75], ["hematoxylin", "CHEMICAL", 80, 91], ["eosin", "CHEMICAL", 96, 101], ["Livers", "ORGAN", 0, 6], ["formalin", "SIMPLE_CHEMICAL", 67, 75], ["hematoxylin", "SIMPLE_CHEMICAL", 80, 91], ["eosin", "SIMPLE_CHEMICAL", 96, 101], ["mRNA", "RNA", 47, 51], ["extracting mRNA", "PROBLEM", 36, 51], ["4% formalin", "TREATMENT", 64, 75], ["hematoxylin", "TREATMENT", 80, 91], ["eosin staining", "TEST", 96, 110]]], ["Histopathologic analyses were carried in a double blinded manner by a qualified veterinary pathologist (A.B.).", [["Histopathologic analyses", "TEST", 0, 24]]], ["Quantification of the lesions was carried out by counting the number of lesions per field; an average of ten fields per mouse and five mice per group were scored.", [["lesions", "ANATOMY", 22, 29], ["lesions", "ANATOMY", 72, 79], ["lesions", "PATHOLOGICAL_FORMATION", 22, 29], ["lesions", "PATHOLOGICAL_FORMATION", 72, 79], ["mouse", "ORGANISM", 120, 125], ["mice", "ORGANISM", 135, 139], ["mouse", "SPECIES", 120, 125], ["mice", "SPECIES", 135, 139], ["mouse", "SPECIES", 120, 125], ["mice", "SPECIES", 135, 139], ["the lesions", "PROBLEM", 18, 29], ["lesions", "OBSERVATION", 22, 29], ["lesions", "OBSERVATION", 72, 79]]], ["The assessment of the severity of hepatitis was done by evaluating tissues on a scale of 0\u20133 where the scores were representative of grades of 0 (none/minimal inflammation), 1 (mild hepatitis), 2 (moderate hepatitis with limited necrotic foci) and 3 (severe hepatitis that includes marked necrosis and displays multifocal to coalescing hepatocellular hyperplasia and hypertrophy with vacuolation).Statistical analysis ::: Materials and MethodsAll data are expressed as the mean \u00b1 s.d. (standard deviation).", [["tissues", "ANATOMY", 67, 74], ["necrotic foci", "ANATOMY", 229, 242], ["hepatocellular hyperplasia", "ANATOMY", 336, 362], ["hepatitis", "DISEASE", 34, 43], ["inflammation", "DISEASE", 159, 171], ["hepatitis", "DISEASE", 182, 191], ["hepatitis", "DISEASE", 206, 215], ["necrotic", "DISEASE", 229, 237], ["hepatitis", "DISEASE", 258, 267], ["necrosis", "DISEASE", 289, 297], ["hyperplasia", "DISEASE", 351, 362], ["hypertrophy", "DISEASE", 367, 378], ["tissues", "TISSUE", 67, 74], ["hepatocellular hyperplasia", "PATHOLOGICAL_FORMATION", 336, 362], ["The assessment", "TEST", 0, 14], ["hepatitis", "PROBLEM", 34, 43], ["a scale", "TEST", 78, 85], ["the scores", "TEST", 99, 109], ["minimal inflammation", "PROBLEM", 151, 171], ["mild hepatitis)", "PROBLEM", 177, 192], ["moderate hepatitis", "PROBLEM", 197, 215], ["limited necrotic foci", "PROBLEM", 221, 242], ["severe hepatitis", "PROBLEM", 251, 267], ["marked necrosis", "PROBLEM", 282, 297], ["multifocal to coalescing hepatocellular hyperplasia", "PROBLEM", 311, 362], ["hypertrophy", "PROBLEM", 367, 378], ["hepatitis", "OBSERVATION", 34, 43], ["minimal", "OBSERVATION_MODIFIER", 151, 158], ["inflammation", "OBSERVATION", 159, 171], ["mild", "OBSERVATION_MODIFIER", 177, 181], ["hepatitis", "OBSERVATION", 182, 191], ["moderate", "OBSERVATION_MODIFIER", 197, 205], ["hepatitis", "OBSERVATION", 206, 215], ["necrotic", "OBSERVATION_MODIFIER", 229, 237], ["foci", "OBSERVATION", 238, 242], ["severe", "OBSERVATION_MODIFIER", 251, 257], ["hepatitis", "OBSERVATION", 258, 267], ["marked", "OBSERVATION_MODIFIER", 282, 288], ["necrosis", "OBSERVATION", 289, 297], ["multifocal", "OBSERVATION_MODIFIER", 311, 321], ["coalescing", "OBSERVATION_MODIFIER", 325, 335], ["hepatocellular hyperplasia", "OBSERVATION", 336, 362], ["hypertrophy", "OBSERVATION", 367, 378], ["vacuolation", "OBSERVATION_MODIFIER", 384, 395]]], ["Number of samples is shown in figures or/and figure legends for each experimental cohort.", [["samples", "ANATOMY", 10, 17]]], ["Statistical analyses were performed using Microsoft Excel or GraphPad Prism software, and differences were determined by an unpaired two-tailed Student's t-test.", [["Statistical analyses", "TEST", 0, 20]]], ["A P-value< 0.05 was considered statistically significant.", [["A P-value", "TEST", 0, 9]]]], "PMC7123810": [["Because bioterrorism is difficult to predict or prevent, reliable platforms to rapidly detect and identify bioterrorism agents are important in order to minimize the spread and wide use of these agents and to protect the public health.", [["bioterrorism", "PROBLEM", 8, 20], ["bioterrorism agents", "TREATMENT", 107, 126], ["these agents", "TREATMENT", 189, 201]]], ["These platforms must be sensitive, specific, and must also be able to accurately detect a variety of pathogens, including modified or previously uncharacterized agents, directly from complex sample matrices.", [["pathogens", "PROBLEM", 101, 110]]], ["Recent developments in laboratory prototype devices have been evaluated and were commercialized.", [["laboratory prototype devices", "TREATMENT", 23, 51]]], ["Various commercial tests that utilize biochemical, immunological, nucleic acid, and bioluminescence procedures are currently available to identify biological threat agents.", [["Various commercial tests", "TEST", 0, 24], ["nucleic acid", "TREATMENT", 66, 78], ["bioluminescence procedures", "TREATMENT", 84, 110]]], ["Recent developed tests identify bioterrorism agents using DNA aptamers, biochips, evanescent wave biosensors, cantilevers, living cells, and other innovative technologies.", [["cells", "ANATOMY", 130, 135], ["DNA", "CELLULAR_COMPONENT", 58, 61], ["cells", "CELL", 130, 135], ["tests", "TEST", 17, 22], ["bioterrorism agents", "TREATMENT", 32, 51], ["DNA aptamers", "TREATMENT", 58, 70], ["biochips", "TREATMENT", 72, 80], ["evanescent wave biosensors", "TREATMENT", 82, 108], ["cantilevers, living cells", "TREATMENT", 110, 135]]], ["This review describes current and developing technologies against bioterrorism and considers challenges to rapid, accurate detect biothreat agents.", [["bioterrorism", "PROBLEM", 66, 78], ["biothreat agents", "TREATMENT", 130, 146]]], ["Although there is no ideal platform, many of these technologies have proved valuable for the detection and identification of bioterrorism agents.IntroductionVarious tests have been developed to detect and identify biothreat agents.", [["the detection", "TEST", 89, 102], ["bioterrorism agents", "TREATMENT", 125, 144], ["IntroductionVarious tests", "TEST", 145, 170], ["biothreat agents", "TREATMENT", 214, 230], ["no", "UNCERTAINTY", 18, 20]]], ["Some of these tests were available before 11 September 2001; other tests have been developed since that time.", [["these tests", "TEST", 8, 19], ["other tests", "TEST", 61, 72]]], ["This review describes documented current and developing technologies for detection and identification of bioterrorism weapons and addresses the challenges associated with detection in complex sample matrices.DefinitionsA bioterrorism attack is the deliberate release of viruses, bacteria, toxins or other harmful agents used to cause illness or death in people, animals, or plants.", [["illness", "DISEASE", 334, 341], ["death", "DISEASE", 345, 350], ["people", "ORGANISM", 354, 360], ["people", "SPECIES", 354, 360], ["detection", "TEST", 73, 82], ["bioterrorism weapons", "PROBLEM", 105, 125], ["DefinitionsA bioterrorism attack", "PROBLEM", 208, 240], ["viruses", "PROBLEM", 270, 277], ["bacteria", "PROBLEM", 279, 287], ["toxins", "PROBLEM", 289, 295], ["illness", "PROBLEM", 334, 341], ["death", "PROBLEM", 345, 350], ["viruses", "OBSERVATION", 270, 277]]], ["These agents are typically found in nature, but it is possible that they could be mutated or altered to increase their ability to cause disease, make them resistant to current medicines, or to increase their ability to be spread around the environment.", [["disease", "PROBLEM", 136, 143], ["current medicines", "TREATMENT", 168, 185]]], ["Biological agents can be spread through the air, water, or in food.", [["Biological agents", "TREATMENT", 0, 17]]], ["Terrorists tend to use biological agents because they are extremely difficult to detect and do not cause illness for several hours to several days.", [["illness", "DISEASE", 105, 112], ["biological agents", "TREATMENT", 23, 40], ["illness", "PROBLEM", 105, 112]]], ["Some bioterrorism agents, like the smallpox virus, can be spread from person to person and some, like anthrax, cannot.DefinitionsBioterrorism is an attractive weapon because the toxicants are relatively easy and inexpensive to obtain, can be easily disseminated, and can cause widespread fear and panic beyond the actual physical damage.", [["anthrax", "DISEASE", 102, 109], ["Bioterrorism", "CHEMICAL", 129, 141], ["panic", "DISEASE", 297, 302], ["smallpox virus", "ORGANISM", 35, 49], ["person", "SPECIES", 70, 76], ["person", "SPECIES", 80, 86], ["smallpox virus", "SPECIES", 35, 49], ["Some bioterrorism agents", "TREATMENT", 0, 24], ["the smallpox virus", "PROBLEM", 31, 49], ["panic", "PROBLEM", 297, 302], ["the actual physical damage", "PROBLEM", 310, 336]]], ["A biological weapon is useful to terrorists mainly as a method of creating mass panic and disruption to a state or a country.", [["panic", "DISEASE", 80, 85], ["creating mass panic", "PROBLEM", 66, 85], ["mass", "OBSERVATION", 75, 79]]], ["However, technologists have warned of the potential power which genetic engineering might place in the hands of future bio-terrorists.20th Century ::: HistoryBy the time World War I began, attempts to use anthrax were directed at animal populations.", [["anthrax", "DISEASE", 205, 212], ["anthrax", "TREATMENT", 205, 212]]], ["Anton Dilger was sent to the United States in 1915 carrying cultures of glanders, a virulent disease of horses and mules.", [["glanders", "CANCER", 72, 80], ["horses", "ORGANISM", 104, 110], ["horses", "SPECIES", 104, 110], ["a virulent disease of horses and mules", "PROBLEM", 82, 120]]], ["He used stevedores working in the docks in Baltimore to infect horses with glanders while they were waiting to be shipped to Britain.", [["horses", "ORGANISM", 63, 69]]], ["Dilger was under suspicion as being a German agent, but was never arrested.", [["a German agent", "TREATMENT", 36, 50]]], ["Dilger eventually fled to Madrid, Spain, where he died during the Influenza Pandemic of 1918.", [["Influenza", "DISEASE", 66, 75]]], ["Germany and its allies infected French cavalry horses and many of Russia\u2019s mules and horses on the Eastern Front.", [["French cavalry horses", "SPECIES", 32, 53], ["Russia\u2019s mules", "SPECIES", 66, 80], ["infected", "OBSERVATION_MODIFIER", 23, 31]]]], "PMC7120812": [["IntroductionDespite the advances in medical sciences, the threat posed by viruses has remained a serious problem, particularly outside industrialized countries.", [["a serious problem", "PROBLEM", 95, 112], ["viruses", "OBSERVATION", 74, 81]]], ["While the human immunodeficiency virus (HIV) and the hepatitis B and C viruses (HBV, HCV) continue to claim millions of lives every year, viruses like the SARS coronavirus appear as human pathogens and novel variants of well-known viruses, like the H1N1/09 influenza virus, cause pandemics of global dimensions.", [["human immunodeficiency virus (HIV)", "DISEASE", 10, 44], ["hepatitis B", "DISEASE", 53, 64], ["SARS coronavirus", "DISEASE", 155, 171], ["influenza virus", "DISEASE", 257, 272], ["human immunodeficiency virus", "ORGANISM", 10, 38], ["HIV", "ORGANISM", 40, 43], ["hepatitis B and C viruses", "ORGANISM", 53, 78], ["HBV", "ORGANISM", 80, 83], ["HCV", "ORGANISM", 85, 88], ["SARS coronavirus", "ORGANISM", 155, 171], ["human", "ORGANISM", 182, 187], ["H1N1/09 influenza virus", "ORGANISM", 249, 272], ["human", "SPECIES", 10, 15], ["immunodeficiency virus (HIV", "SPECIES", 16, 43], ["hepatitis B and C viruses", "SPECIES", 53, 78], ["SARS coronavirus", "SPECIES", 155, 171], ["human", "SPECIES", 182, 187], ["H1N1/09 influenza virus", "SPECIES", 249, 272], ["human immunodeficiency virus", "SPECIES", 10, 38], ["HIV", "SPECIES", 40, 43], ["hepatitis B and C viruses", "SPECIES", 53, 78], ["HBV", "SPECIES", 80, 83], ["HCV", "SPECIES", 85, 88], ["SARS coronavirus", "SPECIES", 155, 171], ["human", "SPECIES", 182, 187], ["H1N1/09 influenza virus", "SPECIES", 249, 272], ["the human immunodeficiency virus", "PROBLEM", 6, 38], ["HIV", "PROBLEM", 40, 43], ["the hepatitis B", "PROBLEM", 49, 64], ["C viruses", "PROBLEM", 69, 78], ["HBV", "PROBLEM", 80, 83], ["HCV", "PROBLEM", 85, 88], ["viruses", "PROBLEM", 138, 145], ["the SARS coronavirus", "PROBLEM", 151, 171], ["human pathogens", "PROBLEM", 182, 197], ["novel variants of well-known viruses", "PROBLEM", 202, 238], ["the H1N1/09 influenza virus", "PROBLEM", 245, 272]]], ["Thus, there is a pressing unmet medical need to develop new antiviral drugs.", [["new antiviral drugs", "TREATMENT", 56, 75], ["antiviral drugs", "OBSERVATION", 60, 75]]], ["While small molecules have dominated antivirals for decades, biologics like monoclonal antibodies and nucleic acids therapies have more recently been considered promising alternatives (1).IntroductionAmong the various oligonucleotide-based strategies, RNA interference (RNAi) is widely regarded as a particularly powerful technology (2\u20134).", [["nucleic acids", "CHEMICAL", 102, 115], ["nucleic acids", "SIMPLE_CHEMICAL", 102, 115], ["monoclonal antibodies", "PROTEIN", 76, 97], ["dominated antivirals", "TREATMENT", 27, 47], ["biologics", "TREATMENT", 61, 70], ["monoclonal antibodies", "TREATMENT", 76, 97], ["nucleic acids therapies", "TREATMENT", 102, 125], ["the various oligonucleotide-based strategies", "TREATMENT", 206, 250], ["small", "OBSERVATION_MODIFIER", 6, 11], ["molecules", "OBSERVATION", 12, 21]]], ["RNAi is a posttranscriptional gene silencing mechanism that is triggered by double-stranded RNA.", [["double-stranded RNA", "RNA", 76, 95], ["a posttranscriptional gene silencing mechanism", "PROBLEM", 8, 54], ["posttranscriptional gene silencing", "OBSERVATION", 10, 44], ["stranded RNA", "OBSERVATION", 83, 95]]], ["For applications in mammalian cells, small interfering RNAs (siRNA) of approximately 19 base pairs with two nucleotide overhangs at the 3\u2032 ends of both strands become incorporated into the RNA-induced silencing complex (RISC) and induce cleavage of a complementary target RNA.", [["mammalian cells", "ANATOMY", 20, 35], ["nucleotide", "CHEMICAL", 108, 118], ["nucleotide", "CHEMICAL", 108, 118], ["mammalian cells", "CELL", 20, 35], ["small interfering RNAs", "GENE_OR_GENE_PRODUCT", 37, 59], ["RNA-induced silencing complex", "GENE_OR_GENE_PRODUCT", 189, 218], ["RISC", "GENE_OR_GENE_PRODUCT", 220, 224], ["mammalian cells", "CELL_TYPE", 20, 35], ["small interfering RNAs", "RNA", 37, 59], ["3\u2032 ends", "DNA", 136, 143], ["RNA-induced silencing complex", "PROTEIN", 189, 218], ["RISC", "PROTEIN", 220, 224], ["complementary target RNA", "RNA", 251, 275], ["applications in mammalian cells", "TREATMENT", 4, 35], ["small interfering RNAs (siRNA)", "PROBLEM", 37, 67], ["two nucleotide overhangs", "TREATMENT", 104, 128], ["a complementary target RNA", "PROBLEM", 249, 275], ["mammalian cells", "OBSERVATION", 20, 35], ["small", "OBSERVATION_MODIFIER", 37, 42], ["interfering RNAs", "OBSERVATION", 43, 59]]], ["Moreover, the technology has been developed into a new therapeutic approach and approximately a dozen clinical trials based on RNAi are currently underway.", [["a new therapeutic approach", "TREATMENT", 49, 75], ["RNAi", "TREATMENT", 127, 131]]], ["Among these trials are various applications of RNAi to treat infections with the respiratory syncytial virus, HBV and HIV (5).IntroductionSilencing of endogenously expressed genes has become a routine procedure and predesigned or validated siRNAs with silencing guarantee against virtually any human or murine gene are commercially available.", [["infections", "DISEASE", 61, 71], ["respiratory syncytial virus", "DISEASE", 81, 108], ["respiratory syncytial virus", "ORGANISM", 81, 108], ["HBV", "ORGANISM", 110, 113], ["human", "ORGANISM", 294, 299], ["murine", "ORGANISM", 303, 309], ["human or murine gene", "DNA", 294, 314], ["respiratory syncytial virus", "SPECIES", 81, 108], ["HIV", "SPECIES", 118, 121], ["human", "SPECIES", 294, 299], ["murine", "SPECIES", 303, 309], ["respiratory syncytial virus", "SPECIES", 81, 108], ["HBV", "SPECIES", 110, 113], ["HIV", "SPECIES", 118, 121], ["human", "SPECIES", 294, 299], ["various applications", "TREATMENT", 23, 43], ["RNAi", "TREATMENT", 47, 51], ["infections", "PROBLEM", 61, 71], ["the respiratory syncytial virus", "PROBLEM", 77, 108], ["HBV", "PROBLEM", 110, 113], ["HIV", "PROBLEM", 118, 121], ["a routine procedure", "TREATMENT", 191, 210], ["silencing guarantee", "TREATMENT", 252, 271], ["respiratory syncytial", "ANATOMY", 81, 102]]], ["In contrast, the design of siRNAs with high antiviral activity still remains a challenging task.", [["siRNAs", "PROBLEM", 27, 33], ["high antiviral activity", "PROBLEM", 39, 62], ["siRNAs", "OBSERVATION", 27, 33], ["high", "OBSERVATION_MODIFIER", 39, 43], ["antiviral activity", "OBSERVATION", 44, 62]]], ["Several features have been described that influence the success of an RNAi approach (6):Thermodynamic design of the siRNA.Structure of the siRNA antisense strand.Structure of the target RNA.", [["siRNA antisense strand", "DNA", 139, 161], ["target RNA", "RNA", 179, 189], ["an RNAi approach", "TREATMENT", 67, 83], ["the siRNA", "PROBLEM", 112, 121], ["siRNA", "ANATOMY", 116, 121], ["siRNA antisense strand", "OBSERVATION", 139, 161], ["target RNA", "OBSERVATION", 179, 189]]]], "PMC7440163": [["IntroductionThe typical chest computed tomography (CT) findings of the novel coronavirus disease 2019 (COVID-19) appear as multiple patchy, ground-glass opacities that progress to or co-exist with bilateral consolidations in multiple lobes and with peripheral distribution[1\u20133]; however, the cystic features of COVID-19 on CT have not yet been reported in the literature.", [["lobes", "ANATOMY", 234, 239], ["cystic", "ANATOMY", 292, 298], ["coronavirus disease", "DISEASE", 77, 96], ["lobes", "CANCER", 234, 239], ["The typical chest computed tomography (CT)", "TEST", 12, 54], ["the novel coronavirus disease", "PROBLEM", 67, 96], ["COVID", "TEST", 103, 108], ["multiple patchy, ground-glass opacities", "PROBLEM", 123, 162], ["bilateral consolidations in multiple lobes", "PROBLEM", 197, 239], ["peripheral distribution", "PROBLEM", 249, 272], ["COVID", "TEST", 311, 316], ["CT", "TEST", 323, 325], ["chest", "ANATOMY", 24, 29], ["coronavirus disease", "OBSERVATION", 77, 96], ["multiple", "OBSERVATION_MODIFIER", 123, 131], ["patchy", "OBSERVATION_MODIFIER", 132, 138], ["ground-glass opacities", "OBSERVATION", 140, 162], ["bilateral", "ANATOMY_MODIFIER", 197, 206], ["consolidations", "OBSERVATION", 207, 221], ["multiple", "OBSERVATION_MODIFIER", 225, 233], ["lobes", "ANATOMY_MODIFIER", 234, 239], ["peripheral", "ANATOMY_MODIFIER", 249, 259], ["distribution", "OBSERVATION_MODIFIER", 260, 272], ["cystic", "OBSERVATION_MODIFIER", 292, 298]]], ["Here, we report the chest CT findings of cystic lesions in 2 patients confirmed to have COVID-19 pneumonia.", [["chest", "ANATOMY", 20, 25], ["cystic lesions", "ANATOMY", 41, 55], ["cystic lesions", "DISEASE", 41, 55], ["pneumonia", "DISEASE", 97, 106], ["cystic lesions", "PATHOLOGICAL_FORMATION", 41, 55], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["the chest CT", "TEST", 16, 28], ["cystic lesions", "PROBLEM", 41, 55], ["COVID", "TEST", 88, 93], ["pneumonia", "PROBLEM", 97, 106], ["chest", "ANATOMY", 20, 25], ["cystic", "OBSERVATION_MODIFIER", 41, 47], ["lesions", "OBSERVATION", 48, 55], ["pneumonia", "OBSERVATION", 97, 106]]], ["Of note, written informed consent was obtained from both patients to publish this case report.Case 1 ::: Case reportA 38-year-old man diagnosed with severe COVID-19-related pneumonia (6 days) was admitted to the intensive care unit.", [["COVID-19", "CHEMICAL", 156, 164], ["pneumonia", "DISEASE", 173, 182], ["patients", "ORGANISM", 57, 65], ["man", "ORGANISM", 130, 133], ["patients", "SPECIES", 57, 65], ["man", "SPECIES", 130, 133], ["severe COVID", "PROBLEM", 149, 161], ["pneumonia", "PROBLEM", 173, 182], ["severe", "OBSERVATION_MODIFIER", 149, 155], ["pneumonia", "OBSERVATION", 173, 182]]], ["The primary CT findings showed bilateral, patchy, ground-glass opacities with co-existing consolidations (Fig. 1A).", [["The primary CT findings", "TEST", 0, 23], ["bilateral, patchy, ground-glass opacities", "PROBLEM", 31, 72], ["co-existing consolidations", "PROBLEM", 78, 104], ["bilateral", "ANATOMY_MODIFIER", 31, 40], ["patchy", "OBSERVATION_MODIFIER", 42, 48], ["ground-glass opacities", "OBSERVATION", 50, 72], ["co-existing", "OBSERVATION_MODIFIER", 78, 89], ["consolidations", "OBSERVATION", 90, 104]]], ["The patient presented with shortness of breath, chest pain, 92% percutaneous oxygen saturation, and 26 breaths/minute; the patient was thus given 5 L/minute of oxygen by mask.", [["chest", "ANATOMY", 48, 53], ["percutaneous", "ANATOMY", 64, 76], ["shortness of breath", "DISEASE", 27, 46], ["chest pain", "DISEASE", 48, 58], ["oxygen", "CHEMICAL", 77, 83], ["oxygen", "CHEMICAL", 160, 166], ["oxygen", "CHEMICAL", 77, 83], ["oxygen", "CHEMICAL", 160, 166], ["patient", "ORGANISM", 4, 11], ["chest", "ORGANISM_SUBDIVISION", 48, 53], ["oxygen", "SIMPLE_CHEMICAL", 77, 83], ["patient", "ORGANISM", 123, 130], ["oxygen", "SIMPLE_CHEMICAL", 160, 166], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 123, 130], ["shortness of breath", "PROBLEM", 27, 46], ["chest pain", "PROBLEM", 48, 58], ["percutaneous oxygen saturation", "TEST", 64, 94], ["oxygen", "TREATMENT", 160, 166], ["chest", "ANATOMY", 48, 53]]], ["However, 26 days later, follow-up CT findings showed multiple cysts in the ground-glass opacities (bilaterally) and the development of a \u223c20% left pneumothorax.", [["cysts", "ANATOMY", 62, 67], ["left pneumothorax", "ANATOMY", 142, 159], ["cysts", "DISEASE", 62, 67], ["left pneumothorax", "DISEASE", 142, 159], ["cysts", "PATHOLOGICAL_FORMATION", 62, 67], ["follow-up CT findings", "TEST", 24, 45], ["multiple cysts in the ground-glass opacities", "PROBLEM", 53, 97], ["a \u223c20% left pneumothorax", "PROBLEM", 135, 159], ["multiple", "OBSERVATION_MODIFIER", 53, 61], ["cysts", "OBSERVATION", 62, 67], ["ground", "OBSERVATION_MODIFIER", 75, 81], ["glass opacities", "OBSERVATION", 82, 97], ["bilaterally", "ANATOMY_MODIFIER", 99, 110], ["left", "ANATOMY_MODIFIER", 142, 146], ["pneumothorax", "OBSERVATION", 147, 159]]], ["The cysts had a smooth inner wall and the maximum diameter of these cysts was \u223c5 cm (Fig. 1B).", [["cysts", "ANATOMY", 4, 9], ["smooth inner wall", "ANATOMY", 16, 33], ["cysts", "ANATOMY", 68, 73], ["cysts", "CANCER", 4, 9], ["smooth inner wall", "TISSUE", 16, 33], ["cysts", "PATHOLOGICAL_FORMATION", 68, 73], ["The cysts", "PROBLEM", 0, 9], ["these cysts", "PROBLEM", 62, 73], ["cysts", "OBSERVATION", 4, 9], ["smooth", "OBSERVATION_MODIFIER", 16, 22], ["inner", "OBSERVATION_MODIFIER", 23, 28], ["wall", "OBSERVATION_MODIFIER", 29, 33], ["maximum", "OBSERVATION_MODIFIER", 42, 49], ["diameter", "OBSERVATION_MODIFIER", 50, 58], ["cysts", "OBSERVATION", 68, 73], ["\u223c5 cm", "OBSERVATION_MODIFIER", 78, 83]]], ["At this time, real-time fluorescent polymerase chain reaction of the patient's sputum was negative for COVID-19 nucleic acid.", [["sputum", "ANATOMY", 79, 85], ["COVID-19 nucleic acid", "CHEMICAL", 103, 124], ["patient", "ORGANISM", 69, 76], ["sputum", "ORGANISM_SUBSTANCE", 79, 85], ["COVID-19 nucleic acid", "SIMPLE_CHEMICAL", 103, 124], ["patient", "SPECIES", 69, 76], ["the patient's sputum", "TEST", 65, 85], ["COVID", "TEST", 103, 108], ["nucleic acid", "TEST", 112, 124]]], ["The patient continued to be given 4 L/minute of oxygen by mask, as well as an antitussive, phlegm-dispelling treatment.", [["oxygen", "CHEMICAL", 48, 54], ["oxygen", "CHEMICAL", 48, 54], ["patient", "ORGANISM", 4, 11], ["oxygen", "SIMPLE_CHEMICAL", 48, 54], ["patient", "SPECIES", 4, 11], ["oxygen", "TREATMENT", 48, 54], ["mask", "TREATMENT", 58, 62], ["an antitussive", "TREATMENT", 75, 89], ["phlegm", "PROBLEM", 91, 97], ["dispelling treatment", "TREATMENT", 98, 118]]], ["The third CT scan, which was performed 5 days after the second CT scan, showed that the left pneumothorax and 1 small cyst on the left pulmonary margin had disappeared; the remaining cysts were slightly reduced in size (Fig. 1C).", [["left pneumothorax", "ANATOMY", 88, 105], ["cyst", "ANATOMY", 118, 122], ["left pulmonary margin", "ANATOMY", 130, 151], ["cysts", "ANATOMY", 183, 188], ["pneumothorax", "DISEASE", 93, 105], ["cyst", "CANCER", 118, 122], ["pulmonary", "ORGAN", 135, 144], ["cysts", "PATHOLOGICAL_FORMATION", 183, 188], ["The third CT scan", "TEST", 0, 17], ["the second CT scan", "TEST", 52, 70], ["the left pneumothorax", "PROBLEM", 84, 105], ["1 small cyst on the left pulmonary margin", "PROBLEM", 110, 151], ["the remaining cysts", "PROBLEM", 169, 188], ["left", "ANATOMY_MODIFIER", 88, 92], ["pneumothorax", "OBSERVATION", 93, 105], ["small", "OBSERVATION_MODIFIER", 112, 117], ["cyst", "OBSERVATION", 118, 122], ["left", "ANATOMY_MODIFIER", 130, 134], ["pulmonary", "ANATOMY", 135, 144], ["margin", "ANATOMY_MODIFIER", 145, 151], ["disappeared", "OBSERVATION_MODIFIER", 156, 167], ["remaining", "OBSERVATION_MODIFIER", 173, 182], ["cysts", "OBSERVATION", 183, 188], ["slightly", "OBSERVATION_MODIFIER", 194, 202], ["reduced", "OBSERVATION_MODIFIER", 203, 210], ["size", "OBSERVATION_MODIFIER", 214, 218], ["Fig", "OBSERVATION_MODIFIER", 220, 223]]], ["The patient was discharged from the hospital 21 days after the third CT scan.Case 2 ::: Case reportA 35-year-old man diagnosed with severe COVID-19 pneumonia (9 days) was admitted to the intensive care unit.", [["COVID", "DISEASE", 139, 144], ["pneumonia", "DISEASE", 148, 157], ["patient", "ORGANISM", 4, 11], ["man", "ORGANISM", 113, 116], ["patient", "SPECIES", 4, 11], ["man", "SPECIES", 113, 116], ["the third CT scan", "TEST", 59, 76], ["severe COVID", "PROBLEM", 132, 144], ["pneumonia", "PROBLEM", 148, 157], ["severe", "OBSERVATION_MODIFIER", 132, 138], ["pneumonia", "OBSERVATION", 148, 157]]], ["The primary CT findings showed bilateral, patchy, ground-glass opacities and consolidations (Fig. 2A and B).", [["The primary CT findings", "TEST", 0, 23], ["bilateral, patchy, ground-glass opacities", "PROBLEM", 31, 72], ["consolidations", "PROBLEM", 77, 91], ["bilateral", "ANATOMY_MODIFIER", 31, 40], ["patchy", "OBSERVATION_MODIFIER", 42, 48], ["ground-glass opacities", "OBSERVATION", 50, 72], ["consolidations", "OBSERVATION", 77, 91]]], ["The patient developed acute respiratory distress syndrome (ARDS) and type I respiratory failure; as such, the patient was given assisted respiration via a noninvasive ventilator (the inspiratory positive airway pressure ranged from 20 to 26 cm H2O; the expiratory positive airway pressure ranged from 5 to 10 cm H2O), as well as anti-infective, antivirus treatment.", [["respiratory", "ANATOMY", 28, 39], ["respiratory", "ANATOMY", 76, 87], ["airway", "ANATOMY", 204, 210], ["airway", "ANATOMY", 273, 279], ["acute respiratory distress syndrome", "DISEASE", 22, 57], ["ARDS", "DISEASE", 59, 63], ["type I respiratory failure", "DISEASE", 69, 95], ["H2O", "CHEMICAL", 244, 247], ["H2O", "CHEMICAL", 312, 315], ["H2O", "CHEMICAL", 244, 247], ["H2O", "CHEMICAL", 312, 315], ["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 110, 117], ["airway", "MULTI-TISSUE_STRUCTURE", 204, 210], ["airway", "MULTI-TISSUE_STRUCTURE", 273, 279], ["antivirus", "SIMPLE_CHEMICAL", 345, 354], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 110, 117], ["acute respiratory distress syndrome", "PROBLEM", 22, 57], ["ARDS", "PROBLEM", 59, 63], ["type I respiratory failure", "PROBLEM", 69, 95], ["assisted respiration", "TREATMENT", 128, 148], ["a noninvasive ventilator", "TREATMENT", 153, 177], ["the inspiratory positive airway pressure", "TEST", 179, 219], ["the expiratory positive airway pressure", "TEST", 249, 288], ["anti-infective", "TREATMENT", 329, 343], ["antivirus treatment", "TREATMENT", 345, 364], ["acute", "OBSERVATION_MODIFIER", 22, 27], ["respiratory distress", "OBSERVATION", 28, 48], ["syndrome", "OBSERVATION", 49, 57], ["ARDS", "OBSERVATION", 59, 63], ["respiratory failure", "OBSERVATION", 76, 95], ["airway pressure", "OBSERVATION", 204, 219], ["airway", "ANATOMY", 273, 279]]], ["Forty days later, the CT scan findings showed bilateral, patchy consolidations, and multiple cystic lesions (bilaterally) with peripheral distribution (Fig. 2C and D).", [["cystic lesions", "ANATOMY", 93, 107], ["cystic lesions", "PATHOLOGICAL_FORMATION", 93, 107], ["the CT scan findings", "TEST", 18, 38], ["bilateral, patchy consolidations", "PROBLEM", 46, 78], ["multiple cystic lesions", "PROBLEM", 84, 107], ["bilateral", "ANATOMY_MODIFIER", 46, 55], ["patchy", "OBSERVATION_MODIFIER", 57, 63], ["consolidations", "OBSERVATION", 64, 78], ["multiple", "OBSERVATION_MODIFIER", 84, 92], ["cystic", "OBSERVATION_MODIFIER", 93, 99], ["lesions", "OBSERVATION", 100, 107], ["bilaterally", "ANATOMY_MODIFIER", 109, 120], ["peripheral", "ANATOMY_MODIFIER", 127, 137], ["distribution", "OBSERVATION_MODIFIER", 138, 150]]], ["At present, real-time fluorescent polymerase chain reaction of the patient's sputum was negative for COVID-19 nucleic acid.", [["sputum", "ANATOMY", 77, 83], ["COVID-19 nucleic acid", "CHEMICAL", 101, 122], ["patient", "ORGANISM", 67, 74], ["sputum", "ORGANISM_SUBSTANCE", 77, 83], ["COVID-19 nucleic acid", "SIMPLE_CHEMICAL", 101, 122], ["patient", "SPECIES", 67, 74], ["the patient's sputum", "TEST", 63, 83], ["COVID", "TEST", 101, 106], ["nucleic acid", "TEST", 110, 122]]], ["To treat the patient's paroxysmal cough, which featured a little white mucus, as well as to address the patient's 97% percutaneous oxygen saturation with 19 breaths/minute, the patient's antitussive, phlegm-dispelling treatment was continued.", [["white mucus", "ANATOMY", 65, 76], ["percutaneous", "ANATOMY", 118, 130], ["paroxysmal cough", "DISEASE", 23, 39], ["oxygen", "CHEMICAL", 131, 137], ["phlegm", "DISEASE", 200, 206], ["oxygen", "CHEMICAL", 131, 137], ["patient", "ORGANISM", 13, 20], ["mucus", "ORGANISM_SUBSTANCE", 71, 76], ["patient", "ORGANISM", 104, 111], ["oxygen", "SIMPLE_CHEMICAL", 131, 137], ["patient", "ORGANISM", 177, 184], ["patient", "SPECIES", 13, 20], ["patient", "SPECIES", 104, 111], ["patient", "SPECIES", 177, 184], ["the patient's paroxysmal cough", "PROBLEM", 9, 39], ["a little white mucus", "PROBLEM", 56, 76], ["percutaneous oxygen saturation", "TEST", 118, 148], ["the patient's antitussive", "TREATMENT", 173, 198], ["phlegm", "PROBLEM", 200, 206], ["dispelling treatment", "TREATMENT", 207, 227]]], ["Two days later, the multiple cystic lesions were slightly reduced in size on follow-up CT (Fig. 2E and F).", [["cystic lesions", "ANATOMY", 29, 43], ["cystic lesions", "PATHOLOGICAL_FORMATION", 29, 43], ["the multiple cystic lesions", "PROBLEM", 16, 43], ["follow-up CT", "TEST", 77, 89], ["multiple", "OBSERVATION_MODIFIER", 20, 28], ["cystic", "OBSERVATION_MODIFIER", 29, 35], ["lesions", "OBSERVATION", 36, 43], ["slightly", "OBSERVATION_MODIFIER", 49, 57], ["reduced", "OBSERVATION_MODIFIER", 58, 65], ["size", "OBSERVATION_MODIFIER", 69, 73]]], ["At the time this paper was submitted for publication, the patient had been transferred to the rehabilitation department.DiscussionTo date, the papers published on COVID-19 have not discussed the presence of cystic lesions in association with this disease.", [["cystic lesions", "ANATOMY", 207, 221], ["patient", "ORGANISM", 58, 65], ["cystic lesions", "PATHOLOGICAL_FORMATION", 207, 221], ["patient", "SPECIES", 58, 65], ["cystic lesions", "PROBLEM", 207, 221], ["this disease", "PROBLEM", 242, 254], ["cystic", "OBSERVATION_MODIFIER", 207, 213], ["lesions", "OBSERVATION", 214, 221]]], ["In both of our cases, the pulmonary cystic lesions of COVID-19 were found on CT.DiscussionThe pulmonary cystic lesions and pneumothorax that were found may have been complications associated with mechanical ventilation.[4,5] The incidence of barotrauma in patients with ARDS following ventilation therapy was 6.5%.[6] Most ventilation-associated cysts were small (<1 cm in diameter) and featured a thick wall with no appreciable internal structure, and were found in a subpleural location.[7] However, some of the literature reported that ARDS might independently result in cyst formation.[7,8] The pulmonary cysts were observed in severe acute respiratory syndrome patients who received only short-term, low-pressure, and volume ventilation or received no mechanical ventilation at all.[7] The reasons for this might include the development of ischemic parenchymal damage, lung fibrosis, low lung compliance, and inflammatory exudate in the airway.[7\u20139]DiscussionThe pulmonary cysts and pneumothorax that were observed in both of our cases occurred more than 30 days after symptom onset; both patients were in the intermediate and late stages of ARDS, which is when fibrous processes begin to appear.[10] Case 1 did not receive mechanical ventilation therapy; therefore, we speculate that ischemic parenchymal damage, lung fibrosis, and low lung compliance may have led to the formation of cysts and the development of a pneumothorax.", [["pulmonary cystic lesions", "ANATOMY", 26, 50], ["pulmonary cystic lesions", "ANATOMY", 94, 118], ["cysts", "ANATOMY", 346, 351], ["wall", "ANATOMY", 404, 408], ["subpleural", "ANATOMY", 469, 479], ["cyst", "ANATOMY", 574, 578], ["pulmonary cysts", "ANATOMY", 599, 614], ["parenchymal", "ANATOMY", 854, 865], ["lung", "ANATOMY", 874, 878], ["lung", "ANATOMY", 893, 897], ["airway", "ANATOMY", 942, 948], ["pulmonary cysts", "ANATOMY", 968, 983], ["fibrous", "ANATOMY", 1167, 1174], ["parenchymal", "ANATOMY", 1299, 1310], ["lung", "ANATOMY", 1319, 1323], ["lung", "ANATOMY", 1342, 1346], ["cysts", "ANATOMY", 1391, 1396], ["pulmonary cystic lesions", "DISEASE", 94, 118], ["pneumothorax", "DISEASE", 123, 135], ["barotrauma", "DISEASE", 242, 252], ["ARDS", "DISEASE", 270, 274], ["ARDS", "DISEASE", 539, 543], ["pulmonary cysts", "DISEASE", 599, 614], ["acute respiratory syndrome", "DISEASE", 639, 665], ["ischemic parenchymal damage", "DISEASE", 845, 872], ["fibrosis", "DISEASE", 879, 887], ["pulmonary cysts", "DISEASE", 968, 983], ["pneumothorax", "DISEASE", 988, 1000], ["ARDS", "DISEASE", 1147, 1151], ["ischemic parenchymal damage", "DISEASE", 1290, 1317], ["fibrosis", "DISEASE", 1324, 1332], ["cysts", "DISEASE", 1391, 1396], ["pneumothorax", "DISEASE", 1422, 1434], ["pulmonary cystic lesions", "PATHOLOGICAL_FORMATION", 26, 50], ["pulmonary cystic lesions", "PATHOLOGICAL_FORMATION", 94, 118], ["patients", "ORGANISM", 256, 264], ["cysts", "PATHOLOGICAL_FORMATION", 346, 351], ["cyst", "PATHOLOGICAL_FORMATION", 574, 578], ["pulmonary cysts", "PATHOLOGICAL_FORMATION", 599, 614], ["patients", "ORGANISM", 666, 674], ["parenchymal", "TISSUE", 854, 865], ["lung", "ORGAN", 874, 878], ["lung", "ORGAN", 893, 897], ["airway", "MULTI-TISSUE_STRUCTURE", 942, 948], ["pulmonary cysts", "PATHOLOGICAL_FORMATION", 968, 983], ["patients", "ORGANISM", 1094, 1102], ["parenchymal", "TISSUE", 1299, 1310], ["lung", "ORGAN", 1319, 1323], ["lung", "ORGAN", 1342, 1346], ["cysts", "PATHOLOGICAL_FORMATION", 1391, 1396], ["patients", "SPECIES", 256, 264], ["patients", "SPECIES", 666, 674], ["patients", "SPECIES", 1094, 1102], ["the pulmonary cystic lesions", "PROBLEM", 22, 50], ["COVID", "TEST", 54, 59], ["CT", "TEST", 77, 79], ["The pulmonary cystic lesions", "PROBLEM", 90, 118], ["pneumothorax", "PROBLEM", 123, 135], ["mechanical ventilation", "TREATMENT", 196, 218], ["barotrauma", "PROBLEM", 242, 252], ["ARDS", "PROBLEM", 270, 274], ["ventilation therapy", "TREATMENT", 285, 304], ["associated cysts", "PROBLEM", 335, 351], ["a thick wall", "PROBLEM", 396, 408], ["appreciable internal structure", "PROBLEM", 417, 447], ["ARDS", "PROBLEM", 539, 543], ["cyst formation", "PROBLEM", 574, 588], ["The pulmonary cysts", "PROBLEM", 595, 614], ["severe acute respiratory syndrome", "PROBLEM", 632, 665], ["low-pressure", "TREATMENT", 705, 717], ["volume ventilation", "TREATMENT", 723, 741], ["mechanical ventilation", "TREATMENT", 757, 779], ["ischemic parenchymal damage", "PROBLEM", 845, 872], ["lung fibrosis", "PROBLEM", 874, 887], ["low lung compliance", "PROBLEM", 889, 908], ["inflammatory exudate in the airway", "PROBLEM", 914, 948], ["The pulmonary cysts", "PROBLEM", 964, 983], ["pneumothorax", "PROBLEM", 988, 1000], ["ARDS", "PROBLEM", 1147, 1151], ["fibrous processes", "PROBLEM", 1167, 1184], ["mechanical ventilation therapy", "TREATMENT", 1229, 1259], ["ischemic parenchymal damage", "PROBLEM", 1290, 1317], ["lung fibrosis", "PROBLEM", 1319, 1332], ["low lung compliance", "PROBLEM", 1338, 1357], ["cysts", "PROBLEM", 1391, 1396], ["a pneumothorax", "PROBLEM", 1420, 1434], ["pulmonary", "ANATOMY", 26, 35], ["cystic", "OBSERVATION_MODIFIER", 36, 42], ["lesions", "OBSERVATION", 43, 50], ["pulmonary", "ANATOMY", 94, 103], ["cystic", "OBSERVATION_MODIFIER", 104, 110], ["lesions", "OBSERVATION", 111, 118], ["pneumothorax", "OBSERVATION", 123, 135], ["mechanical ventilation", "OBSERVATION", 196, 218], ["barotrauma", "OBSERVATION", 242, 252], ["ARDS", "OBSERVATION", 270, 274], ["ventilation therapy", "OBSERVATION", 285, 304], ["cysts", "OBSERVATION", 346, 351], ["small", "OBSERVATION_MODIFIER", 357, 362], ["<1 cm", "OBSERVATION_MODIFIER", 364, 369], ["thick", "OBSERVATION_MODIFIER", 398, 403], ["wall", "ANATOMY_MODIFIER", 404, 408], ["no", "UNCERTAINTY", 414, 416], ["appreciable", "OBSERVATION_MODIFIER", 417, 428], ["internal", "OBSERVATION_MODIFIER", 429, 437], ["structure", "OBSERVATION", 438, 447], ["subpleural", "ANATOMY_MODIFIER", 469, 479], ["ARDS", "OBSERVATION", 539, 543], ["cyst", "OBSERVATION", 574, 578], ["pulmonary", "ANATOMY", 599, 608], ["cysts", "OBSERVATION", 609, 614], ["severe", "OBSERVATION_MODIFIER", 632, 638], ["acute", "OBSERVATION_MODIFIER", 639, 644], ["respiratory syndrome", "OBSERVATION", 645, 665], ["volume ventilation", "OBSERVATION", 723, 741], ["mechanical ventilation", "OBSERVATION", 757, 779], ["ischemic", "OBSERVATION_MODIFIER", 845, 853], ["parenchymal", "ANATOMY_MODIFIER", 854, 865], ["damage", "OBSERVATION", 866, 872], ["lung", "ANATOMY", 874, 878], ["fibrosis", "OBSERVATION", 879, 887], ["low", "OBSERVATION_MODIFIER", 889, 892], ["lung", "ANATOMY", 893, 897], ["compliance", "OBSERVATION", 898, 908], ["inflammatory", "OBSERVATION_MODIFIER", 914, 926], ["exudate", "OBSERVATION", 927, 934], ["airway", "ANATOMY", 942, 948], ["pulmonary", "ANATOMY", 968, 977], ["cysts", "OBSERVATION", 978, 983], ["pneumothorax", "OBSERVATION", 988, 1000], ["ARDS", "OBSERVATION", 1147, 1151], ["ischemic", "OBSERVATION_MODIFIER", 1290, 1298], ["parenchymal", "ANATOMY_MODIFIER", 1299, 1310], ["damage", "OBSERVATION", 1311, 1317], ["lung", "ANATOMY", 1319, 1323], ["fibrosis", "OBSERVATION", 1324, 1332], ["low", "OBSERVATION_MODIFIER", 1338, 1341], ["lung", "ANATOMY", 1342, 1346], ["compliance", "OBSERVATION", 1347, 1357], ["cysts", "OBSERVATION", 1391, 1396], ["pneumothorax", "OBSERVATION", 1422, 1434]]], ["Case 2 received a noninvasive ventilator; thus, the application of the ventilator may have constituted an additional reason for the formation of cysts and the development of a pneumothorax.DiscussionRecent histological examinations reported bilateral diffuse alveolar damage with cellular fibromyxoid exudates in COVID-19.[11] Pulmonary cystic lesions may form in response to cellular fibromyxoid exudates, which form a valve in the bronchus.", [["cysts", "ANATOMY", 145, 150], ["alveolar", "ANATOMY", 259, 267], ["cellular", "ANATOMY", 280, 288], ["Pulmonary cystic lesions", "ANATOMY", 327, 351], ["cellular fibromyxoid exudates", "ANATOMY", 376, 405], ["valve", "ANATOMY", 420, 425], ["bronchus", "ANATOMY", 433, 441], ["cysts", "DISEASE", 145, 150], ["pneumothorax", "DISEASE", 176, 188], ["alveolar damage", "DISEASE", 259, 274], ["cysts", "PATHOLOGICAL_FORMATION", 145, 150], ["alveolar", "TISSUE", 259, 267], ["cellular", "CELL", 280, 288], ["cystic lesions", "PATHOLOGICAL_FORMATION", 337, 351], ["cellular", "CELL", 376, 384], ["valve", "PATHOLOGICAL_FORMATION", 420, 425], ["bronchus", "ORGAN", 433, 441], ["a noninvasive ventilator", "TREATMENT", 16, 40], ["the ventilator", "TREATMENT", 67, 81], ["cysts", "PROBLEM", 145, 150], ["a pneumothorax", "PROBLEM", 174, 188], ["histological examinations", "TEST", 206, 231], ["bilateral diffuse alveolar damage", "PROBLEM", 241, 274], ["cellular fibromyxoid exudates", "PROBLEM", 280, 309], ["COVID", "TEST", 313, 318], ["Pulmonary cystic lesions", "PROBLEM", 327, 351], ["cellular fibromyxoid exudates", "PROBLEM", 376, 405], ["a valve in the bronchus", "PROBLEM", 418, 441], ["cysts", "OBSERVATION", 145, 150], ["pneumothorax", "OBSERVATION", 176, 188], ["bilateral", "ANATOMY_MODIFIER", 241, 250], ["diffuse", "OBSERVATION_MODIFIER", 251, 258], ["alveolar damage", "OBSERVATION", 259, 274], ["cellular", "OBSERVATION_MODIFIER", 280, 288], ["fibromyxoid exudates", "OBSERVATION", 289, 309], ["Pulmonary", "ANATOMY", 327, 336], ["cystic", "OBSERVATION_MODIFIER", 337, 343], ["lesions", "OBSERVATION", 344, 351], ["cellular", "OBSERVATION_MODIFIER", 376, 384], ["fibromyxoid exudates", "OBSERVATION", 385, 405], ["valve", "OBSERVATION", 420, 425], ["bronchus", "ANATOMY", 433, 441]]], ["Since these lesions cause emphysema and bullae, phlegm-dispelling treatment options may have been more appropriate and effective for both of our cases.DiscussionIn conclusion, COVID-19 may independently result in pulmonary cyst formation and the development of a pneumothorax; however, the use of a ventilator to manage the symptoms of this disease may be another reason underlying the formation of these lesions in patients affected by this virus.AcknowledgmentsWe thank our colleague, Xinyi Wang, for helpful discussions in article revision.", [["lesions", "ANATOMY", 12, 19], ["bullae", "ANATOMY", 40, 46], ["pulmonary cyst", "ANATOMY", 213, 227], ["lesions", "ANATOMY", 405, 412], ["emphysema", "DISEASE", 26, 35], ["bullae", "DISEASE", 40, 46], ["phlegm", "DISEASE", 48, 54], ["pulmonary cyst", "DISEASE", 213, 227], ["pneumothorax", "DISEASE", 263, 275], ["lesions", "PATHOLOGICAL_FORMATION", 12, 19], ["bullae", "PATHOLOGICAL_FORMATION", 40, 46], ["pulmonary cyst", "MULTI-TISSUE_STRUCTURE", 213, 227], ["lesions", "PATHOLOGICAL_FORMATION", 405, 412], ["patients", "ORGANISM", 416, 424], ["patients", "SPECIES", 416, 424], ["these lesions", "PROBLEM", 6, 19], ["emphysema", "PROBLEM", 26, 35], ["bullae", "PROBLEM", 40, 46], ["phlegm", "PROBLEM", 48, 54], ["dispelling treatment options", "TREATMENT", 55, 83], ["pulmonary cyst formation", "PROBLEM", 213, 237], ["a pneumothorax", "PROBLEM", 261, 275], ["a ventilator", "TREATMENT", 297, 309], ["the symptoms", "PROBLEM", 320, 332], ["this disease", "PROBLEM", 336, 348], ["these lesions", "PROBLEM", 399, 412], ["this virus", "PROBLEM", 437, 447], ["article revision", "TREATMENT", 526, 542], ["lesions", "OBSERVATION", 12, 19], ["emphysema", "OBSERVATION", 26, 35], ["bullae", "OBSERVATION", 40, 46], ["phlegm", "OBSERVATION", 48, 54], ["pulmonary", "ANATOMY", 213, 222], ["cyst", "OBSERVATION", 223, 227], ["pneumothorax", "OBSERVATION", 263, 275], ["lesions", "OBSERVATION", 405, 412]]]], "PMC7380501": [["IntroductionCOrona VIrus Disease (COVID-19) has presented an out of the ordinary challenge before us.", [["COVID-19", "CHEMICAL", 34, 42], ["IntroductionCOrona VIrus Disease", "PROBLEM", 0, 32], ["VIrus Disease", "OBSERVATION", 19, 32]]], ["As of 12th May 2020, the disease has infected more than four million people globally and claimed the lives of almost three hundred thousand individuals (Situation report-113, 2020).", [["people", "ORGANISM", 69, 75], ["people", "SPECIES", 69, 75], ["the disease", "PROBLEM", 21, 32], ["disease", "OBSERVATION", 25, 32], ["infected", "OBSERVATION_MODIFIER", 37, 45]]], ["COVID-19 is caused by the novel corona virus SARS-CoV-2 (Report of WHO 2020).", [["COVID", "TEST", 0, 5]]], ["Currently, there is no clinically proven medicine to treat this ailment (Sanders et al. 2020).", [["no", "UNCERTAINTY", 20, 22]]], ["This strategy is widely adopted across the world and many countries have imposed nationwide lockdowns (Situation report-91 2020).IntroductionThe first case in India was reported on 30th January 2020 (Situation report-3 2020).", [["widely", "OBSERVATION_MODIFIER", 17, 23]]], ["Government of India took an active step towards containing the spread of this disease by initially imposing a 21-day nationwide lockdown from 25th March 2020 and later extending it for 2 more weeks.", [["this disease", "PROBLEM", 73, 85]]], ["This measure of abundant precaution has helped to suppress the frequency and magnitude of social contacts within the country (Situation report-91 2020).", [["abundant precaution", "TREATMENT", 16, 35], ["abundant", "OBSERVATION_MODIFIER", 16, 24], ["precaution", "OBSERVATION", 25, 35]]], ["This quarantine period is also accompanied with continuous contact tracing of the increasing infected patients by local government authorities and functioning at war-footing of the health care system.IntroductionEpidemiology is a branch of medicine that deals with the incidence, distribution and possible control of diseases in a population.", [["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["control of diseases", "PROBLEM", 306, 325], ["increasing", "OBSERVATION_MODIFIER", 82, 92], ["infected", "OBSERVATION_MODIFIER", 93, 101], ["diseases", "OBSERVATION", 317, 325]]]], "PMC7134263": [["IntroductionAgriculture is the main factor for the survival of humans and it also provides food, fuel and other services in line with ecosystems.", [["humans", "ORGANISM", 63, 69], ["humans", "SPECIES", 63, 69], ["humans", "SPECIES", 63, 69], ["main", "OBSERVATION_MODIFIER", 31, 35]]], ["Agriculture is also a crucial origin of environmental downgrading, adding to climate variation, decreasing freshwater resources, detracting soil fertility and contaminating the environment over fertilizer and pesticide [1, 2].", [["decreasing freshwater resources", "TREATMENT", 96, 127], ["detracting soil fertility", "PROBLEM", 129, 154]]], ["Essentially, food production relies on the lofty natural resources it is derogating.", [["food production", "OBSERVATION", 13, 28]]], ["Sfs therefore not only requires that all people always have access to sufficient and nutritious food, but food be formed with minimal environmental brunt.", [["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47], ["minimal", "OBSERVATION_MODIFIER", 126, 133], ["environmental brunt", "OBSERVATION", 134, 153]]], ["Today, Agriculture is not only a dominating factor of environmental degradation, it is a major force compelling the Earth System beyond the \u2018safe-operating space\u2019 for humanity [4, 5].IntroductionKnowing that we have not achieve Sf s today and given the fact that we will probably need to double food production by 2050 so that we can feed 9 billion people with rising demand for meat and dairy products [6], there is a drastic need for changes in the food system.", [["meat", "ANATOMY", 379, 383], ["people", "ORGANISM", 349, 355], ["meat", "ORGANISM_SUBDIVISION", 379, 383], ["people", "SPECIES", 349, 355], ["environmental degradation", "PROBLEM", 54, 79], ["meat and dairy products", "TREATMENT", 379, 402], ["changes in the food system", "PROBLEM", 436, 462]]], ["We need to increase the production of food in the right locations at fair prices, protecting livelihoods to farmers and reducing the environmental cost of agriculture.", [["right", "ANATOMY_MODIFIER", 50, 55]]], ["Recently, the market for organic food (ORF) has increased, and call for fair sustainable farming.IntroductionIt is worth mentioning that this research is aimed at developing a mobile application for marketing organic farm products with the functionality of automated geo-location services, preferred goods delivery services, easy access to different organic farm produce.", [["a mobile application", "TREATMENT", 174, 194], ["organic farm products", "TREATMENT", 209, 230]]], ["Although a considerable amount of study can be found in the literature which identifies the attitude of dairy farmers towards organic farming [7, 8], economic and social implications of organic agriculture [9], these did not take mobile and real-time, geo-location into due consideration.", [["considerable", "OBSERVATION_MODIFIER", 11, 23], ["amount", "OBSERVATION_MODIFIER", 24, 30]]], ["The contributions of this work are:Ensuring real time information delivery on changing trends and key discoveries in the organic farm produce.Providing organic farmers cultivating crops with an e-commerce platform for easy facilitation of their business.Enabling practicing organic farmers form a cluster around themselves thereby empowering them with the benefits that comes with economics of scale.", [["an e-commerce platform", "TREATMENT", 191, 213]]]]}